{
    "title": "Review of Vitamin D trials - Grant",
    "slug": "review-of-vitamin-d-trials-grant",
    "aliases": [
        "/Review+of+Vitamin+D+trials+-+Grant+Jan+2012",
        "/2302"
    ],
    "tiki_page_id": 2302,
    "date": "2012-01-10",
    "categories": [
        "Evidence for D",
        "Intervention"
    ],
    "tags": [
        "CKD",
        "CYPA",
        "CYPR",
        "Evidence for D",
        "Intervention",
        "antibiotics",
        "anxiety",
        "asthma",
        "asthma receptor",
        "atopic dermatitis",
        "autoimmune",
        "autoimmune and pregnancy",
        "bacteria",
        "bariatric surgery",
        "blood clotting",
        "blood levels",
        "bone",
        "bone cancer",
        "bone loss",
        "bone mineral density",
        "bone stress fractures",
        "brain",
        "breathing",
        "cancer",
        "cancer in VDR",
        "cardiovascular",
        "child",
        "childhood cancer",
        "childhood pneumonia",
        "childhood viruses",
        "cholesterol",
        "cognitive",
        "colon cancer",
        "cystic fibrosis",
        "depression",
        "depression and pregnancy",
        "dermatology",
        "diabetes",
        "diabetes and vitamin d receptor",
        "dialysis",
        "dosage",
        "falls fractures",
        "genetics",
        "health risk",
        "heart failure",
        "high dose",
        "hip fractures",
        "hypertension",
        "immunity",
        "influenza",
        "intervention",
        "kidney",
        "life span",
        "melanoma",
        "metabolic",
        "metabolic conditions",
        "metabolic syndrome",
        "mononucleosis",
        "mood disorders",
        "mortality",
        "multiple sclerosis",
        "multiple sclerosis and pregnancy",
        "osteoporosis",
        "pain",
        "pediatric autoimmune",
        "pneumonia",
        "pregnancy",
        "rheumatoid arthritis",
        "rickets",
        "skin cancer",
        "therapeutic intervention",
        "transplant",
        "trauma surgery",
        "tuberculosis",
        "virus",
        "virus and cardiovascular",
        "virus and cognitive",
        "viruses and pregnancy",
        "viruses and vitamin d receptor",
        "vitamin d",
        "vitamin d and viruses",
        "vitamin d blood test",
        "vitamin d receptor",
        "weight loss"
    ]
}


# This web page consists of 3 sections

1. Summary table of Vitamin D Clinical Trials ( in English)

1. References for every entry in the summary table (that is, the references are a superset of the table)

1. Abstracts include all but two of the entries in the summary table, as well as items not in the summary table

There are no hyperlinks between the table entries and the references, abstracts

If you want to get more information on an item in the table you will need to search for the name of one of the authors and find the correct year.

First: Highlight author

- FireFox:  hit cntrl F (control + F key at the same time), then down arrow in lower left of screen

- Chrome (with efTwo add-on loaded) hit F2 key 

## <a href="/posts/click-here" style="color: red; text-decoration: underline;" title="This link has an unknown page_id: 2303">CLICK HERE</a> for  **<span style="color:#F00;">Nov 2012 update</span>** 

# See also by Dr. Grant

* [Vitamin D overview by Grant - Jan 2011](/posts/vitamin-d-overview-by-grant) - Requirements for Vitamin D Across the Life Span

* [Evidence for Vitamin D - Grant Aug 2011](/posts/evidence-for-vitamin-d-grant)

* [Dr. Grant on vitamin D and mortality in VitaminDWiki](/posts/dr-grant-on-vitamin-d-and-mortality-in-vitamindwiki)

- - - - - - - - - - - - - - - - - - - - - - - - - - - 

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">

<HTML>

<HEAD>

<META HTTP-EQUIV="CONTENT-TYPE" CONTENT="text/html; charset=windows-1252">

<TITLE></TITLE>

<META NAME="GENERATOR" CONTENT="OpenOffice.org 3.3  (Win32)">

<META NAME="AUTHOR" CONTENT="Bill">

<META NAME="CREATED" CONTENT="20111204;10330000">

<META NAME="CHANGEDBY" CONTENT="Bill">

<META NAME="CHANGED" CONTENT="20120110;17500000">

<STYLE TYPE="text/css">

<!--

@page { size: landscape; margin-right: 1.25in; margin-top: 1in; margin-bottom: 0.5in }

P { margin-bottom: 0.08in; direction: ltr; color: #000000; text-align: left; widows: 2; orphans: 2 }

P.western { font-family: "Times New Roman", serif; font-size: 12pt; so-language: en-US }

P.cjk { font-family: "Times New Roman", serif; font-size: 12pt; so-language: zh-CN }

P.ctl { font-family: "Times New Roman", serif; font-size: 12pt; so-language: ar-SA }

H1 { margin-top: 0.19in; margin-bottom: 0.19in; direction: ltr; color: #ff0000; text-align: left; widows: 2; orphans: 2; page-break-before: auto; page-break-after: auto }

H1.western { font-family: "Times New Roman", serif; font-size: 16pt; so-language: en-US }

H1.cjk { font-family: "Times New Roman", serif; so-language: zh-CN }

H1.ctl { font-family: "Times New Roman", serif; so-language: ar-SA }

H3 { margin-top: 0.19in; margin-bottom: 0.19in; direction: ltr; color: #000000; text-align: left; widows: 2; orphans: 2; page-break-after: auto }

H3.western { font-size: 13pt; so-language: en-US }

H3.cjk { font-family: "Times New Roman", serif; font-size: 13pt; so-language: zh-CN }

H3.ctl { font-family: "Times New Roman", serif; font-size: 13pt; so-language: ar-SA }

H4 { margin-bottom: 0.04in; direction: ltr; color: #000000; text-align: left; widows: 2; orphans: 2 }

H4.western { font-size: 14pt; so-language: en-US }

H4.cjk { font-family: "Times New Roman", serif; font-size: 14pt; so-language: zh-CN }

H4.ctl { font-family: "Times New Roman", serif; font-size: 14pt; so-language: ar-SA }

A:link { color: #0000ff }

-->

</STYLE>

</HEAD>

<BODY LANG="en-US" TEXT="#000000" LINK="#0000ff" DIR="LTR">

<P CLASS="western" STYLE="margin-bottom: 0in">William B. Grant, Ph.D.</P>

<P CLASS="western" STYLE="margin-bottom: 0in">Sunlight, Nutrition,

and Health Research Center</P>

<P CLASS="western" STYLE="margin-bottom: 0in">P.O. Box 641603</P>

<P CLASS="western" STYLE="margin-bottom: 0in">San Francisco, CA

94164-1603, USA		</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.sunarc.org/">www.sunarc.org</A></U></FONT>	</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="mailto:wbgrant@infionline.net"><SPAN LANG="nl-NL">wbgrant@infionline.net</SPAN></A></U></FONT><SPAN LANG="nl-NL">	</SPAN></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in">This is a preliminary

summary of what has been demonstrated with vitamin D supplementation

in randomized controlled trials (RCTs). If I&rsquo;ve missed any

important studies other than for falls and fractures, please let me

know.</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in">Since many early RCTs

did not use more than 400 IU/d vitamin D3, they did not find any

beneficial effects. The Institute of Medicine did not find any RCTs

that they wanted to accept for any health outcome other than

beneficial effects for bones [Chung, 2009, 2011; Ross, 2011].</P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=2 STYLE="font-size: 11pt">Table 1. Summary of findings

from RCTs with vitamin D</FONT></P>

<TABLE WIDTH=816 BORDER=1 BORDERCOLOR="#000000" CELLPADDING=7 CELLSPACING=0>

<COL WIDTH=129>

<COL WIDTH=250>

<COL WIDTH=256>

<COL WIDTH=123>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2 STYLE="font-size: 11pt"><B>Outcome</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2 STYLE="font-size: 11pt">Conditions</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2 STYLE="font-size: 11pt">Finding</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2 STYLE="font-size: 11pt">Reference</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>All cause mortality </B></FONT>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Mean oral in take 528 IU/d</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>RR =  0.93 (95% CI, 0.87-0.99)</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Autier and Gandini, 2007</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>daily </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) (800 IU), calcium (1000 mg), both, or

placebo for 24-62 months, with a follow-up of 3 yr after

intervention</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>(HR) = 0.93; 95% confidence interval (CI) =

0.85-1.02]</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Avenell, epub</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Atopic dermatitis</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><BR>

</P>

</TD>

<TD WIDTH=256>

<P><BR>

</P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Sidbury, 2008</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=4><B><FONT SIZE=2>Bone loss in winter</FONT></B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>oral cholecalciferol (500 IU/day) and calcium (500

mg/day) during the winter months</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>In the subjects receiving oral vitamin D3 and

calcium, lumbar and femoral BMD increased significantly (lumbar

spine: +0.8%, p = 0.04 versus year 1; femoral neck: +0.1%, p =

0.05 versus year 1), whereas controls continued to lose bone

(intervention group versus control group: lumbar spine, p = 0.03;

femoral neck, p = 0.05).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Meier, 2004</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=4><B><FONT SIZE=2>Cancer, All</FONT></B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>1100 IU/d, 1450 mg/d calcium</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>When analysis was confined to cancers diagnosed

after the first 12 mo, RR for the Ca + D group fell to 0.232 (CI:

0.09, 0.60; P &lt; 0.005) but did not change significantly for the

Ca-only group.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Lappe, 2007</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>daily </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) (800 IU), calcium (1000 mg), both, or

placebo for 24-62 months, with a follow-up of 3 yr after

intervention</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>cancer mortality (HR = 0.85; 95% CI = 0.68-1.06),

and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25)</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Avenell, epub</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=4><B><FONT SIZE=2>Breast, colorectal cancer</FONT></B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>400 IU/d vitamin D3, 1500 mg/d or placebo</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2>In 15,646 women (43%) who were not

taking personal calcium or </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements at randomization, CaD significantly decreased the risk

of total, breast, and invasive breast cancers by 14-20% and

nonsignificantly reduced the risk of colorectal cancer by 17%. In

women taking personal calcium or </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements, CaD did not alter cancer risk (HR: 1.06-1.26).</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Bolland, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Cardiometric</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>In meta-analyses of 10 trials</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>supplementation nonsignificantly reduced systolic

blood pressure (weighted mean difference, -1.9 mm Hg [CI, -4.2 to

0.4 mm Hg]) and did not affect diastolic blood pressure (weighted

mean difference, -0.1 mm Hg [CI, -0.7 to 0.5 mm Hg]).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Pittas, 2010</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Cardiovascular</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Vitamin D supplementation during weight loss</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>more pronounced decrease occurred in the vitamin D

group than in the placebo group in blood concentrations of

parathyroid hormone (-26.5% compared with -18.7%; P = 0.014),

triglycerides (-13.5% compared with +3.0%; P &lt; 0.001), and the

inflammation marker tumor necrosis factor-alpha (-10.2% compared

with -3.2%; P = 0.049).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Zittermann,  2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Cardiovascular disease event</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Pooled study</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2>.Results of secondary analyses in 8

randomized trials showed a slight but statistically nonsignificant

reduction in CVD risk (pooled relative risk, 0.90 [95% CI, 0.77 to

1.05]) with </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation at moderate to high doses (approximately 1000

IU/d) but not with calcium supplementation (pooled relative risk,

1.14 [CI, 0.92 to 1.41]), or a combination of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> and calcium supplementation (pooled relative

risk, 1.04 [CI, 0.92 to 1.18]) compared with placebo.</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Wang, 2010</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>CVD survival</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><BR>

</P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2> conferred

substantial survival benefit (odds ratio for death 0.39, 95%

confidence interval 0.277 to 0.534, p &lt;0.0001).</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Vacek, epub</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Chronic kidney disease</B></FONT></P>

</TD>

<TD WIDTH=250>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Placebo or calcium

(1,200 mg) and vitamin D(3) (800 IU) in fixed or separate

combination.</FONT></P>

<P STYLE="margin-bottom: 0in"><BR>

</P>

<P><FONT SIZE=2>Effect on parathyroid hormone</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>The proportion with a 30% or greater decrease in

iPTH level at 6 months was 50% in all eGFR groups on treatment

versus 6% to 9% for placebo (P &lt; 0.001 for all). The effects of

the intervention on iPTH levels did not differ according to

baseline eGFR (interaction P &gt; 0.1 for all times).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Kooienga, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>1000 IU/d vs. placebo</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>Mean 25(OH)D levels increased significantly higher

in the treatment group (mean increase from baseline: 10.3+/-10.4

ng/mL vs. 0.8+/-6.8 ng/mL, p&lt;0.0001).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Rucker, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Depression</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2 STYLE="font-size: 9pt">Cross-sectional study and

randomized double blind controlled trial of 20,000 or 40,000 IU

vitamin D per week versus placebo for 1 year.</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>In the two groups given vitamin D, but not in the

placebo group, there was a significant improvement in BDI scores

after 1 year. There was a significant decrease in serum

parathyroid hormone in the two vitamin D groups without a

concomitant increase in serum calcium.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Jorde, 2008</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Falls, fractures</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>700-1000 IU/d</FONT></P>

</TD>

<TD WIDTH=256>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Pooled RR = 0.81 (95%

CI 0.71 to 0.92)</FONT></P>

<P><FONT SIZE=2>No effect for 400 IU/d</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Bischoff-Ferrari, 2009b</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Falls</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Our study population consisted of 242 individuals

recruited by advertisements and mailing lists (mean [ +/- SD] age,

77 +/- 4 years). All serum 25-hydroxyvitamin D (25[OH]D) levels

were below 78 nmol/l. Individuals received in a double blinded

fashion either 1000 mg of calcium or 1000 mg of calcium plus 800

IU of vitamin D per day over a treatment period of 12 months,

which was followed by a treatment-free but still blinded

observation period of 8 months.</FONT></P>

</TD>

<TD WIDTH=256>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Compared to calcium

mono, supplementation with calcium plus vitamin D resulted in a

significant decrease in the number of subjects with first falls of

27% at month 12 (RR = 0.73; CI = 0.54-0.96) and 39% at month 20

(RR = 0.61; CI = 0.34-0.76).</FONT></P>

<P><FONT SIZE=2>Concerning secondary endpoints, we observed

significant improvements in quadriceps strength of 8%, a decrease

in body sway of 28%, and a decrease in time needed to perform the

TUG test of 11%.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Pfeifer, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Non-vertebrate fractures</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>700-1000 IU/d</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>pooled RR was 0.80 (95% CI, 0.72-0.89;</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Bischoff-Ferrari, 2009a</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Gastric bypass</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2 STYLE="font-size: 9pt">We evaluated three doses of

vitamin D3 (800, 2,000, and 5,000 IU/day) in a prospective,

randomized pilot trial of 45 patients undergoing Roux-en-Y gastric

bypass.</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2 STYLE="font-size: 9pt">At 12 months, the 800-,

2,000-, and 5,000-IU groups had a mean +/- SD increase in 25OHD of

27.5 +/- 40.0, 60.2 +/- 37.4, and 66.1 +/- 42.2 nmol/L,

respectively (p = 0.09) with a maximum increase in each group of

87.4, 114.8, and 129.8 nmol/L. Forty-four percent, 78%, and 70%

achieved 25OHD levels &gt;or=75 nmol/L (p = 0.38).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Goldner, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=4><B><FONT SIZE=2>Glucose (fasting plasma) (FPG)</FONT></B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>A total of 314 Caucasian adults

without diabetes received either 500 mg calcium citrate and 700 IU

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) or placebos

daily for 3 years in a double-blind, randomized, controlled trial

designed for bone-related outcomes.</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2>Among participants with IFG at

baseline, those who took combined calcium-</FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements had a lower rise in FPG at 3

years compared with those on placebo (0.02 mmol/l [0.4 mg/dl] vs.

0.34 mmol/l [6.1 mg/dl], respectively, P = 0.042) and a lower

increase in HOMA-IR (0.05 vs. 0.91, P = 0.031).</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Pitas, 2007</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Haemodialysis</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>HD patients were included in this study if their

serum 25(OH)D level was &lt;75 mmol/L. Oral 25(OH)D(3) was

administered daily at 10-30 microg/day based on the severity of

the deficiency.</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2 STYLE="font-size: 9pt">After 6 months of treatment

[mean daily 25(OH)D(3): 16 +/- 5 microg/day], the serum 25(OH)D

level increased (30 +/- 19 to 126 +/- 46 nmol/ L, P &lt; 0.001),

with 13% of patients in group 1, 57% in group 2 and 30% in group

3. The serum intact parathyroid hormone (iPTH) level decreased

(235 +/- 186 to 189 +/- 137 pg/mL, P = 0.05), except in group 1.

Bone alkaline phosphatase (BALP) showed a tendency to normalize

(23 +/- 16 to 18.3 +/- 11 microg/L, P &lt; 0.05), leading to a

decrease in alfacalcidol administration from 66% to 43% (P &lt;

0.05), except in group 1. The KDOQI targets achieved increased

significantly for serum calcium (76% to 85%) and phosphate levels

(66% to 77%) in all patients. The serum albumin level increased in

all groups (34.6 +/- 4 to 36.8 +/- 4 g/L, P &lt; 0.05), without

any significant improvement in normalized protein catabolic rate

(nPCR) or C-reactive proteins (CRP).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Jean, 2008</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Heart failure, congestive</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>either 50 mug </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3)/d plus 500 mg Ca/d [D(+) group] or

placebo plus 500 mg Ca/d [D(-) group] for 9 mo</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>Compared with baseline, parathyroid hormone was

significantly lower and the antiinflammatory cytokine interleukin

10 was significantly higher in the D(+) group after 9 mo. The

proinflammatory cytokine tumor necrosis factor alpha increased in

the D(-) group but remained constant in the D(+) group. The

survival rate did not differ significantly between the study

groups during the follow-up period.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Schleithoff, 2006</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Infectious diseases</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><BR>

</P>

</TD>

<TD WIDTH=256>

<P><BR>

</P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Yamshchikov, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Infections, symptomatic upper respiratory tract</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>50 microg vitamin D3 (2000 IU) daily or matching

placebo for 12 weeks.</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>The mean 25-hydroxyvitamin D level at baseline was

similar in both groups (64.3+/-25.4 nmol/l in the vitamin D group;

63.0+/-25.8 nmol/l in the placebo group; n.s.). After 12 weeks,

25-hydroxyvitamin D levels increased significantly to 88.5+/-23.2

nmol/l in the vitamin D group, whereas there was no change in

vitamin D levels in the placebo group. There was no benefit of

vitamin D3 supplementation in decreasing the incidence or severity

of symptomatic URIs during winter.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Li-Ng,  2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Influenza</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>800 or 2000 IU/d</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>40 or 90% reduction</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Aloia &amp; Li-Ng, 2007</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Influenza type A</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>1100 IU/d, no other oral intake</FONT></P>

</TD>

<TD WIDTH=256>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>RR: 0.36; 95% CI: 0.17,

0.79; P = 0.006</FONT></P>

<P><FONT SIZE=2>No effect for type B</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Urashima, 2010</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Insulin sensitivity</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>120,000 IU/fortnight</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>Seventy-one of the recruited subjects completed

the study (35 in supplemented group, 36 in control group). There

was an increase in oral glucose insulin sensitivity (OGIS) with

supplementation by per protocol analysis (P = 0.038;

intention-to-treat analysis P = 0.055). The age- and baseline

25-hydroxyvitamin D level-adjusted difference in change in OGIS

was highly significant (mean difference 41.1 +/- 15.5; P = 0.01).

No changes in secondary outcome measures (insulin secretion, basal

indices of insulin sensitivity, blood pressure or lipid profile)

were found with supplementation.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Nagpal, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>double-blind intervention administering 100 microg

(4000 IU) vitamin D(3) (n 42) or placebo (n 39) daily for 6 months

to South Asian women, aged 23-68 years, living in Auckland, New

Zealand</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>Significant improvements were seen in insulin

sensitivity and IR (P = 0.003 and 0.02, respectively), and fasting

insulin decreased (P = 0.02) with supplementation compared with

placebo.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Von hurst, 2010</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>participants with low serum 25(OH)D

levels were thereafter randomized to receive capsules of 20,000 IU

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) or

identical-looking placebo twice weekly for 6 months.</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2 STYLE="font-size: 9pt">The 52

participants with high serum 25(OH)D levels (85.6 &plusmn; 13.5

nmol/L [mean &plusmn; SD]) had significantly higher insulin

sensitivity index (ISI) and lower HbA(1c) and triglycerides (TGs)

than the 108 participants with low serum 25(OH)D (40.3 &plusmn;

12.8 nmol/L), but the differences in ISI and TGs were not

significant after adjustments. After supplementation, serum

25(OH)D was 142.7 &plusmn; 25.7 and 42.9 &plusmn; 17.3 nmol/L in

49 of 51 completing participants randomized to </FONT><FONT SIZE=2 STYLE="font-size: 9pt">vitamin

D</FONT><FONT SIZE=2 STYLE="font-size: 9pt"> and 45 of 53

randomized to placebo, respectively. At the end of the study,

there were no statistically significant differences in the outcome

variables between the two groups.</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Grimnes, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>cholecalciferol (2000 IU once daily) or calcium

carbonate (400 mg twice daily) for 16 wk.</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2 STYLE="font-size: 9pt">The

disposition index increased in the </FONT><FONT SIZE=2 STYLE="font-size: 9pt">vitamin

D</FONT><FONT SIZE=2 STYLE="font-size: 9pt"> group and decreased

in the no-</FONT><FONT SIZE=2 STYLE="font-size: 9pt">vitamin D</FONT><FONT SIZE=2 STYLE="font-size: 9pt">

group (adjusted mean change &plusmn; SE: 300 &plusmn; 130 compared

with -126 &plusmn; 127, respectively; P = 0.011), which was

explained by an improvement in insulin secretion (62 &plusmn; 39

compared with -36 &plusmn; 37 mU &middot; L(-1) &middot; min,

respectively; P = 0.046). Hb A(1c) increased less, but

nonsignificantly, in the </FONT><FONT SIZE=2 STYLE="font-size: 9pt">vitamin

D</FONT><FONT SIZE=2 STYLE="font-size: 9pt"> group than in the

no-</FONT><FONT SIZE=2 STYLE="font-size: 9pt">vitamin D</FONT><FONT SIZE=2 STYLE="font-size: 9pt">

group (0.06 &plusmn; 0.03% compared with 0.14 &plusmn; 0.03%,

respectively; P = 0.081).</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Mitri, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=4><B><FONT SIZE=2>Muscle strength</FONT></B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2 STYLE="font-size: 9pt">6-month supplementation

(December to May) of daily calcium plus monthly placebo

(calcium/placebo group) or daily calcium plus oral cholecalciferol

(150,000 IU once a month during the first 2 months, followed by

90,000 IU once a month for the last 4 months; calcium/vitamin D

group)</FONT></P>

</TD>

<TD WIDTH=256>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>SHF was increased in

the calcium/vitamin D group by 16.4% (p = 0.0001) and SKE by 24.6%

(p = 0.0007).</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>[strength of hip flexors (SHF) and knee extensors

(SKE)]</FONT></P>

<P><BR>

</P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Moreira-Pfrimer, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>800 or 1600 IU/d plus vibration</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>Same improvements with both doses</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Verschueren, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Musculoskeletal parameters</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>One hundred seventy-nine girls, ages

10-17 yr, were randomly assigned to receive weekly oral </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> doses of 1,400 IU (equivalent to 200 IU/d)

or 14,000 IU (equivalent to 2,000 IU/d) in a double-blind,

placebo-controlled, 1-yr protocol.</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>In the overall group of girls, lean mass increased

significantly in both treatment groups (P &lt; or = 0.05); bone

area and total hip BMC increased in the high-dose group (P &lt;

0.02). In premenarcheal girls, lean mass increased significantly

in both treatment groups, and there were consistent trends for

increments in BMD and/or BMC at several skeletal sites, reaching

significance at lumbar spine BMD in the low-dose group and at the

trochanter BMC in both treatment groups. There was no significant

change in lean mass, BMD, or BMC in postmenarcheal girls.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>El-Hajj, 2006</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Multiple sclerosis</B></FONT></P>

</TD>

<TD WIDTH=250>

<P LANG="da-DK"><FONT SIZE=2>6000 IU/d vitamin D2 vs. 1000 IU/d

vitamin D2</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>There were 4 relapses with high-dose D2 vs none

with low-dose D2 (p = 0.04).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Stein, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Neuromuscular</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>8400 IU/week</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>significantly reduced sway compared with treatment

with placebo (P = 0.047) in patients with elevated baseline sway

but not in patients with normal baseline sway.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Lips, 2010</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Physical performance</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><BR>

</P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>gait speed was higher among subjects supplemented

with vitamin (whether trained or not) than in non-supplemented

subjects (838+/-147 and 768+/-127 m/12 min, respectively, p=0.02).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Bunout, 2006</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Pneumonia</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Children, 100,000 IU once</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>Children in the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

group survived longer without experiencing a repeat episode (72

days vs. 59 days; HR 0.71; 95% CI 0.53-0.95; P = 0.02).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Manaseki-Holland, 2010</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=4><FONT SIZE=2>Oral </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

(1000 IU for &lt;1 year and 2000 IU for &gt;1 year) (n=100) or

placebo (lactose) (n=100) once a day for 5 days, from enrolment.</FONT></FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2>Median duration (SE, 95% CI) of

resolution of severe pneumonia was similar in the two groups

[</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>: 72 (3.7,

64.7-79.3) hours; placebo: 64 (4.5, 55.2-72.8)hours]. Duration of

hospitalization and time to resolution of tachypnea, chest

retractions, and inability to feed were also comparable between

the two groups.</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Choudhary &amp; Gupta, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Pregnancy</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>4000 IU/d</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>No adverse effects on serum or urine calcium</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Hollis, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Stress fractures</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Navy females, 800 IU/d, 2000 mg/d calcium</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>21% lower incidence</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Lappe, 2008</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Testosterone</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Participants received either 83 &mu;g (3,332 IU)

vitamin D daily for 1 year (n = 31) or placebo (n =2 3).</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2 STYLE="font-size: 9pt">Compared to baseline

values, a significant increase in total testosterone levels (from

10.7 &plusmn; 3.9 nmol/l to 13.4 &plusmn; 4.7 nmol/l; p &lt;

0.001), bioactive testosterone (from 5.21 &plusmn; 1.87 nmol/l to

6.25 &plusmn; 2.01 nmol/l; p = 0.001), and free testosterone

levels (from 0.222 &plusmn; 0.080 nmol/l to 0.267 &plusmn; 0.087

nmol/l; p = 0.001) were observed in the vitamin D supplemented

group. By contrast, there was no significant change in any

testosterone measure in the placebo group</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Pilz, 2011</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Tooth loss</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>Elderly, taking supplements or not</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>During the randomized trial, 11 of the 82 subjects

(13%) taking supplements and 17 of the 63 subjects (27%) taking

placebo lost one or more teeth (OR = 0.4; 95% CI: 0.2 to 0.9).</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Krall, 2001</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><FONT SIZE=2><B>Tuberculosis</B></FONT></P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>The subjects were randomised to receive vitamin D

(0.25 mg/day) or placebo in a double blind method, during the 6th

initial week of Tb treatment.</FONT></P>

</TD>

<TD WIDTH=256>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>One hundred percent of

the vitamin D group and only 76.7% of the placebo group had sputum

conversion. This difference is statistically significant

(p=0.002).</FONT></P>

<P><BR>

</P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Nursyam, 2006</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2 STYLE="font-size: 9pt">The intervention was

100,000 IU of cholecalciferol or placebo at inclusion and again 5

and 8 months after the start of treatment.</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=4><FONT SIZE=2 STYLE="font-size: 9pt">Overall

mortality was 15% (54 of 365) at 1 year of follow-up and similar

in both arms (30 of 187 for </FONT><FONT SIZE=2 STYLE="font-size: 9pt">vitamin

D</FONT><FONT SIZE=2 STYLE="font-size: 9pt"> treated and 24 of 178

for placebo; relative risk, 1.19 [0.58-1.95]).</FONT></FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Wejse, 2009</FONT></P>

</TD>

</TR>

<TR VALIGN=TOP>

<TD WIDTH=129>

<P><BR>

</P>

</TD>

<TD WIDTH=250>

<P><FONT SIZE=2>A single oral dose of 2.5 mg (100,000 IU) vitamin

D</FONT></P>

</TD>

<TD WIDTH=256>

<P><FONT SIZE=2>significantly enhanced the ability of

participants' whole blood to restrict BCG-lux luminescence in

vitro without affecting antigen-stimulated IFN-gamma responses.</FONT></P>

</TD>

<TD WIDTH=123>

<P><FONT SIZE=2>Martineau, 2011</FONT></P>

</TD>

</TR>

</TABLE>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<BR>

</P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; page-break-before: always">

<FONT COLOR="#b80047"><FONT SIZE=4>References</FONT></FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Ahearn TU, McCullough ML, Flanders WD, Long Q,

Sidelnikov E, </FONT><FONT SIZE=2>Fedirko</FONT><FONT SIZE=2> V,

Daniel CR, Rutherford RE, Shaukat A, </FONT><FONT SIZE=2>Bostick</FONT><FONT SIZE=2>

RM. A randomized clinical trial of the effects of supplemental

calcium and vitamin D3 on markers of their metabolism in normal

mucosa of colorectal adenoma patients. </FONT><FONT SIZE=2>Cancer

Res</FONT><FONT SIZE=2>. 2011 Jan 15;71(2):413-23. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Aloia</FONT><FONT SIZE=2> JF, </FONT><FONT SIZE=2>Li-Ng</FONT><FONT SIZE=2>

M. Re: epidemic influenza and vitamin D. </FONT><FONT SIZE=2>Epidemiol

Infect</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>2007</FONT><FONT SIZE=2>

Oct;135(7):1095-6; author reply 1097-8. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized

controlled trial of vitamin D3 supplementation in African American

women. </FONT><FONT SIZE=2>Arch Intern Med</FONT><FONT SIZE=2>. 2005

Jul 25;165(14):1618-23.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/17846391?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=1"><FONT SIZE=2>Autier

P, Gandini S. Vitamin D supplementation and total mortality: a

meta-analysis of randomized controlled trials.</FONT></A></U></FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>Arch Intern Med</FONT><FONT SIZE=2>. 2007 Sep

10;167(16):1730-7. </FONT></FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Avenell</FONT><FONT SIZE=2> A, </FONT><FONT SIZE=2>Cook</FONT><FONT SIZE=2>

JA, Maclennan GS, Macpherson GC. Vitamin D supplementation to prevent

infections: a sub-study of a randomised placebo-controlled trial in

older people (RECORD trial, ISRCTN 51647438). </FONT><FONT SIZE=2>Age

Ageing</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>2007</FONT><FONT SIZE=2>

Sep;36(5):574-7. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Avenell A, Maclennan GS, Jenkinson DJ, McPherson GC,

McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C,

Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA; the

RECORD Trial Group. Long-Term Follow-Up for Mortality and Cancer in a

Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium

(RECORD Trial). </FONT><FONT SIZE=2>J Clin Endocrinol Metab</FONT><FONT SIZE=2>.

2011 Nov 23. [Epub ahead of print]</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav

JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J.

Fall prevention with supplemental and active forms of vitamin D: a

meta-analysis of randomised controlled trials. </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Bischoff-Ferrari%20HA%2C%20Dawson-Hughes%20B%2C%20Staehelin%20HB%2C%20Orav%20JE%2C%20Stuck%20AE"><FONT SIZE=2>BMJ.</FONT></A></U></FONT><FONT SIZE=2>

2009b Oct 1;339:b3692. doi: 10.1136/bmj.b3692.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock

J, Giovannucci E, Willett WC. Benefit-risk assessment of vitamin D

supplementation. </FONT><FONT SIZE=2>Osteoporos Int</FONT><FONT SIZE=2>.

2010 Jul;21(7):1121-32.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E,

Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D

supplementation: a meta-analysis of randomized controlled trials.

</FONT><FONT SIZE=2>JAMA</FONT><FONT SIZE=2>. 2005 May

11;293(18):2257-64. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT SIZE=2>Bischoff-Ferrari HA, Willett WC, Wong JB,

Stuck AE, Staehelin HB, Orav EJ, Thoma A, Kiel DP, Henschkowski J.

</FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19307517?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=65"><FONT SIZE=2>Prevention

of nonvertebral fractures with oral vitamin D and dose dependency: a

meta-analysis of randomized controlled trials.</FONT></A></U></FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>Arch Intern Med</FONT><FONT SIZE=2>. 2009a Mar

23;169(6):551-61. </FONT></FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Bjelakovic G, Gluud LL, Nikolova D, Whitfield K,

Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation for prevention of mortality in

adults. </FONT><FONT SIZE=2>Cochrane Database Syst Rev</FONT><FONT SIZE=2>.

2011 Jul 6;(7):CD007470. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Bolland</FONT><FONT SIZE=2> MJ, Grey A, Gamble GD, Reid

IR. Calcium and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements and health outcomes: a reanalysis of the Women's Health

Initiative (WHI) limited-access data set. </FONT><FONT SIZE=2>Am J

Clin Nutr</FONT><FONT SIZE=2>. 2011 Oct;94(4):1144-9.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Bunout D, Barrera G, Leiva L, Gattas V, de la Maza MP,

Avenda&ntilde;o M, Hirsch S. Effects of vitamin D supplementation and

exercise training on physical performance in Chilean vitamin D

deficient elderly subjects. </FONT><FONT SIZE=2>Exp Gerontol</FONT><FONT SIZE=2>.

2006 Aug;41(8):746-52. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Burgi AA, Gorham ED, Garland CF, Mohr SB, Garland FC,

Zeng K, Thompson K, Lappe JM. High serum 25-hydroxyvitamin D is

associated with a low incidence of stress fractures. </FONT><FONT SIZE=2>J

Bone Miner Res</FONT><FONT SIZE=2>. 2011 Oct;26(10):2371-7.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Burleigh E, McColl J, Potter J. Does vitamin D stop

inpatients falling? A randomised controlled trial. </FONT><FONT SIZE=2>Age

Ageing</FONT><FONT SIZE=2>. 2007 Sep;36(5):507-13. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Choudhary N, Gupta P. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

Supplementation for Severe Pneumonia A </FONT><FONT SIZE=2>Randomized

Controlled Trial</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>Indian

Pediatr</FONT><FONT SIZE=2>. 2011 Aug 15. pii: S097475591100214-1.

[Epub ahead of print]</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al.

(2009). Vitamin D and calcium: a systematic review of health

outcomes. </FONT><FONT SIZE=2><I>Evid Rep Technol Assess (Full

Rep)</I></FONT><FONT SIZE=2>(183), 1-420. (Prepared by Tufts

Evidence-based Practice Center under Contract No. 290-2007-10055-I).

AHRQ Publication No. 09-E015, Rockville, MD: Agency for Healthcare

Research and Quality. August 2009.

(http://www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf)</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA.

Vitamin D With or Without Calcium Supplementation for Prevention of

Cancer and Fractures: An Updated Meta-analysis for the U.S.

Preventive Services Task Force. </FONT><FONT SIZE=2>Ann Intern Med</FONT><FONT SIZE=2>.

2011 Dec 20;155(12):827-38.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Dean AJ, Bellgrove MA, Hall T, Phan WM, Eyles DW,

Kvaskoff D, McGrath JJ. Effects of </FONT><FONT SIZE=2>vitamin d</FONT><FONT SIZE=2>

supplementation on cognitive and emotional functioning in young

adults - a </FONT><FONT SIZE=2>randomised controlled trial</FONT><FONT SIZE=2>.

</FONT><FONT SIZE=2>PLoS One</FONT><FONT SIZE=2>. 2011;6(11):e25966. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Dhesi</FONT><FONT SIZE=2> JK, Jackson SH, Bearne LM,

Moniz C, Hurley MV, Swift CG, Allain TJ. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation improves neuromuscular function

in older people who fall. </FONT><FONT SIZE=2>Age Ageing</FONT><FONT SIZE=2>.

</FONT><FONT SIZE=2>2004</FONT><FONT SIZE=2> Nov;33(6):589-95.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>El-Hajj Fuleihan G, Nabulsi M, Tamim H, Maalouf J,

Salamoun M, Khalife H, Choucair M, Arabi A, Vieth R. Effect of

vitamin D replacement on musculoskeletal parameters in school

children: a randomized controlled trial. </FONT><FONT SIZE=2>J Clin

Endocrinol Metab</FONT><FONT SIZE=2>. 2006 Feb;91(2):405-12.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Fedirko</FONT><FONT SIZE=2> V, </FONT><FONT SIZE=2>Bostick</FONT><FONT SIZE=2>

RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen

V, Dash C. Effects of vitamin D and calcium supplementation on

markers of apoptosis in normal colon mucosa: a randomized,

double-blind, placebo-controlled clinical trial. </FONT><FONT SIZE=2>Cancer

Prev Res (Phila)</FONT><FONT SIZE=2>. 2009 Mar;2(3):213-23. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Fedirko</FONT><FONT SIZE=2> V, </FONT><FONT SIZE=2>Bostick</FONT><FONT SIZE=2>

RM, Flanders WD, Long Q, Sidelnikov E, Shaukat A, Daniel CR,

Rutherford RE, Woodard JJ. Effects of vitamin d and calcium on

proliferation and differentiation in normal colon mucosa: a

randomized clinical trial. </FONT><FONT SIZE=2>Cancer Epidemiol

Biomarkers Prev</FONT><FONT SIZE=2>. 2009 Nov;18(11):2933-41.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Fedirko</FONT><FONT SIZE=2> V, </FONT><FONT SIZE=2>Bostick</FONT><FONT SIZE=2>

RM, Long Q, Flanders WD, McCullough ML, Sidelnikov E, Daniel CR,

Rutherford RE, Shaukat A. Effects of supplemental vitamin D and

calcium on oxidative DNA damage marker in normal colorectal mucosa: a

randomized clinical trial. </FONT><FONT SIZE=2>Cancer Epidemiol

Biomarkers Prev</FONT><FONT SIZE=2>. 2010 Jan;19(1):280-91.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR,

Prince RL. Effects of three monthly oral 150,000 IU cholecalciferol

supplementation on falls, mobility and muscle strength in older

postmenopausal women: a </FONT><FONT SIZE=2>randomised controlled

trial</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>J Bone Miner Res</FONT><FONT SIZE=2>.

2011 Sep 28. doi: 10.1002/jbmr.524. [Epub ahead of print]</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Goldner WS, Stoner JA, Lyden E, Thompson J, Taylor K,

Larson L, Erickson J, McBride C. Finding the optimal dose of vitamin

D following Roux-en-Y gastric bypass: a prospective, randomized pilot

clinical trial. </FONT><FONT SIZE=2>Obes Surg</FONT><FONT SIZE=2>.

2009 Feb;19(2):173-9.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Grimnes G, Figenschau Y, Alm&aring;s B, Jorde R. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2>, insulin secretion, sensitivity, and lipids:

results from a case-control study and a </FONT><FONT SIZE=2>randomized

controlled trial</FONT><FONT SIZE=2> using hyperglycemic clamp

technique. </FONT><FONT SIZE=2>Diabetes</FONT><FONT SIZE=2>. 2011

Nov;60(11):2748-57. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Heaney</FONT><FONT SIZE=2> RP, Recker RR, Grote J, Horst

RL, Armas LA. </FONT><FONT SIZE=2>Vitamin</FONT><FONT SIZE=2> D(3) is

more potent than </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2> D(2)

in humans. </FONT><FONT SIZE=2>J Clin Endocrinol Metab</FONT><FONT SIZE=2>.

2011 Mar;96(3):E447-52.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL.

Vitamin D supplementation during pregnancy: double-blind, randomized

clinical trial of safety and effectiveness. </FONT><FONT SIZE=2>J

Bone Miner Res</FONT><FONT SIZE=2>. 2011 Oct;26(10):2341-57.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Hopkins MH, Owen J, Ahearn T, </FONT><FONT SIZE=2>Fedirko</FONT><FONT SIZE=2>

V, Flanders WD, Jones DP, </FONT><FONT SIZE=2>Bostick</FONT><FONT SIZE=2>

RM. Effects of supplemental vitamin D and calcium on biomarkers of

inflammation in colorectal adenoma patients: a randomized, controlled

clinical trial. </FONT><FONT SIZE=2>Cancer Prev Res (Phila)</FONT><FONT SIZE=2>.

2011 Oct;4(10):1645-54.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Houghton LA, Vieth R. The case against ergocalciferol

(vitamin D2) as a vitamin supplement. </FONT><FONT SIZE=2>Am J Clin

Nutr</FONT><FONT SIZE=2>. 2006 Oct;84(4):694-7.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor

B, Chazot C. Daily oral 25-hydroxycholecalciferol supplementation for

vitamin D deficiency in haemodialysis patients: effects on mineral

metabolism and bone markers. </FONT><FONT SIZE=2>Nephrol Dial

Transplant</FONT><FONT SIZE=2>. 2008 Nov;23(11):3670-6. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K.

Effects of vitamin D supplementation on symptoms of depression in

overweight and obese subjects: randomized double blind trial. </FONT><FONT SIZE=2>J

Intern Med</FONT><FONT SIZE=2>. 2008 Dec;264(6):599-609. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Kooienga L, Fried L, Scragg R, Kendrick J, Smits G,

Chonchol M. The effect of combined calcium and vitamin D3

supplementation on serum intact parathyroid hormone in moderate CKD.

</FONT><FONT SIZE=2>Am J Kidney Dis</FONT><FONT SIZE=2>. 2009

Mar;53(3):408-16. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Krall EA, Wehler C, Garcia RI, Harris SS, Dawson-Hughes

B. Calcium and vitamin D supplements reduce tooth loss in the

elderly. </FONT><FONT SIZE=2>Am J Med</FONT><FONT SIZE=2>. 2001 Oct

15;111(6):452-6.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Kumar GT, Sachdev HS, Chellani H, Rehman AM, Singh V,

Arora H, Filteau S. Effect of weekly </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements on mortality, morbidity, and growth of low birthweight

term infants in India up to age 6 months: </FONT><FONT SIZE=2>randomised

controlled trial</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>BMJ</FONT><FONT SIZE=2>.

2011 May 31;342:d2975. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT SIZE=2>Lappe J, Cullen D, Haynatzki G, Recker R,

Ahlf R, Thompson K. </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/18433305?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=1"><FONT SIZE=2>Calcium

and vitamin d supplementation decreases incidence of stress fractures

in female navy recruits.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>J

Bone Miner Res</FONT><FONT SIZE=2>. 2008 May;23(5):741-9.</FONT></FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Lappe</FONT><FONT SIZE=2> JM, Travers-Gustafson D,

Davies KM, Recker RR, Heaney RP. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

and calcium supplementation reduces cancer risk: results of a

randomized trial. </FONT><FONT SIZE=2>Am J Clin Nutr</FONT><FONT SIZE=2>.

2007 Jun;85(6):1586-91. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT SIZE=2>Li-Ng M, Aloia JF, Pollack S, Cunha BA,

Mikhail M, Yeh J, Berbari N. </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19296870?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=70"><FONT SIZE=2>A

randomized controlled trial of vitamin D3 supplementation for the

prevention of symptomatic upper respiratory tract infections.</FONT></A></U></FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>Epidemiol Infect</FONT><FONT SIZE=2>. 2009

Oct;137(10):1396-404.</FONT></FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Lips P, Binkley N, Pfeifer M, Recker R, Samanta S, Cohn

DA, Chandler J, Rosenberg E, Papanicolaou DA. Once-weekly dose of

8400 IU vitamin D(3) compared with placebo: effects on neuromuscular

function and tolerability in older adults with vitamin D

insufficiency. </FONT><FONT SIZE=2>Am J Clin Nutr</FONT><FONT SIZE=2>.

2010 Apr;91(4):985-91. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J,

Zulf Mughal M, Chandramohan D, Walraven G. Effects of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplementation to children diagnosed with

pneumonia in </FONT><FONT SIZE=2>Kabul</FONT><FONT SIZE=2>: a

randomised controlled trial. </FONT><FONT SIZE=2>Trop Med Int Health</FONT><FONT SIZE=2>.

2010 Oct;15(10):1148-55. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT SIZE=2 STYLE="font-size: 11pt">Manaseki-Holland S,

Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D,

Walraven G. </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20723187"><FONT SIZE=2 STYLE="font-size: 11pt">Effects

of vitamin D supplementation to children diagnosed with pneumonia in

Kabul: a randomised controlled trial.</FONT></A></U></FONT><FONT SIZE=2 STYLE="font-size: 11pt">

</FONT><FONT SIZE=2 STYLE="font-size: 11pt">Trop Med Int Health</FONT><FONT SIZE=2 STYLE="font-size: 11pt">.

</FONT><FONT SIZE=2 STYLE="font-size: 11pt">2010 Oct;15(10):1148-55.</FONT></FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Martineau</FONT><FONT SIZE=2> AR, Timms PM, Bothamley

GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC,

Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward

NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM,

Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA,

Eldridge SM, Griffiths CJ. High-dose </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

during intensive-phase antimicrobial treatment of pulmonary

tuberculosis: a double-blind randomised controlled trial. </FONT><FONT SIZE=2>Lancet</FONT><FONT SIZE=2>.

2011 Jan 15;377(9761):242-50. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Martineau</FONT><FONT SIZE=2> AR, </FONT><FONT SIZE=2>Wilkinson</FONT><FONT SIZE=2>

RJ, </FONT><FONT SIZE=2>Wilkinson</FONT><FONT SIZE=2> KA, Newton SM,

Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ,

Rainbow SJ, Berry JL, Griffiths CJ. A single dose of vitamin D

enhances immunity to mycobacteria. </FONT><FONT SIZE=2>Am J Respir

Crit Care Med</FONT><FONT SIZE=2>. 2007 Jul 15;176(2):208-13. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Meier</FONT><FONT SIZE=2> C, </FONT><FONT SIZE=2>Woitge</FONT><FONT SIZE=2>

HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin

D3 and calcium during winter prevents seasonal bone loss: a

randomized controlled open-label prospective trial. </FONT><FONT SIZE=2>J

Bone Miner Res</FONT><FONT SIZE=2>. 2004 Aug;19(8):1221-30. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> and calcium

supplementation on pancreatic &beta; cell function, insulin

sensitivity, and glycemia in adults at high risk of diabetes: the

Calcium and </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> for

Diabetes Mellitus (CaDDM) </FONT><FONT SIZE=2>randomized controlled

trial</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>Am J Clin Nutr</FONT><FONT SIZE=2>.

2011 Aug;94(2):486-94. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Moreira-Pfrimer LD, Pedrosa MA, Teixeira L,

Lazaretti-Castro M. Treatment of vitamin D deficiency increases lower

limb muscle strength in institutionalized older people independently

of regular physical activity: a randomized double-blind controlled

trial. </FONT><FONT SIZE=2>Ann Nutr Metab</FONT><FONT SIZE=2>.

2009;54(4):291-300. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Nagpal J, Pande JN, Bhartia A. A double-blind,

randomized, placebo-controlled trial of the short-term effect of

vitamin D3 supplementation on insulin sensitivity in apparently

healthy, middle-aged, centrally obese men. </FONT><FONT SIZE=2>Diabet

Med</FONT><FONT SIZE=2>. 2009 Jan;26(1):19-27.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Nursyam EW, Amin Z, Rumende CM. The effect of vitamin D

as supplementary treatment in patients with moderately advanced

pulmonary tuberculous lesion. </FONT><FONT SIZE=2>Acta Med Indones</FONT><FONT SIZE=2>.

2006 Jan-Mar;38(1):3-5.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Papaioannou A, Kennedy CC, Giangregorio L, Ioannidis G,

Pritchard J, Hanley DA, Farrauto L, DeBeer J, Adachi JD. A </FONT><FONT SIZE=2>randomized

controlled trial</FONT><FONT SIZE=2> of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

dosing strategies after acute hip fracture: no advantage of loading

doses over daily supplementation. </FONT><FONT SIZE=2>BMC

Musculoskelet Disord</FONT><FONT SIZE=2>. 2011 Jun 20;12:135.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Pfeifer M, Begerow B, Minne HW, Suppan K,

Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and

calcium supplementation on falls and parameters of muscle function in

community-dwelling older individuals. </FONT><FONT SIZE=2>Osteoporos

Int</FONT><FONT SIZE=2>. 2009 Feb;20(2):315-22. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J,

Obermayer-Pietsch B, Wehr E, Zittermann A. Effect of vitamin D

supplementation on testosterone levels in men. </FONT><FONT SIZE=2><SPAN LANG="de-DE">Horm

Metab Res</SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">. 2011

Mar;43(3):223-5. </SPAN></FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2><SPAN LANG="de-DE">Pittas AG, Chung M, Trikalinos T,

Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM.

</SPAN></FONT><FONT SIZE=2>Systematic review: Vitamin D and

cardiometabolic outcomes. </FONT><FONT SIZE=2>Ann Intern Med</FONT><FONT SIZE=2>.

2010 Mar 2;152(5):307-14. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Pittas</FONT><FONT SIZE=2> AG, Harris SS, Stark PC,

Dawson-Hughes B. The effects of calcium and </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplementation on blood glucose and markers of

inflammation in nondiabetic adults. </FONT><FONT SIZE=2>Diabetes

Care</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>2007</FONT><FONT SIZE=2>

Apr;30(4):980-6.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM,

Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs

CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary

reference intakes for calcium and vitamin D from the Institute of

Medicine: what clinicians need to know. </FONT><FONT SIZE=2>J Clin

Endocrinol Metab</FONT><FONT SIZE=2>. 2011 Jan;96(1):53-8. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon

AW. Vitamin D insufficiency and treatment with oral vitamin D3 in

northern-dwelling patients with chronic kidney disease. </FONT><FONT SIZE=2>J

Nephrol</FONT><FONT SIZE=2>. 2009 Jan-Feb;22(1):75-82.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Schleithoff</FONT><FONT SIZE=2> SS, Zittermann A,

Tenderich G, Berthold HK, Stehle P, Koerfer R. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation improves cytokine profiles in

patients with congestive heart failure: a double-blind, randomized,

placebo-controlled trial. </FONT><FONT SIZE=2>Am J Clin Nutr</FONT><FONT SIZE=2>.

</FONT><FONT SIZE=2>2006</FONT><FONT SIZE=2> Apr;83(4):754-9.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Scragg R, Khaw KT, Murphy S. Effect of winter oral

vitamin D3 supplementation on cardiovascular risk factors in elderly

adults. </FONT><FONT SIZE=2>Eur J Clin Nutr</FONT><FONT SIZE=2>. 1995

Sep;49(9):640-6.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Sidbury R, Sullivan AF, Thadhani RI, Camargo CA Jr.

Randomized controlled trial of vitamin D supplementation for

winter-related atopic dermatitis in Boston: a pilot study. </FONT><FONT SIZE=2>Br

J Dermatol</FONT><FONT SIZE=2>. 2008 Jul;159(1):245-7. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield

MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ. A

randomized trial of high-dose vitamin D2 in relapsing-remitting

multiple sclerosis. </FONT><FONT SIZE=2>Neurology</FONT><FONT SIZE=2>.

2011 Oct 25;77(17):1611-8.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E,

Vitolins MZ, Zeitouni NC, Larson J, Stefanick ML. Calcium plus

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation and

the risk of nonmelanoma and melanoma skin cancer: post hoc analyses

of the women's health initiative </FONT><FONT SIZE=2>randomized

controlled trial</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>J Clin

Oncol</FONT><FONT SIZE=2>. 2011 Aug 1;29(22):3078-84. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Toss G, Magnusson P. Is a daily supplementation with 40

microgram </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

sufficient? A </FONT><FONT SIZE=2>randomised controlled trial</FONT><FONT SIZE=2>.

</FONT><FONT SIZE=2>Eur J Nutr</FONT><FONT SIZE=2>. 2011 Nov 16.

[Epub ahead of print]</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Urashima</FONT><FONT SIZE=2> M, Segawa T, Okazaki M,

Kurihara M, Wada Y, Ida H. Randomized trial of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplementation to prevent seasonal influenza A

in schoolchildren. </FONT><FONT SIZE=2>Am J Clin Nutr</FONT><FONT SIZE=2>.

2010 May;91(5):1255-60.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard

PA. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> Deficiency and

</FONT><FONT SIZE=2>Supplementation</FONT><FONT SIZE=2> and Relation

to </FONT><FONT SIZE=2>Cardiovascular</FONT><FONT SIZE=2> Health. </FONT><FONT SIZE=2>Am

J Cardiol</FONT><FONT SIZE=2>. 2011 Nov 7. [Epub ahead of print]</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Verschueren SM, Bogaerts A, Delecluse C, Claessens AL,

Haentjens P, Vanderschueren D, Boonen S. The effects of whole-body

vibration training and vitamin D supplementation on muscle strength,

muscle mass, and bone density in institutionalized elderly women: a

6-month randomized, controlled trial. </FONT><FONT SIZE=2>J Bone

Miner Res</FONT><FONT SIZE=2>. 2011 Jan;26(1):42-9.</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>von Hurst PR, Stonehouse W, Coad J. Vitamin D

supplementation reduces insulin resistance in South Asian women

living in New Zealand who are insulin resistant and vitamin D

deficient - a randomised, placebo-controlled trial. </FONT><FONT SIZE=2><SPAN LANG="de-DE">Br

J Nutr</SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">. 2010

Feb;103(4):549-55. </SPAN></FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2><SPAN LANG="de-DE">Wang</SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">

L, </SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">Manson</SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">

JE, Song Y, Sesso HD. </SPAN></FONT><FONT SIZE=2>Systematic review:

</FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> and calcium

supplementation in prevention of cardiovascular events. </FONT><FONT SIZE=2>Ann

Intern Med</FONT><FONT SIZE=2>. </FONT><FONT SIZE=2>2010</FONT><FONT SIZE=2>

Mar 2;152(5):315-23</FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Wejse</FONT><FONT SIZE=2> C, Gomes VF, Rabna P,

Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M.

</FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> as supplementary

treatment for tuberculosis: a double-blind, randomized,

placebo-controlled trial. </FONT><FONT SIZE=2>Am J Respir Crit Care

Med</FONT><FONT SIZE=2>. 2009 May 1;179(9):843-50. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<FONT SIZE=2>Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR,

Tangpricha V. Vitamin D for treatment and prevention of infectious

diseases: a systematic review of randomized controlled trials. </FONT><FONT SIZE=2>Endocr

Pract</FONT><FONT SIZE=2>. 2009 Jul-Aug;15(5):438-49. </FONT>

</P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT SIZE=2>Zittermann A, Frisch S, Berthold HK,

G&ouml;tting C, Kuhn J, Kleesiek K, Stehle P, Koertke H, Koerfer R.

</FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19321573?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&amp;ordinalpos=63"><FONT SIZE=2>Vitamin

D supplementation enhances the beneficial effects of weight loss on

cardiovascular disease risk markers.</FONT></A></U></FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>Am J Clin Nutr</FONT><FONT SIZE=2>. 2009

May;89(5):1321-7.</FONT></FONT></P>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in; background: #ffffff">

<FONT SIZE=4><FONT COLOR="#b80047"><FONT SIZE=4><B>Abstracts</B></FONT></FONT></FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19797342"><FONT SIZE=2>BMJ.</FONT></A></U></FONT><FONT SIZE=2>

2009 Oct 1;339:b3692. doi: 10.1136/bmj.b3692.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Fall

prevention with supplemental and active forms of vitamin D: a

meta-analysis of randomised controlled trials.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bischoff-Ferrari

HA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dawson-Hughes

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Staehelin

HB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Orav

JE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stuck

AE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Theiler

R</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wong

JB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Egli

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kiel

DP</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Henschkowski

J</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Centre on Aging and

Mobility, University of Zurich, Switzerland. heike.bischoff@usz.ch</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To test the efficacy of

supplemental vitamin D and active forms of vitamin D with or without

calcium in preventing falls among older individuals.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SOURCES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We searched Medline, the

Cochrane central register of controlled trials, BIOSIS, and Embase up

to August 2008 for relevant articles. Further studies were identified

by consulting clinical experts, bibliographies, and abstracts. We

contacted authors for additional data when necessary. Review methods

Only double blind randomised controlled trials of older individuals

(mean age 65 years or older) receiving a defined oral dose of

supplemental vitamin D (vitamin D(3) (cholecalciferol) or vitamin

D(2) (ergocalciferol)) or an active form of vitamin D

(1alpha-hydroxyvitamin D(3) (1alpha-hydroxycalciferol) or

1,25-dihydroxyvitamin D(3) (1,25-dihydroxycholecalciferol)) and with

sufficiently specified fall assessment were considered for inclusion.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Eight randomised

controlled trials (n=2426) of supplemental vitamin D met our

inclusion criteria. Heterogeneity among trials was observed for dose

of vitamin D (700-1000 IU/day v 200-600 IU/day; P=0.02) and achieved

25-hydroxyvitamin D(3) concentration (25(OH)D concentration: &lt;60

nmol/l v &gt;or=60 nmol/l; P=0.005). High dose supplemental vitamin D

reduced fall risk by 19% (pooled relative risk (RR) 0.81, 95% CI 0.71

to 0.92; n=1921 from seven trials), whereas achieved serum 25(OH)D

concentrations of 60 nmol/l or more resulted in a 23% fall reduction

(pooled RR 0.77, 95% CI 0.65 to 0.90). Falls were not notably reduced

by low dose supplemental vitamin D (pooled RR 1.10, 95% CI 0.89 to

1.35; n=505 from two trials) or by achieved serum 25-hydroxyvitamin D

concentrations of less than 60 nmol/l (pooled RR 1.35, 95% CI 0.98 to

1.84). Two randomised controlled trials (n=624) of active forms of

vitamin D met our inclusion criteria. Active forms of vitamin D

reduced fall risk by 22% (pooled RR 0.78, 95% CI 0.64 to 0.94).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Supplemental vitamin D in

a dose of 700-1000 IU a day reduced the risk of falling among older

individuals by 19% and to a similar degree as active forms of vitamin

D. Doses of supplemental vitamin D of less than 700 IU or serum

25-hydroxyvitamin D concentrations of less than 60 nmol/l may not

reduce the risk of falling among older individuals.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=vitamin%20d%20stress%20fractures%20garland"><FONT SIZE=2>J

Bone Miner Res.</FONT></A></U></FONT><FONT SIZE=2> 2011

Oct;26(10):2371-7. doi: 10.1002/jbmr.451.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>High

serum 25-hydroxyvitamin D is associated with a low incidence of

</FONT><FONT SIZE=2>stress fractures</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Burgi

AA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gorham

ED</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Garland

CF</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mohr

SB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Garland

FC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Zeng

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Thompson

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lappe

JM</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Behavioral

Sciences and Epidemiology, Naval Health Research Center, San Diego,

CA, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Low serum

25-hydroxyvitamin D [25(OH)D] concentrations are associated with hip

</FONT><FONT SIZE=2>fractures</FONT><FONT SIZE=2>, but the

dose-response relationship of serum 25(OH)D with risk of </FONT><FONT SIZE=2>stress

fractures</FONT><FONT SIZE=2> in young women is unknown. This nested

case-control study in a cohort of female Navy recruits was designed

to determine whether those with low prediagnostic serum 25(OH)D

concentrations had greater risk of </FONT><FONT SIZE=2>stress</FONT><FONT SIZE=2>

fracture. Sera were drawn in 2002-2009 from 600 women who were

diagnosed subsequently with </FONT><FONT SIZE=2>stress</FONT><FONT SIZE=2>

fracture of the tibia or fibula and 600 matched controls who did not

experience a </FONT><FONT SIZE=2>stress</FONT><FONT SIZE=2> fracture.

The 25(OH)D concentration was measured using the DiaSorin

radioimmunoassay method. Controls were individually matched to cases

on race (white, black, or other), length of service (&plusmn;30

days), and day blood was drawn (&plusmn;2 days). There was

approximately half the risk of </FONT><FONT SIZE=2>stress</FONT><FONT SIZE=2>

fracture in the top compared with the bottom quintile of serum

25(OH)D concentration (odds ratio [OR]</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>0.51,

95% CI 0.34-0.76, p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&le;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>0.01).

The range of serum 25(OH)D in the lowest quintile was 1.5 to 19.7

(mean 13.9) ng/mL, whereas in the highest it was 39.9 to 112 (mean

49.7) ng/mL. It is concluded that there was a monotonic inverse

dose-response gradient between serum 25(OH)D and risk of </FONT><FONT SIZE=2>stress</FONT><FONT SIZE=2>

fracture. There was double the risk of </FONT><FONT SIZE=2>stress

fractures</FONT><FONT SIZE=2> of the tibia and fibula in women with

serum 25(OH)D concentrations of less than 20</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>ng/mL

compared to those with concentrations of 40</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>ng/mL

or greater. A target for prevention of </FONT><FONT SIZE=2>stress

fractures</FONT><FONT SIZE=2> would be a serum 25(OH)D concentration

of 40</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>ng/mL

or greater, achievable with 4000</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>IU/d

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

supplementation.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Autier%20P%2C%20Gandini%20S.%20%202007"><FONT SIZE=2>Arch

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2007</FONT><FONT SIZE=2>

Sep 10;167(16):1730-7.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D supplementation and total mortality: a meta-analysis of randomized

controlled trials.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Autier

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gandini

S</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>International Agency for

Research on Cancer, 150 cours Albert Thomas, F-69372 Lyon, France.

autierp@iacr.fr</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Ecological and

observational studies suggest that low vitamin D status could be

associated with higher mortality from life-threatening conditions

including cancer, cardiovascular disease, and diabetes mellitus that

account for 60% to 70% of total mortality in high-income countries.

We examined the risk of dying from any cause in subjects who

participated in randomized trials testing the impact of vitamin D

supplementation (ergocalciferol [vitamin D(2)] or cholecalciferol

[vitamin D(3)]) on any health condition.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The literature up to

November 2006 was searched without language restriction using the

following databases: PubMed, ISI Web of Science (Science Citation

Index Expanded), EMBASE, and the Cochrane Library.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We identified 18

independent randomized controlled trials, including 57 311

participants. A total of 4777 deaths from any cause occurred during a

trial size-adjusted mean of 5.7 years. Daily doses of vitamin D

supplements varied from 300 to 2000 IU. The trial size-adjusted mean

daily vitamin D dose was 528 IU. In 9 trials, there was a 1.4- to

5.2-fold difference in serum 25-hydroxyvitamin D between the

intervention and control groups. The summary relative risk for

mortality from any cause was 0.93 (95% confidence interval,

0.87-0.99). There was neither indication for heterogeneity nor

indication for publication biases. The summary relative risk did not

change according to the addition of calcium supplements in the

intervention.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Intake of ordinary doses

of vitamin D supplements seems to be associated with decreases in

total mortality rates. The relationship between baseline vitamin D

status, dose of vitamin D supplements, and total mortality rates

remains to be investigated. Population-based, placebo-controlled

randomized trials with total mortality as the main end point should

be organized for confirming these findings.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19321573"><FONT SIZE=2>Am

J Clin Nutr.</FONT></A></U></FONT><FONT SIZE=2> 2009

May;89(5):1321-7. Epub 2009 Mar 25.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D supplementation enhances the beneficial effects of weight loss on

cardiovascular disease risk markers.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Zittermann

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Frisch

S</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Berthold

HK</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>G&ouml;tting

C</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kuhn

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kleesiek

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stehle

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Koertke

H</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Koerfer

R</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 LANG="de-DE" CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in">

<FONT SIZE=2>Source</FONT></H3>

<P LANG="de-DE" STYLE="margin-bottom: 0in"><FONT SIZE=2>Klinik f&uuml;r

Thorax- und Kardiovaskularchirurgie and Institut f&uuml;r

Laboratoriums- und Transfusionsmedizin, Herzzentrum NRW, Ruhr

Universit&auml;t Bochum, Bad Oeynhausen, Germany.

azittermann@hdz-nrw.de</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>High blood concentrations

of parathyroid hormone and low concentrations of the vitamin D

metabolites 25-hydroxyvitamin D [25(OH)D] and calcitriol are

considered new cardiovascular disease risk markers. However, there is

also evidence that calcitriol increases lipogenesis and decreases

lipolysis.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We investigated the effect

of vitamin D on weight loss and traditional and nontraditional

cardiovascular disease risk markers in overweight subjects.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Healthy overweight

subjects (n = 200) with mean 25(OH)D concentrations of 30 nmol/L (12

ng/mL) received vitamin D (83 microg/d) or placebo in a double-blind

manner for 12 mo while participating in a weight-reduction program.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Weight loss was not

affected significantly by vitamin D supplementation (-5.7 +/- 5.8 kg)

or placebo (-6.4 +/- 5.6 kg). However, mean 25(OH)D and calcitriol

concentrations increased by 55.5 nmol/L and 40.0 pmol/L,

respectively, in the vitamin D group but by only 11.8 nmol/L and 9.3

pmol/L, respectively, in the placebo group (P &lt; 0.001), whereas a

more pronounced decrease occurred in the vitamin D group than in the

placebo group in blood concentrations of parathyroid hormone (-26.5%

compared with -18.7%; P = 0.014), triglycerides (-13.5% compared with

+3.0%; P &lt; 0.001), and the inflammation marker tumor necrosis

factor-alpha (-10.2% compared with -3.2%; P = 0.049). The beneficial

biochemical effects were independent of the loss in body weight, fat

mass, and sex. However, compared with placebo, vitamin D

supplementation also increased LDL-cholesterol concentrations (+5.4%

compared with -2.5%; P &lt; 0.001).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The results indicate that

a vitamin D supplement of 83 microg/d does not adversely affect

weight loss and is able to significantly improve several

cardiovascular disease risk markers in overweight subjects with

inadequate vitamin D status participating in a weight-reduction

program. This trial was registered at clinicaltrials.gov as

NCT00493012.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Lappe%20J%2C%20Cullen%20D%2C%20Haynatzki%20G%2C%20Recker%20R"><FONT SIZE=2>J

Bone Miner Res.</FONT></A></U></FONT><FONT SIZE=2> 2008

May;23(5):741-9.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Calcium

and vitamin d supplementation decreases incidence of stress fractures

in female navy recruits.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lappe

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Cullen

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Haynatzki

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Recker

R</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ahlf

R</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Thompson

K</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Creighton University

Osteoporosis Research Center, Omaha, Nebraska, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTRODUCTION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Stress fractures (SFx) are

one of the most common and debilitating overuse injuries seen in

military recruits, and they are also problematic for nonmilitary

athletic populations. The goal of this randomized double-blind,

placebo-controlled study was to determine whether a calcium and

vitamin D intervention could reduce the incidence of SFx in female

recruits during basic training.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MATERIALS

AND METHODS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We recruited 5201 female

Navy recruit volunteers and randomized them to 2000 mg calcium and

800 IU vitamin D/d or placebo. SFx were ascertained when recruits

reported to the Great Lakes clinic with symptoms. All SFx were

confirmed with radiography or technetium scan according to the usual

Navy protocol.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A total of 309 subjects

were diagnosed with a SFx resulting in an incidence of 5.9% per 8 wk.

Using intention-to-treat analysis by including all enrolled subjects,

we found that the calcium and vitamin D group had a 20% lower

incidence of SFx than the control group (5.3% versus 6.6%,

respectively, p = 0.0026 for Fisher's exact test). The per protocol

analysis, including only the 3700 recruits who completed the study,

found a 21% lower incidence of fractures in the supplemented versus

the control group (6.8% versus 8.6%, respectively, p = 0.02 for

Fisher's exact test).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Generalizing the findings

to the population of 14,416 women who entered basic training at the

Great Lakes during the 24 mo of recruitment, calcium and vitamin D

supplementation for the entire cohort would have prevented

approximately 187 persons from fracturing. Such a decrease in SFx

would be associated with a significant decrease in morbidity and

financial costs.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20219962"><FONT SIZE=2>Am

J Clin Nutr.</FONT></A></U></FONT><FONT SIZE=2> 2010

May;91(5):1255-60. Epub 2010 Mar 10.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Randomized

trial of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation to prevent seasonal influenza A in schoolchildren.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Urashima</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

M</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Segawa

T</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Okazaki

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kurihara

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wada

Y</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ida

H</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of Molecular

Epidemiology, Jikei University School of Medicine, Nishi-shimbashi

3-25-8, Minato-ku, Tokyo 105-8461, Japan. </FONT><FONT SIZE=2>urashima</FONT><FONT SIZE=2>@jikei.ac.jp</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To our knowledge, no

rigorously designed clinical trials have evaluated the relation

between </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> and

physician-diagnosed seasonal influenza.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We investigated the effect

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplements on

the incidence of seasonal influenza A in schoolchildren.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>From December 2008 through

March 2009, we conducted a randomized, double-blind,

placebo-controlled trial comparing </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

supplements (1200 IU/d) with placebo in schoolchildren. The primary

outcome was the incidence of influenza A, diagnosed with influenza

antigen testing with a nasopharyngeal swab specimen.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Influenza A occurred in 18

of 167 (10.8%) children in the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

group compared with 31 of 167 (18.6%) children in the placebo group

[relative risk (RR), 0.58; 95% CI: 0.34, 0.99; P = 0.04]. The

reduction in influenza A was more prominent in children who had not

been taking other </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements (RR: 0.36; 95% CI: 0.17, 0.79; P = 0.006) and who started

nursery school after age 3 y (RR: 0.36; 95% CI: 0.17, 0.78; P =

0.005). In children with a previous diagnosis of asthma, asthma

attacks as a secondary outcome occurred in 2 children receiving

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) compared with 12

children receiving placebo (RR: 0.17; 95% CI: 0.04, 0.73; P = 0.006).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This study suggests that

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) supplementation

during the winter may reduce the incidence of influenza A, especially

in specific subgroups of schoolchildren. This trial was registered at

https://center.umin.ac.jp as UMIN000001373.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/22184690"><FONT SIZE=2>Ann

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> 2011 Dec

20;155(12):827-38.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D With or Without Calcium Supplementation for Prevention of Cancer

and Fractures: An Updated Meta-analysis for the U.S. Preventive

Services Task Force.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Chung

M</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Lee

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Terasawa

T</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Lau

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Trikalinos

TA</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Tufts Evidence-based

Practice Center, Institute for Clinical Research and Health Policy

Studies, Tufts Medical Center, Boston, Massachusetts, and Department

of Medicine, Fujita Health University School of Medicine, Tsu, Japan.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Background: Studies

suggest that vitamin D supplementation may reduce cancer and fracture

risks. Purpose: To examine the benefits and harms of vitamin D with

or without calcium supplementation on clinical outcomes of cancer and

fractures in adults. Data Sources: English-language studies

identified from MEDLINE and the Cochrane Central Register of

Controlled Trials through July 2011. Study Selection: Randomized,

controlled trials (RCTs), prospective cohort studies, and nested

case-control studies reporting incidence of or death from cancer and

fracture outcomes. Data Extraction: Multiple reviewers extracted

details about participant characteristics, including baseline vitamin

D status and use of supplements; details of statistical analyses,

including adjustments for confounding; and methodological quality.

Differences were resolved by consensus. Data Synthesis: 19 RCTs (3

for cancer and 16 for fracture outcomes) and 28 observational studies

(for cancer outcomes) were analyzed. Limited data from RCTs suggested

that high-dose (1000 IU/d) vitamin D supplementation can reduce the

risk for total cancer, and data from observational studies suggested

that higher blood 25-hydroxyvitamin D (25-[OH]D) concentrations might

be associated with increased risk for cancer. Mixed-effects

dose-response meta-analyses showed that each 10-nmol/L increase in

blood 25-(OH)D concentration was associated with a 6% (95% CI, 3% to

9%) reduced risk for colorectal cancer but no statistically

significant dose-response relationships for prostate and breast

cancer. Random-effects model meta-analysis showed that combined

vitamin D and calcium supplementation reduced fracture risk (pooled

relative risk, 0.88 [CI, 0.78 to 0.99]) in older adults, but the

effects differed according to study setting: institution (relative

risk, 0.71 [CI, 0.57 to 0.89]) versus community-dwelling (relative

risk, 0.89 [CI, 0.76 to 1.04]). One RCT showed adverse outcomes

associated with supplementation, including increased risk for renal

and urinary tract stones. Limitations: Most trial participants were

older (aged &ge;65 years) postmenopausal women. Observational studies

were heterogeneous and were limited by potential confounders.

Conclusion: Combined vitamin D and calcium supplementation can reduce

fracture risk, but the effects may be smaller among

community-dwelling older adults than among institutionalized elderly

persons. Appropriate dose and dosing regimens, however, require

further study. Evidence is not sufficiently robust to draw

conclusions regarding the benefits or harms of vitamin D

supplementation for the prevention of cancer. Primary Funding Source:

Agency for Healthcare Research and Quality.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20723187"><FONT SIZE=2>Trop

Med Int Health.</FONT></A></U></FONT><FONT SIZE=2> 2010

Oct;15(10):1148-55. doi: 10.1111/j.1365-3156.2010.02578.x. Epub 2010

Aug 17.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

to children diagnosed with pneumonia in Kabul: a randomised

controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Manaseki-Holland</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

S</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Qader

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Isaq

Masher M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bruce

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Zulf

Mughal M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Chandramohan

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Walraven

G</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Kabul Medical University,

Kabul, Afghanistan.</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&ensp;</FONT></FONT><FONT SIZE=2>Aga

Khan Health Services, Kabul, Afghanistan </FONT>

</P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVES:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To determine whether (i)

supplementation of oral 100,000 iu of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) (cholecalciferol) along with antibiotics

will reduce the duration of illness in children with pneumonia; (ii)

supplementation will reduce the risk of repeat episodes.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Double-blind individually

randomised placebo-controlled trial in an inner-city hospital in

Kabul, of 453 children aged 1-36 months, diagnosed with non-severe or

severe pneumonia at the outpatient clinic. Children with rickets,

other concurrent severe diseases, very severe pneumonia or wheeze,

were excluded. Children were given </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

or placebo drops additional to routine pneumonia treatment.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Two hundred and

twenty-four children received </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3;)

and 229 received placebo. There was no significant difference in the

mean number of days to recovery between the </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) (4.74 days; SD 2.22) and placebo arms (4.98

days; SD 2.89; P = 0.17). The risk of a repeat episode of pneumonia

within 90 days of supplementation was lower in the intervention

(92/204; 45%) than the placebo group [122/211; (58%; relative risk

0.78; 95% CI 0.64, 0.94; P = 0.01]. Children in the </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) group survived longer without experiencing a

repeat episode (72 days vs. 59 days; HR 0.71; 95% CI 0.53-0.95; P =

0.02).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A single high-dose oral

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) supplementation

to young children along with antibiotic treatment for pneumonia could

reduce the occurrence of repeat episodes of pneumonia.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Pittas%2C%20%20Chung"><FONT SIZE=2>Ann

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> 2010 Mar

2;152(5):307-14.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Systematic

review: Vitamin D and cardiometabolic outcomes.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2><SPAN LANG="de-DE">Pittas</SPAN></FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2><SPAN LANG="de-DE">

AG</SPAN></FONT></U></FONT></A><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Chung

M</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Trikalinos

T</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Mitri

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Brendel

M</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Patel

K</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Lichtenstein

AH</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Lau

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Balk

EM</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Tufts Medical Center and

Friedman School of Nutrition Science and Policy, and Jean Mayer USDA

Human Nutrition Research Center on Aging, Tufts University, Boston,

Massachusetts 02111, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D may modify risk

for cardiometabolic outcomes (type 2 diabetes, hypertension, or

cardiovascular disease).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PURPOSE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To examine the association

between vitamin D status, including the effect of vitamin D

supplementation, and cardiometabolic outcomes in generally healthy

adults.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SOURCES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>English-language studies

in MEDLINE (inception to 4 November 2009) and the Cochrane Central

Register of Controlled Trials (fourth quarter of 2009).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>STUDY

SELECTION: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>11 reviewers screened

citations to identify longitudinal cohort studies that reported

associations between vitamin D status and cardiometabolic outcomes,

including randomized trials of vitamin D supplementation.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

EXTRACTION: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>5 independent reviewers

extracted data about study conduct, participant characteristics,

outcomes, and quality. Differences were resolved by consensus.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SYNTHESIS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>13 observational studies

(14 cohorts) and 18 trials were eligible. Three of 6 analyses (from 4

different cohorts) reported a lower incident diabetes risk in the

highest versus the lowest vitamin D status groups. Eight trials found

no effect of vitamin D supplementation on glycemia or incident

diabetes. In meta-analysis of 3 cohorts, lower 25-hydroxyvitamin D

concentration was associated with incident hypertension (relative

risk, 1.8 [95% CI, 1.3 to 2.4]). In meta-analyses of 10 trials,

supplementation nonsignificantly reduced systolic blood pressure

(weighted mean difference, -1.9 mm Hg [CI, -4.2 to 0.4 mm Hg]) and

did not affect diastolic blood pressure (weighted mean difference,

-0.1 mm Hg [CI, -0.7 to 0.5 mm Hg]). Lower 25-hydroxyvitamin D

concentration was associated with incident cardiovascular disease in

5 of 7 analyses (6 cohorts). Four trials found no effect of

supplementation on cardiovascular outcomes.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>LIMITATIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Studies included primarily

white participants. Observational studies were heterogeneous. Several

trials reported post hoc analyses.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The association between

vitamin D status and cardiometabolic outcomes is uncertain. Trials

showed no clinically significant effect of vitamin D supplementation

at the dosages given.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PRIMARY

FUNDING SOURCE: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>National Institute of

Diabetes and Digestive and Kidney Disease, the National Institutes of

Health Office of Dietary Supplements, U.S. Food and Drug

Administration, Agency for Healthcare Research and Quality, and

Public Health Agency of Canada.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Bischoff-Ferrari%20HA%2C%20Willett%20WC%2C%20Wong%20JB%2C%20Stuck%20"><FONT SIZE=2>Arch

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> 2009 Mar

23;169(6):551-61.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Prevention

of nonvertebral fractures with oral vitamin D and dose dependency: a

meta-analysis of randomized controlled trials.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bischoff-Ferrari

HA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Willett

WC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wong

JB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stuck

AE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Staehelin

HB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Orav

EJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Thoma

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kiel

DP</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Henschkowski

J</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Centre on Aging and

Mobility, University of Zurich, University Hospital, Switzerland.

heike.bischoff@usz.ch</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Antifracture efficacy with

supplemental vitamin D has been questioned by recent trials.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We performed a

meta-analysis on the efficacy of oral supplemental vitamin D in

preventing nonvertebral and hip fractures among older individuals (&gt;

or =65 years). We included 12 double-blind randomized controlled

trials (RCTs) for nonvertebral fractures (n = 42 279) and 8 RCTs for

hip fractures (n = 40 886) comparing oral vitamin D, with or without

calcium, with calcium or placebo. To incorporate adherence to

treatment, we multiplied the dose by the percentage of adherence to

estimate the mean received dose (dose x adherence) for each trial.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The pooled relative risk

(RR) was 0.86 (95% confidence interval [CI], 0.77-0.96) for

prevention of nonvertebral fractures and 0.91 (95% CI, 0.78-1.05) for

the prevention of hip fractures, but with significant heterogeneity

for both end points. Including all trials, antifracture efficacy

increased significantly with a higher dose and higher achieved blood

25-hydroxyvitamin D levels for both end points. Consistently, pooling

trials with a higher received dose of more than 400 IU/d resolved

heterogeneity. For the higher dose, the pooled RR was 0.80 (95% CI,

0.72-0.89; n = 33 265 subjects from 9 trials) for nonvertebral

fractures and 0.82 (95% CI, 0.69-0.97; n = 31 872 subjects from 5

trials) for hip fractures. The higher dose reduced nonvertebral

fractures in community-dwelling individuals (-29%) and

institutionalized older individuals (-15%), and its effect was

independent of additional calcium supplementation.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Nonvertebral fracture

prevention with vitamin D is dose dependent, and a higher dose should

reduce fractures by at least 20% for individuals aged 65 years or

older</FONT>.</P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21177785"><FONT SIZE=2><SPAN LANG="de-DE">J

Clin Endocrinol Metab.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

2011 Mar;96(3):E447-52. </SPAN></FONT><FONT SIZE=2>Epub 2010 Dec 22.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin</FONT><FONT SIZE=2>

D(3) is more potent than </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D(2) in humans.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Heaney</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

RP</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Recker

RR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Grote

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Horst

RL</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Armas

LA</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Creighton University, 601

North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA.

rheaney@creighton.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Current unitage for the

calciferols suggests that equimolar quantities of vitamins D(2) (</FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>)

and D(3) (D3) are biologically equivalent. Published studies yield

mixed results.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The aim of the study was

to compare the potencies of </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>

and D3.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The trial used a

single-blind, randomized design in 33 healthy adults. Calciferols

were dosed at 50,000 IU/wk for 12 wk. Principal outcome variables

were area under the curve for incremental total 25-hydroxyvitamin D

[25(OH)D] and change in calciferol content of sc fat.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Incremental mean (sd)

25(OH)D area under the curve at 12 wk was 1366 ng &middot; d/ml (516)

for the </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>-treated group and

2136 (606) for the D3 (P &lt; 0.001). Mean (sd) steady-state 25(OH)D

increments showed similar differences: 24 ng/ml for </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>

(10.3) and 45 ng/ml (16.2) for D3 (P &lt;0.001). Subcutaneous fat

content of </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2> rose by 50

&mu;g/kg in the </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>-treated

group, and D3 content rose by 104 &mu;g/kg in the D3-treated group.

Total calciferol in fat rose by only 33 ng/kg in the </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>-treated,

whereas it rose by 104 &mu;g/kg in the D3-treated group.

Extrapolating to total body fat D3, storage amounted to just 17% of

the administered dose.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>D3 is approximately 87%

more potent in raising and maintaining serum 25(OH)D concentrations

and produces 2- to 3-fold greater storage of </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D than does equimolar </FONT><FONT SIZE=2>D2</FONT><FONT SIZE=2>. For

neither was there evidence of sequestration in fat, as had been

postulated for doses in this range. Given its greater potency and

lower cost, D3 should be the preferred treatment option when

correcting </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2> D

deficiency.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Houghton%202006%20vitamin%20d2"><FONT SIZE=2>Am

J Clin Nutr.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2006</FONT><FONT SIZE=2>

Oct;84(4):694-7.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>The

case against ergocalciferol (</FONT><FONT SIZE=2>vitamin D2</FONT><FONT SIZE=2>)

as a </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2> supplement.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Houghton</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

LA</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Vieth

R</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>School of Nutrition and

Dietetics, Acadia University, Wolfville, Canada.

lisa.</FONT><FONT SIZE=2>houghton</FONT><FONT SIZE=2>@acadiau.ca</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Supplemental </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D is available in 2 distinct forms: ergocalciferol (</FONT><FONT SIZE=2>vitamin

D2</FONT><FONT SIZE=2>) and cholecalciferol (</FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D3). Pharmacopoeias have officially regarded these 2 forms as

equivalent and interchangeable, yet this presumption of equivalence

is based on studies of rickets prevention in infants conducted 70 y

ago. The emergence of 25-hydroxyvitamin D as a measure of </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D status provides an objective, quantitative measure of the

biological response to </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D administration. As a result, </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D3 has proven to be the more potent form of </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D in all primate species, including humans. Despite an emerging body

of evidence suggesting several plausible explanations for the greater

bioefficacy of </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2> D3,

the form of </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2> D used in

major preparations of prescriptions in North America is </FONT><FONT SIZE=2>vitamin

D2</FONT><FONT SIZE=2>. The case that </FONT><FONT SIZE=2>vitamin D2</FONT><FONT SIZE=2>

should no longer be considered equivalent to </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D3 is based on differences in their efficacy at raising serum

25-hydroxyvitamin D, diminished binding of </FONT><FONT SIZE=2>vitamin

D2</FONT><FONT SIZE=2> metabolites to </FONT><FONT SIZE=2>vitamin</FONT><FONT SIZE=2>

D binding protein in plasma, and a nonphysiologic metabolism and

shorter shelf life of </FONT><FONT SIZE=2>vitamin D2</FONT><FONT SIZE=2>.

</FONT><FONT SIZE=2>Vitamin D2</FONT><FONT SIZE=2>, or

ergocalciferol, should not be regarded as a nutrient suitable for

supplementation or fortification.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20130093"><FONT SIZE=2><SPAN LANG="de-DE">Am

J Clin Nutr.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

2010 Apr;91(4):985-91. </SPAN></FONT><FONT SIZE=2>Epub 2010 Feb 3.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Once-weekly

dose of 8400 IU vitamin D(3) compared with placebo: effects on

neuromuscular function and tolerability in older adults with vitamin

D insufficiency.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Lips

P</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Binkley

N</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Pfeifer

M</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Recker

R</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Samanta

S</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Cohn

DA</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Chandler

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Rosenberg

E</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Papanicolaou

DA</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Endocrinology, Vrije Universiteit Medisch Centrum, Amsterdam, The

Netherlands. p.lips@vumc.nl</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D insufficiency,

which is prevalent in older individuals, is associated with bone and

muscle weakness and falls.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We examined the effects of

a weekly dose of 8400 IU vitamin D(3) on postural stability, muscle

strength, and safety.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In this double-blind

trial, subjects aged &gt; or =70 y with serum 25-hydroxyvitamin D

[25(OH)D] concentrations &lt; or =20 but &gt; or =6 ng/mL were

randomly assigned to receive a weekly dose of 8400 IU vitamin D(3) (n

= 114) or a placebo (n = 112). Mediolateral body sway with eyes open

(assessed with the AccuSway(PLUS) platform; Advanced Medical

Technology Inc, Watertown, MA) was the primary endpoint. Secondary

endpoints included the short physical performance battery (SPPB) and

serum 25(OH)D concentrations. An analysis of covariance model was

used for treatment comparisons. Safety and tolerability were

monitored.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Serum 25(OH)D

concentrations rose significantly (from 13.9 to 26.2 ng/mL, P &lt;

0.001) in patients treated with 8400 IU vitamin D(3) but not in

patients treated with the placebo. After 16 wk, neither mediolateral

sway nor SPPB differed significantly between treatment groups.

However, in the post hoc analysis of patients subgrouped by baseline

sway (&gt; or = 0.46 compared with &lt;0.46 cm), treatment with 8400

IU vitamin D(3) significantly reduced sway compared with treatment

with placebo (P = 0.047) in patients with elevated baseline sway but

not in patients with normal baseline sway. Adverse experiences and

incidences of hypercalcemia, hypercalciuria, and elevated creatinine

were similar with both treatments. In patients treated with 8400 IU

vitamin D(3), but not in placebo-treated patients, parathyroid

hormone decreased significantly.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Weekly treatment with 8400

IU vitamin D(3) raised 25(OH)D concentrations in elderly, vitamin

D-insufficient individuals. Treatment with 8400 IU vitamin D(3) did

not reduce mediolateral sway significantly compared with treatment

with placebo in this population, although in post hoc analysis,

treatment with 8400 IU vitamin D(3) reduced sway in the subgroup of

patients who had elevated sway at baseline. Weekly treatment with

8400 IU vitamin D(3) was well tolerated. This trial was registered at

clinicaltrials.gov as NCT00242476.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20648661"><FONT SIZE=2>J

Bone Miner Res.</FONT></A></U></FONT><FONT SIZE=2> 2011

Jan;26(1):42-9.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>The

effects of whole-body vibration training and vitamin D

supplementation on muscle strength, muscle mass, and bone density in

institutionalized elderly women: a 6-month randomized, controlled

trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Verschueren

SM</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Bogaerts

A</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Delecluse

C</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Claessens

AL</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Haentjens

P</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Vanderschueren

D</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Boonen

S</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of

Musculoskeletal Rehabilitation, Department of Rehabilitation Sciences

and, Faculty of Kinesiology and Rehabilitation Sciences, Katholieke

Universiteit Leuven, Leuven, Belgium.

sabine.verschueren@faber.kuleuven.be</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Sarcopenia and

osteoporosis represent a growing public health problem. We studied

the potential benefit of whole-body vibration (WBV) training given a

conventional or a high dose of daily vitamin D supplementation in

improving strength, muscle mass, and bone density in postmenopausal

women. In a 2 &times; 2 factorial-design trial, 113 institutionalized

elderly females aged over 70 years (mean age 79.6 years) were

randomly assigned either to a WBV or a no-training group, receiving

either a conventional dose (880 IU/day) or a high dose (1600 IU/day)

of vitamin D(3). The primary aim was to determine the effects of 6

months of WBV and/or vitamin D supplementation on isometric and

dynamic strength, leg muscle mass, and hip bone mineral density

(BMD). Additionally, the increase in 25-hydroxyvitamin D [25(OH)D]

levels between conventional and high-dose supplementation was

compared. After 6 months of treatment, dynamic muscle strength, hip

BMD, and vitamin D serum levels improved significantly in all groups,

whereas isometric strength and muscle mass did not change. When

compared with no training, the WBV program did not result in

additional improvements. When compared with 880 IU, a high dose of

1600 IU of vitamin D did result in higher serum vitamin D levels but

did not result in additional improvements. In institutionalized women

older than 70 years, the WBV training protocol tested is not more

efficient in enhancing muscle mass, strength, and hip BMD compared

with vitamin D supplementation. A higher dose of 1600 IU of vitamin D

does not provide additional musculoskeletal benefit in this

population compared with conventional doses.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19729890"><FONT SIZE=2>Ann

Nutr Metab.</FONT></A></U></FONT><FONT SIZE=2> 2009;54(4):291-300.

Epub 2009 Aug 31.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Treatment

of vitamin D deficiency increases lower limb muscle strength in

institutionalized older people independently of regular physical

activity: a randomized double-blind controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Moreira-Pfrimer

LD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pedrosa

MA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Teixeira

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lazaretti-Castro

M</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of Endocrinology,

School of Medicine, Federal University of S&atilde;o Paulo/UNIFESP,

S&atilde;o Paulo, Brazil. lindapfrimer@hotmail.com</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>AIMS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To investigate the effects

of a 6-month supplementation with calcium and cholecalciferol on

biochemical parameters and muscle strength of institutionalized

elderly.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This prospective,

double-blind, placebo-controlled, randomized trial included Brazilian

institutionalized people &gt; or =60 years of age receiving a 6-month

supplementation (December to May) of daily calcium plus monthly

placebo (calcium/placebo group) or daily calcium plus oral

cholecalciferol (150,000 IU once a month during the first 2 months,

followed by 90,000 IU once a month for the last 4 months;

calcium/vitamin D group). Fasting blood samples for 25(OH)D, PTH and

calcium determination were collected (n = 56) and muscle tests were

performed (n = 46) to measure the strength of hip flexors (SHF) and

knee extensors (SKE) before (baseline) and after the 6-month

intervention (6 months).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Due to seasonal

variations, serum 25(OH)D significantly enhanced in both groups after

treatment, but the calcium/vitamin D group had significantly higher

25 (OH)D levels than the calcium/placebo group (84 vs. 33%,

respectively; p &lt; 0.0001). No cases of hypercalcemia were

observed. While the calcium/placebo group showed no improvement in

SHF and SKE at 6 months (p = 0.93 and p = 0.61, respectively), SHF

was increased in the calcium/vitamin D group by 16.4% (p = 0.0001)

and SKE by 24.6% (p = 0.0007).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The suggested

cholecalciferol supplementation was safe and efficient in enhancing

25(OH)D levels and lower limb muscle strength in the elderly, in the

absence of any regular physical exercise practice.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/16797903"><FONT SIZE=2>Exp

Gerontol.</FONT></A></U></FONT><FONT SIZE=2> 2006 Aug;41(8):746-52.

Epub 2006 Jun 22.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

and exercise training on physical performance in Chilean </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> deficient elderly subjects.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Bunout</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

D</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Barrera

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Leiva

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gattas

V</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>de

la Maza MP</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Avenda&ntilde;o

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hirsch

S</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>INTA, University of Chile,

Santiago, Chile. dbunout@inta.cl</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The aim was to assess the

effects of resistance training and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation on physical performance of healthy elderly subjects.

Ninety-six subjects, aged 70 years or more with 25 OH </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> levels of 16 ng/ml or less, were randomized to

a resistance training or control group. Trained and control groups

were further randomized to receive in a double blind fashion, </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> 400 IU plus 800 mg of calcium per day or

calcium alone. Subjects were followed for nine months. Serum 25 OH

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> increased from

12.4+/-2.2 to 25.8+/-6.5 ng/ml among subjects supplemented with

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>. Trained subjects

had significant improvements in quadriceps muscle strength, the short

physical performance test and timed up and go. The latter improved

more in trained subjects supplemented with </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>. At the end of the follow up, gait speed was

higher among subjects supplemented with vitamin (whether trained or

not) than in non-supplemented subjects (838+/-147 and 768+/-127 m/12

min, respectively, p=0.02). Romberg ratio was lower among

supplemented controls than non-supplemented trained subjects

(128+/-40% and 144+/-37%, respectively, p=0.05). In conclusion,

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

improved gait speed and body sway, and training improved muscle

strength.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19258546"><FONT SIZE=2>Cancer

Prev Res (Phila).</FONT></A></U></FONT><FONT SIZE=2> 2009

Mar;2(3):213-23. Epub 2009 Mar 3.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of vitamin D and calcium supplementation on markers of apoptosis in

normal colon mucosa: a randomized, double-blind, placebo-controlled

clinical trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Fedirko</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

V</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bostick

RM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Flanders

WD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Long

Q</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Shaukat

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rutherford

RE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Daniel

CR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Cohen

V</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dash

C</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Epidemiology, Rollins School of Public Health, Emory University,

Atlanta, Georgia 30322, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To further clarify and/or

develop calcium and vitamin D as chemopreventive agents against

colorectal cancer in humans, understand the mechanisms by which these

agents reduce risk for the disease, and develop &quot;treatable&quot;

biomarkers of risk for colorectal cancer, we conducted a pilot,

randomized, double-blind, placebo-controlled, 2 x 2 factorial

clinical trial to test the effects of calcium and vitamin D3, alone

and in combination on markers of apoptosis, in the normal colorectal

mucosa. Ninety-two men and women with at least one

pathology-confirmed colorectal adenoma were treated with 2.0 g/d

calcium or 800 IU/d vitamin D3, alone or in combination, versus

placebo over 6 months. Overall expression and colorectal crypt

distributions of Bcl-2 (an apoptosis inhibitor) and Bax (an apoptosis

promoter) in biopsies of normal-appearing rectal mucosa were detected

by automated immunohistochemistry and quantified by image analysis.

After 6 months of treatment, Bax expression along the full lengths of

crypts increased 56% (P = 0.02) in the vitamin D group and 33% in

both the calcium (P = 0.31) and calcium plus vitamin D (P = 0.36)

groups relative to the placebo group. The vitamin D treatment effect

was more pronounced in the upper 40%, or differentiation zone, of

crypts (80%; P = 0.01). There were no statistically significant

treatment effects on Bcl-2 expression. Overall, these preliminary

results suggest that calcium and vitamin D, individually or together,

may enhance apoptosis in the normal human colorectal epithelium, and

the strongest treatment effects may be vitamin D related and in the

upper sections of the colorectal crypts.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19861511"><FONT SIZE=2>Cancer

Epidemiol Biomarkers Prev.</FONT></A></U></FONT><FONT SIZE=2> 2009

Nov;18(11):2933-41. Epub 2009 Oct 27.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of vitamin d and calcium on proliferation and differentiation in

normal colon mucosa: a randomized clinical trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Fedirko</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

V</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bostick

RM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Flanders

WD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Long

Q</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Sidelnikov

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Shaukat

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Daniel

CR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rutherford

RE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Woodard

JJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Epidemiology, Rollins School of Public Health, Winship Cancer

Institute, Emory University, Atlanta, Georgia, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To investigate the

potential efficacy of calcium and vitamin D in reducing risk for

colorectal neoplasms and to develop &quot;treatable&quot; phenotypic

biomarkers of risk for colorectal neoplasms, we conducted a pilot,

randomized, double-blind, placebo-controlled, 2 x 2 factorial

clinical trial to test the effects of these agents on cell cycle

markers in the normal colorectal mucosa. Ninety-two men and women

with at least one pathology-confirmed colorectal adenoma were treated

with 2 g/day calcium and/or 800 IU/day vitamin D(3) versus placebo

over 6 months. Overall expression and distributions of p21(waf1/cip1)

(marker of differentiation), MIB-1 (marker of short-term

proliferation), and hTERT (marker of long-term proliferation) in

colorectal crypts in the normal-appearing rectal mucosa were detected

by automated immunohistochemistry and quantified by image analysis.

In the calcium, vitamin D, and calcium plus vitamin D groups relative

to the placebo, p21 expression increased by 201% (P = 0.03), 242% (P

= 0.005), and 25% (P = 0.47), respectively, along the full lengths of

colorectal crypts after 6 months of treatment. There were no

statistically significant changes in the expression of either MIB-1

or hTERT in the crypts overall; however, the proportion of hTERT, but

not MIB-1, expression that extended into the upper 40% of the crypts

was reduced by 15% (P = 0.02) in the vitamin D plus calcium group

relative to the placebo. These results indicate that calcium and

vitamin D promote colorectal epithelial cell differentiation and may

&quot;normalize&quot; the colorectal crypt proliferative zone in

sporadic adenoma patients, and support further investigation of

calcium and vitamin D as chemopreventive agents against colorectal

neoplasms.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20056649"><FONT SIZE=2>Cancer

Epidemiol Biomarkers Prev.</FONT></A></U></FONT><FONT SIZE=2> 2010

Jan;19(1):280-91.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of supplemental vitamin D and calcium on oxidative DNA damage marker

in normal colorectal mucosa: a randomized clinical trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Fedirko</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

V</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bostick

RM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Long

Q</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Flanders

WD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McCullough

ML</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Sidelnikov

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Daniel

CR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rutherford

RE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Shaukat

A</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Epidemiology, Rollins School of Public Health, Emory University,

Atlanta, GA 30322, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The exact antineoplastic

effects of calcium and vitamin D(3) in the human colon are unclear.

Animal and in vitro studies show that these two agents reduce

oxidative stress; however, these findings have never been

investigated in humans. To address this, we conducted a pilot,

randomized, double-blind, placebo-controlled, 2 x 2 factorial

clinical trial to test the effects of calcium and vitamin D(3) on a

marker of oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine

(8-OH-dG), in the normal colorectal mucosa. Patients (N = 92) with at

least one pathology-confirmed colorectal adenoma were treated with 2

g/d calcium and/or 800 IU/d vitamin D(3) versus placebo over 6

months. Overall labeling and colorectal crypt distribution of 8-OH-dG

in biopsies of normal-appearing rectal mucosa were detected by

standardized automated immunohistochemistry and quantified by image

analysis. After 6 months of treatment, 8-OH-dG labeling along the

full lengths of colorectal crypts decreased by 22% (P = 0.15) and 25%

(P = 0.10) in the calcium and vitamin D(3) groups, respectively, but

not in the calcium plus vitamin D(3) group. The estimated treatment

effects were strongest among participants with higher baseline colon

crypt vitamin D receptor expression (P = 0.05). Overall, these

preliminary results indicate that calcium and vitamin D(3) may

decrease oxidative DNA damage in the normal human colorectal mucosa,

support the hypothesis that 8-OH-dG labeling in colorectal crypts is

a treatable oxidative DNA damage biomarker of risk for colorectal

neoplasms, and provide support for further investigation of calcium

and vitamin D(3) as chemopreventive agents against colorectal

neoplasms.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21084270"><FONT SIZE=2>Cancer

Res.</FONT></A></U></FONT><FONT SIZE=2> 2011 Jan 15;71(2):413-23.

Epub 2010 Nov 17.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

randomized clinical trial of the effects of supplemental calcium and

vitamin D3 on markers of their metabolism in normal mucosa of

colorectal adenoma patients.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ahearn

TU</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McCullough

ML</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Flanders

WD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Long

Q</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Sidelnikov

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Fedirko

V</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Daniel

CR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rutherford

RE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Shaukat

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bostick

RM</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Nutrition and Health

Sciences Program, Graduate Division of Biological and Biomedical

Sciences, Winship Cancer Institute, Emory University, Department of

Epidemiology, Rollins School of Public Health, Atlanta, Georgia

30322, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In cancer cell lines and

rodent models, calcium and vitamin D favorably modulate cell

proliferation, differentiation, and apoptosis in colonic epithelia.

These effects may be modulated by local expression of the calcium

receptor (CaR), the vitamin D receptor (VDR), and the P450

cytochromes, CYP27B1 and CYP24A1; however, they have yet to be

investigated in humans. To address this gap, we conducted a

randomized, double-blinded, placebo-controlled 2&times;2 factorial

clinical trial. Patients with at least one pathology-confirmed

colorectal adenoma were treated with 2 g/d elemental calcium and/or

800 IU/d vitamin D3 versus placebo over 6 months (n=92; 23 per

group). CaR, VDR, CYP27B1, and CYP24A1 expression and distribution in

biopsies of normal appearing rectal mucosa were detected by

standardized, automated immunohistochemistry and quantified by image

analysis. In the calcium-supplemented group, CaR expression increased

27% (P=0.03) and CYP24A1 expression decreased 21% (P=0.79). In the

vitamin D3-supplemented group, CaR expression increased 39% (P=0.01)

and CYP27B1 expression increased 159% (P=0.06). In patients

supplemented with both calcium and vitamin D3, VDR expression

increased 19% (P=0.13) and CaR expression increased 24% (P=0.05).

These results provide mechanistic support for further investigation

of calcium and vitamin D3 as chemopreventive agents against

colorectal neoplasms, and CaR, VDR, CYP27B1, and CYP24A1 as

modifiable, preneoplastic risk biomarkers for colorectal neoplasms.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/22025459"><FONT SIZE=2>Neurology.</FONT></A></U></FONT><FONT SIZE=2>

2011 Oct 25;77(17):1611-8.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

randomized trial of high-dose vitamin D2 in relapsing-remitting

</FONT><FONT SIZE=2>multiple sclerosis</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stein

MS</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Liu

Y</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gray

OM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Baker

JE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kolbe

SC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ditchfield

MR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Egan

GF</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mitchell

PJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Harrison

LC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Butzkueven

H</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kilpatrick

TJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Endocrinology, Royal Melbourne Hospital, Parkville, Victoria,

Australia. Mark.Stein@mh.org.au</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Higher latitude, lower

ultraviolet exposure, and lower serum 25-hydroxyvitamin D (25OHD)

correlate with higher </FONT><FONT SIZE=2>multiple sclerosis</FONT><FONT SIZE=2>

(MS) prevalence, relapse rate, and mortality. We therefore evaluated

the effects of high-dose vitamin D2 (D2) in MS.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Adults with clinically

active relapsing-remitting MS (RRMS) were randomized to 6 months'

double-blind placebo-controlled high-dose vitamin D2, 6,000 IU

capsules, dose adjusted empirically aiming for a serum 25OHD 130-175

nM. All received daily low-dose (1,000 IU) D2 to prevent deficiency.

Brain MRIs were performed at baseline, 4, 5, and 6 months. Primary

endpoints were the cumulative number of new gadolinium-enhancing

lesions and change in the total volume of T2 lesions. Secondary

endpoints were Expanded Disability Status Scale (EDSS) score and

relapses.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Twenty-three people were

randomized, of whom 19 were on established interferon or glatiramer

acetate (Copaxone) treatment. Median 25OHD rose from 54 to 69 nM

(low-dose D2) vs 59 to 120 nM (high-dose D2) (p = 0.002). No

significant treatment differences were detected in the primary MRI

endpoints. Exit EDSS, after adjustment for entry EDSS, was higher

following high-dose D2 than following low-dose D2 (p = 0.05). There

were 4 relapses with high-dose D2 vs none with low-dose D2 (p =

0.04).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We did not find a

therapeutic advantage in RRMS for high-dose D2 over low-dose D2

</FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2>.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CLASSIFICATION

OF EVIDENCE: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This study provides Class

I evidence that high-dose vitamin D2 (targeting 25OHD 130-175 nM),

compared to low-dose </FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2>

(1,000 IU/d), was not effective in reducing MRI lesions in patients

with RRMS.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21724580"><FONT SIZE=2>Cancer

Prev Res (Phila).</FONT></A></U></FONT><FONT SIZE=2> 2011

Oct;4(10):1645-54. Epub 2011 Jun 30.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of supplemental vitamin D and calcium on biomarkers of inflammation

in colorectal adenoma patients: a randomized, controlled clinical

trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hopkins

MH</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Owen

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ahearn

T</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Fedirko

V</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Flanders

WD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Jones

DP</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bostick

RM</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Epidemiology, Rollins School of Public Health, Emory University,

Atlanta, GA 30322, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D and calcium

affect several pathways involved in inflammation, tumor growth, and

immune surveillance relevant to carcinogenesis. Also, epidemiologic

evidence indicates that calcium and vitamin D may reduce risk for

developing colorectal adenomas and cancer. To investigate the effects

of calcium and vitamin D on biomarkers of inflammation in colorectal

adenoma patients, we conducted a pilot, randomized, double-blind,

placebo-controlled, 2 &times; 2 factorial clinical trial (n = 92) of

2 g/d calcium and/or 800 IU/d vitamin D(3) supplementation versus

placebo over 6 months. Plasma concentrations of proinflammatory

markers [C-reactive protein (CRP), TNF-&alpha;, interleukin (IL)-6,

IL-1&beta;, and IL-8] and an anti-inflammatory marker (IL-10) were

measured using ELISAs. After 6 months of treatment, in the vitamin

D(3) supplementation group, CRP decreased 32% overall (P = 0.11), 37%

in men (P = 0.05), and 41% among non-nonsteroidal anti-inflammatory

drug (NSAID) users (P = 0.05) relative to placebo. In the vitamin

D(3) supplementation group, TNF-&alpha; decreased 13%, IL-6 32%,

IL-1&beta; 50%, and IL-8 15%; in the calcium supplementation group,

IL-6 decreased 37%, IL-8 11%, and IL-1&beta; 27%. Although these

changes were not statistically significant, a combined inflammatory

markers z-score decreased 77% (P = 0.003) in the vitamin D(3)

treatment group overall, 83% (P = 0.01) among men, and 48% among

non-NSAID users (P = 0.01). There was no evidence of synergy between

vitamin D(3) and calcium or effects on IL-10. These preliminary

results are consistent with a pattern of reduction in tumor-promoting

inflammation biomarkers with vitamin D(3) or calcium supplementation

alone and support further investigation of vitamin D(3) as a

chemopreventive agent against inflammation and colorectal neoplasms.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Nagpal%2C%20%20Pande%20vitamin%20d"><FONT SIZE=2>Diabet

Med.</FONT></A></U></FONT><FONT SIZE=2> 2009 Jan;26(1):19-27.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

double-blind, randomized, placebo-controlled trial of the short-term

effect of vitamin D3 supplementation on insulin sensitivity in

apparently healthy, middle-aged, centrally obese men.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Nagpal</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

J</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pande

JN</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bhartia

A</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Sitaram Bhartia Institute

of Science and Research, New Delhi, India.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>AIM:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To determine the

short-term effect of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

supplementation on insulin sensitivity in apparently healthy,

middle-aged, centrally obese men.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SUBJECTS

AND METHODS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A double-blind randomized

controlled trial was conducted at a tertiary care facility in which

100 male volunteers aged &gt; or = 35 years received three doses of

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) (120,000 IU

each; supplemented group) fortnightly or placebo (control group).

Hepatic fasting insulin sensitivity [homeostasis model assessment

(HOMA), quantitative insulin-sensitivity check index, HOMA-2],

postprandial insulin sensitivity [oral glucose insulin sensitivity

(OGIS)], insulin secretion (HOMA%B, HOMA2-%B), lipid profile and

blood pressure were measured at baseline and at 6 weeks' follow-up.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Seventy-one of the

recruited subjects completed the study (35 in supplemented group, 36

in control group). There was an increase in OGIS with supplementation

by per protocol analysis (P = 0.038; intention-to-treat analysis P =

0.055). The age- and baseline 25-hydroxyvitamin D level-adjusted

difference in change in OGIS was highly significant (mean difference

41.1 +/- 15.5; P = 0.01). No changes in secondary outcome measures

(insulin secretion, basal indices of insulin sensitivity, blood

pressure or lipid profile) were found with supplementation.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The trial indicates that

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) supplementation

improves postprandial insulin sensitivity (OGIS) in apparently

healthy men likely to have insulin resistance (centrally obese but

non-diabetic).</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19491064"><FONT SIZE=2>Endocr

Pract.</FONT></A></U></FONT><FONT SIZE=2> 2009 Jul-Aug;15(5):438-49.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D for treatment and prevention of infectious diseases: a systematic

review of randomized controlled trials.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Yamshchikov</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

AV</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Desai

NS</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Blumberg

HM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ziegler

TR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Tangpricha

V</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of Infectious

Diseases, Department of Medicine, Emory University School of

Medicine, Atlanta, Georgia 30030, USA. AYAMSHC@emory.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To review the existing

human controlled intervention studies of vitamin D as adjunctive

therapy in settings of infection and provide recommendations for

design and implementation of future studies in this field on the

basis of the evidence reviewed.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We conducted a systematic

review of randomized controlled clinical trials that studied vitamin

D for treatment or prevention of infectious diseases in humans.

Studies from 1948 through 2009 were identified through search terms

in PubMed and Ovid MEDLINE.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Thirteen published

controlled trials were identified by our search criteria. Ten trials

were placebo controlled, and 9 of the 10 were conducted in a rigorous

double-blind design. The selected clinical trials demonstrated

substantial heterogeneity in baseline patient demographics, sample

size, and vitamin D intervention strategies. Serious adverse events

attributable to vitamin D supplementation were rare across all

studies. On the basis of studies reviewed to date, the strongest

evidence supports further research into adjunctive vitamin D therapy

for tuberculosis, influenza, and viral upper respiratory tract

illnesses. In the selected studies, certain aspects of study design

are highlighted to help guide future clinical research in the field.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>More rigorously designed

clinical trials are needed for further evaluation of the relationship

between vitamin D status and the immune response to infection as well

as for delineation of necessary changes in clinical practice and

medical care of patients with vitamin D deficiency in infectious

disease settings.</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/17463418"><FONT SIZE=2>Am

J Respir Crit Care Med.</FONT></A></U></FONT><FONT SIZE=2> 2007 Jul

15;176(2):208-13. Epub 2007 Apr 26.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

single dose of vitamin D enhances immunity to mycobacteria.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Martineau</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

AR</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wilkinson

RJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wilkinson

KA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Newton

SM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kampmann

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hall

BM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Packe

GE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Davidson

RN</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Eldridge

SM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Maunsell

ZJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rainbow

SJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Berry

JL</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Griffiths

CJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Centre for Health

Sciences, Queen Mary's School of Medicine and Dentistry, Barts and

The London, and Department of Clinical Biochemistry, North West

London Hospitals NHS Trust, Northwick Park Hospital, Harrow, E1 2AT,

UK. a.</FONT><FONT SIZE=2>martineau</FONT><FONT SIZE=2>@qmul.ac.uk</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RATIONALE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D was used to

treat tuberculosis (TB) in the preantibiotic era. Prospective studies

to evaluate the effect of vitamin D supplementation on

antimycobacterial immunity have not previously been performed.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVES:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To determine the effect of

vitamin D supplementation on antimycobacterial immunity and vitamin D

status.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A double-blind randomized

controlled trial was conducted in 192 healthy adult TB contacts in

London, United Kingdom. Participants were randomized to receive a

single oral dose of 2.5 mg vitamin D or placebo and followed up at 6

weeks.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MEASUREMENTS

AND MAIN RESULTS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The primary outcome

measure was assessed with a functional whole blood assay (BCG-lux

assay), which measures the ability of whole blood to restrict

luminescence, and thus growth, of recombinant reporter mycobacteria

in vitro; the readout is expressed as a luminescence ratio

(luminescence postinfection/baseline luminescence). IFN-gamma

responses to the Mycobacterium tuberculosis antigens early secretory

antigenic target-6 and culture filtrate protein 10 were determined

with a second whole blood assay. Vitamin D supplementation

significantly enhanced the ability of participants' whole blood to

restrict BCG-lux luminescence in vitro compared with placebo (mean

luminescence ratio at follow-up, 0.57, vs. 0.71, respectively; 95%

confidence interval for difference, 0.01-0.25; p=0.03) but did not

affect antigen-stimulated IFN-gamma secretion.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A single oral dose of 2.5

mg vitamin D significantly enhanced the ability of participants'

whole blood to restrict BCG-lux luminescence in vitro without

affecting antigen-stimulated IFN-gamma responses. Clinical trials

should be performed to determine whether vitamin D supplementation

prevents reactivation of latent TB infection. Clinical trial

registered with www.clinicaltrials.gov (NCT 00157066).</FONT></P>

<P CLASS="western" STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">

<BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19185400"><FONT SIZE=2>Am

J Kidney Dis.</FONT></A></U></FONT><FONT SIZE=2> 2009

Mar;53(3):408-16. Epub 2009 Jan 29.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>The

effect of combined calcium and vitamin D3 supplementation on serum

intact parathyroid hormone in moderate CKD.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kooienga

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Fried

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Scragg

R</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kendrick

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Smits

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Chonchol

M</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of Renal Diseases

and Hypertension, University of Colorado Health Sciences Center,

Denver, CO 80262, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Studies addressing the

effects of vitamin D(3) supplementation on secondary

hyperparathyroidism in patients with moderate chronic kidney disease

are scarce.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>STUDY

DESIGN: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Post hoc analysis of the

randomized clinical trial Vitamin D, Calcium, Lyon Study II (DECALYOS

II) to assess effects according to baseline estimated glomerular

filtration rate (eGFR).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SETTING

&amp;#38; PARTICIPANTS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Multicenter, randomized,

double-blinded, placebo-controlled study of 639 elderly women

randomly assigned to calcium-vitamin D(3) fixed combination; calcium

plus vitamin D(3) separate combination, or placebo.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTERVENTIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Placebo or calcium (1,200

mg) and vitamin D(3) (800 IU) in fixed or separate combination.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OUTCOMES

&amp;#38; MEASUREMENTS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Proportion of participants

with a mean decrease in intact parathyroid hormone (iPTH) level of

30% or greater. eGFR was calculated using the 4-variable Modification

of Diet in Renal Disease (MDRD) Study equation and categorized as 60

or greater, 45 to 59, and less than 45 mL/min/1.73 m(2).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>610 participants had an

eGFR at baseline: 288 (47.2%), 222 (36.4%), and 100 (16.4%) were in

each decreasing eGFR category. Across decreasing eGFR groups, 88%,

86%, and 89% had 25-hydroxyvitamin D (25[OH]D) levels less than 15

ng/mL at baseline. On treatment, similar improvements in the

proportion of participants achieving 25(OH)D levels greater than 30

ng/mL at 6 months were seen in all kidney function groups (43%, 49%,

and 41%, respectively). Active regimens versus placebo increased mean

25(OH)D levels from baseline in all eGFR groups at all times (P &lt;

0.001 for all). The proportion with a 30% or greater decrease in iPTH

level at 6 months was 50% in all eGFR groups on treatment versus 6%

to 9% for placebo (P &lt; 0.001 for all). The effects of the

intervention on iPTH levels did not differ according to baseline eGFR

(interaction P &gt; 0.1 for all times).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>LIMITATIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This study included only

elderly white women.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D(3) was effective

in increasing 25(OH)D and decreasing iPTH levels in patients with

moderate chronic kidney disease.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19229821"><FONT SIZE=2>J

Nephrol.</FONT></A></U></FONT><FONT SIZE=2> 2009 Jan-Feb;22(1):75-82.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D insufficiency and treatment with oral vitamin D3 in

northern-dwelling patients with chronic kidney disease.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rucker

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Tonelli

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Coles

MG</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Yoo

S</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Young

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McMahon

AW</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Medicine,

Division of General Internal Medicine, University of Alberta,

University of Alberta Hospital, Edmonton, Alberta, Canada.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D insufficiency is

common in people living at northern latitudes and those with chronic

kidney disease (CKD). We studied persons with both of these risk

factors to determine the prevalence of vitamin D insufficiency and

whether serum 25-hydroxyvitamin D (25(OH)D) levels were affected by

oral vitamin D3 supplementation.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This was a prospective

controlled trial of 128 patients with stage 3-5 non-dialysis

dependent CKD. Patients were assigned to the intervention (oral

vitamin D3 1,000 IU/day) in a 1:1 ratio at the discretion of the

attending dietitian. Serum biochemical markers were measured at

baseline (May-July) and after 3 months of follow-up. There were 63

control and 65 intervention subjects.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Mean 25(OH)D levels

increased significantly higher in the treatment group (mean increase

from baseline: 10.3+/-10.4 ng/mL vs. 0.8+/-6.8 ng/mL, p&lt;0.0001).

This difference remained significant after adjustment for differing

baseline characteristics between groups (p&lt;0.0001). Treatment with

oral vitamin D3 reduced vitamin D insufficiency by 37%, as compared

with a 2% increase in prevalence among the control group (p&lt;0.0001).

Considering the entire study population, 93% of patients had levels

less than &lt;30 ng/mL at least once during the study.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D insufficiency is

highly prevalent in northern-dwelling patients with stage 3-5 CKD,

and is moderated by oral supplementation with 1,000 IU of vitamin D3

daily.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/7498100"><FONT SIZE=2><SPAN LANG="de-DE">Eur

J Clin Nutr.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

1995 Sep;49(9):640-6.</SPAN></FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effect

of winter oral vitamin D3 supplementation on cardiovascular risk

factors in elderly adults.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Scragg

R</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Khaw

KT</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Murphy

S</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical Gerontology Unit,

University of Cambridge School of Clinical Medicine, Addenbrooke's

Hospital, UK.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A possible role for

vitamin D deficiency in contributing to the winter increase in

cardiovascular disease mortality was investigated by testing the

effect of vitamin D supplementation on blood pressure and other

cardiovascular risk factors during winter.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomised double-blind

trial of vitamin D supplementation in winter.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SUBJECTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Men and women, mean age 70

years (range 63-76) recruited from general practitioner age-sex

registers in Cambridge (UK).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTERVENTION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>95 people received a

single oral dose of 2.5 mg cholecalciferol and 94 received the

placebo at baseline interviews during December 1991. Follow-up

assessment was 5 weeks later during January 1992.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Comparing follow-up with

baseline assessment, serum 25-hydroxyvitamin D increased in the

treated group and decreased slightly in the placebo group [mean

(s.d.) change: 7.2 (+/- 3.8) vs -1.4 (+/- 1.1) ng/ml, P = 0.0001];

while parathyroid hormone decreased in the treated, and increased in

the placebo, group [-0.27 (+/- 0.78) vs 0.13 (+/- 0.75) pmol/l, P =

0.0004]. However, the mean change in blood pressure was similar in

both groups: systolic -5 (+/- 13) vs -5 (+/- 16) mmHg, P = 0.81;

diastolic -1 (+/- 9) vs -1 (+/- 9), P = 0.92; as was the mean change

in serum cholesterol [-0.07 (+/- 0.52) vs -0.05 (+/- 0.60) mmol/l, P

= 0.81]. In contrast, the mean change in radial pulse was

significantly decreased in the treated group compared with placebo

[-2 (+/- 9) vs 1 (+/- 7) beats per min, P = 0.030].</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The failure of vitamin D

supplementation to change blood pressure or serum cholesterol

suggests that the winter increase in these factors is not caused by

decreased vitamin D levels.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/16479024"><FONT SIZE=2>Acta

Med Indones.</FONT></A></U></FONT><FONT SIZE=2> 2006

Jan-Mar;38(1):3-5.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>The

effect of vitamin D as supplementary treatment in patients with

moderately advanced pulmonary tuberculous lesion.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Nursyam

EW</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Amin

Z</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Rumende

CM</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Departement of Internal

Medicine, Faculty of Medicine, University of Indonesia-dr.Cipto

Mangunkusumo Hospital, Jakarta.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>AIM:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>to compare the vitamin D

group of pulmonary tuberculosis patients with a placebo group in

terms of clinical improvement, nutritional status, sputum conversion,

and radiological improvement.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>sixty seven tuberculosis

patient visiting the Pulmonary Clinic, of Cipto Mangunkusumo

Hospital, Jakarta, from January 1st to August 31st, 2001 were

included in this study. The subjects were randomised to receive

vitamin D (0.25 mg/day) or placebo in a double blind method, during

the 6th initial week of Tb treatment. The rate of sputum conversion,

complete blood counts, blood chemistry as well as radiologic

examination were evaluated.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>there were more male

patients than females (39:28), 78.7% were in the productive age

group, 71.6% had low nutritional status, 62.4% with low education

level, and 67.2% with low income. One hundred percent of the vitamin

D group and only 76.7% of the placebo group had sputum conversion.

This difference is statistically significant (p=0.002).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>the sputum conversion had

no correlation with the hemoglobin level, blood clotting time,

calcium level, lymphocyte count, age, sex, and nutritional status.

There were more subjects with radiological improvement in the vitamin

D group.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19296870"><FONT SIZE=2>Epidemiol

Infect.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2009</FONT><FONT SIZE=2>

Oct;137(10):1396-404. Epub </FONT><FONT SIZE=2>2009</FONT><FONT SIZE=2>

Mar 19.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

randomized controlled trial of vitamin D3 supplementation for the

prevention of symptomatic upper respiratory tract infections.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Li-Ng</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

M</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Aloia

JF</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pollack

S</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Cunha

BA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mikhail

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Yeh

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Berbari

N</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Bone Mineral Research

Center, Winthrop University Hospital, Mineola, NY, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D has been shown

to be an important immune system regulator. Vitamin D insufficiency

during winter may cause increased susceptibility to upper respiratory

tract infections (URIs). To determine whether vitamin D

supplementation during the winter season prevents or decreases URI

symptoms, 162 adults were randomized to receive 50 microg vitamin D3

(2000 IU) daily or matching placebo for 12 weeks. A bi-weekly

questionnaire was used to record the incidence and severity of URI

symptoms. There was no difference in the incidence of URIs between

the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively,

P=0.57). There was no difference in the duration or severity of URI

symptoms between the vitamin D and placebo groups [5.4+/-4.8 days vs.

5.3+/-3.1 days, respectively, P=0.86 (95% CI for the difference in

duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at

baseline was similar in both groups (64.3+/-25.4 nmol/l in the

vitamin D group; 63.0+/-25.8 nmol/l in the placebo group; n.s.).

After 12 weeks, 25-hydroxyvitamin D levels increased significantly to

88.5+/-23.2 nmol/l in the vitamin D group, whereas there was no

change in vitamin D levels in the placebo group. There was no benefit

of vitamin D3 supplementation in decreasing the incidence or severity

of symptomatic URIs during winter. Further studies are needed to

determine the role of vitamin D in infection.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21215445"><FONT SIZE=2>Lancet.</FONT></A></U></FONT><FONT SIZE=2>

2011 Jan 15;377(9761):242-50. Epub 2011 Jan 5.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>High-dose

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) during

intensive-phase antimicrobial treatment of pulmonary tuberculosis: a

double-blind randomised controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Martineau</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

AR</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Timms

PM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bothamley

GH</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hanifa

Y</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Islam

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Claxton

AP</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Packe

GE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Moore-Gillon

JC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Darmalingam

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Davidson

RN</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Milburn

HJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Baker

LV</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Barker

RD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Woodward

NJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Venton

TR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Barnes

KE</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mullett

CJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Coussens

AK</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rutterford

CM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mein

CA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Davies

GR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wilkinson

RJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Nikolayevskyy

V</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Drobniewski

FA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Eldridge

SM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Griffiths

CJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Queen Mary University of

London, Barts and The London School of Medicine and Dentistry,

London, UK. a.</FONT><FONT SIZE=2>martineau</FONT><FONT SIZE=2>@qmul.ac.uk</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

was used to treat tuberculosis in the pre-antibiotic era, and its

metabolites induce antimycobacterial immunity in vitro. Clinical

trials investigating the effect of adjunctive </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> on sputum culture conversion are absent.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We undertook a multicentre

randomised controlled trial of adjunctive </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> in adults with sputum smear-positive pulmonary

tuberculosis in London, UK. 146 patients were allocated to receive

2&middot;5 mg </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) or

placebo at baseline and 14, 28, and 42 days after starting standard

tuberculosis treatment. The primary endpoint was time from initiation

of antimicrobial treatment to sputum culture conversion. Patients

were genotyped for TaqI and FokI polymorphisms of the </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> receptor, and interaction analyses were done to

assess the influence of the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

receptor genotype on response to </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3).

This trial is registered with ClinicalTrials.gov number NCT00419068.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>FINDINGS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>126 patients were included

in the primary efficacy analysis (62 assigned to intervention, 64

assigned to placebo). Median time to sputum culture conversion was

36&middot;0 days in the intervention group and 43&middot;5 days in

the placebo group (adjusted hazard ratio 1&middot;39, 95% CI

0&middot;90-2&middot;16; p=0.14). TaqI genotype modified the effect

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

on time to sputum culture conversion (p(interaction)=0&middot;03),

with enhanced response seen only in patients with the tt genotype

(8&middot;09, 95% CI 1&middot;36-48&middot;01; p=0&middot;02). FokI

genotype did not modify the effect of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation (p(interaction)=0&middot;85). Mean serum

25-hydroxyvitamin D concentration at 56 days was 101&middot;4 nmol/L

in the intervention group and 22&middot;8 nmol/L in the placebo group

(95% CI for difference 68&middot;6-88&middot;2; p&lt;0&middot;0001).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTERPRETATION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Administration of four

doses of 2&middot;5 mg </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

increased serum 25-hydroxyvitamin D concentrations in patients

receiving intensive-phase treatment for pulmonary tuberculosis.

</FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> did not

significantly affect time to sputum culture conversion in the whole

study population, but it did significantly hasten sputum culture

conversion in participants with the tt genotype of the TaqI </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> receptor polymorphism.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Krall%2C%20%20Wehler%202001"><FONT SIZE=2>Am

J Med.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2001</FONT><FONT SIZE=2>

Oct 15;111(6):452-6.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Calcium

and vitamin D supplements reduce tooth loss in the elderly.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Krall</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

EA</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wehler

C</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Garcia

RI</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Harris

SS</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dawson-Hughes

B</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Health

Policy and Health Services Research, Boston University Goldman School

of Dental Medicine, 715 Albany Street, Boston, MA O2118, USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PURPOSE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Oral bone and tooth loss

are correlated with bone loss at nonoral sites. Calcium and vitamin D

supplementation slow the rate of bone loss from various skeletal

sites, but it is not known if intake of these nutrients affects oral

bone and, in turn, tooth retention.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SUBJECTS

AND METHODS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Tooth loss was examined in

145 healthy subjects aged 65 years and older who completed a 3-year,

randomized, placebo-controlled trial of the effect of calcium and

vitamin D supplementation on bone loss from the hip, as well as a

2-year follow-up study after discontinuation of study supplements.

Teeth were counted at 18 months and 5 years. A comprehensive oral

examination at 5 years included assessment of caries, oral hygiene,

and periodontal disease. The odds ratio (OR) and 95% confidence

interval (CI) of tooth loss were estimated by stepwise multivariate

logistic regression. Initial age (mean +/- SD) of subjects was 71 +/-

5 years, and the number of teeth remaining was 22 +/- 7.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>During the randomized

trial, 11 of the 82 subjects (13%) taking supplements and 17 of the

63 subjects (27%) taking placebo lost one or more teeth (OR = 0.4;

95% CI: 0.2 to 0.9). During the 2-year follow-up period, 31 of the 77

subjects (40%) with total calcium intake of at least 1000 mg per day

lost one or more teeth compared with 40 of the 68 subjects (59%) who

consumed less (OR = 0.5; 95% CI: 0.2 to 0.9).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>These findings suggest

that intake levels of calcium and vitamin D aimed at preventing

osteoporosis have a beneficial effect on tooth retention.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/18579534"><FONT SIZE=2>Nephrol

Dial Transplant.</FONT></A></U></FONT><FONT SIZE=2> 2008

Nov;23(11):3670-6. Epub 2008 Jun 24.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Daily

oral 25-hydroxycholecalciferol supplementation for vitamin D

deficiency in haemodialysis patients: effects on mineral metabolism

and bone markers.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Jean

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Terrat

JC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Vanel

T</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hurot

JM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lorriaux

C</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mayor

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Chazot

C</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Centre de Rein Artificiel,

42 avenue du 8 mai 1945, 69160, Tassin la Demi-lune, France.

guillaume-jean-crat@wanadoo.fr</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D deficiency is

frequently observed in end-stage renal disease (ESRD) patients;

however, the effects of vitamin D supplementation have rarely been

reported. We aimed to assess the effects of daily 25(OH)D(3)

supplementation on mineral metabolism, bone markers and Kidney

Disease Outcomes Quality Initiative (KDOQI) targets in haemodialysis

(HD) patients for a period of 6 months.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>HD patients were included

in this study if their serum 25(OH)D level was &lt;75 mmol/L. Oral

25(OH)D(3) was administered daily at 10-30 microg/day based on the

severity of the deficiency. Characteristics of the patients were

compared from the baseline to 6 months on the basis of their response

to 25(OH)D(3) administration and the patients were divided into three

groups. Patients who showed partial response [serum 25(OH)D &lt;75

nmol/L] were placed in group 1, those who showed normal response

[serum 25(OH)D ranging from 75 to 150 nmol/L] were placed in group 2

and those who showed excessive response [serum 25(OH)D &gt;150

nmol/L] were placed in group 3.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Of the 253 HD patients,

225 (89%) showed vitamin D insufficiency or deficiency, 172 were

included in the study and 149 patients completed the study. After 6

months of treatment [mean daily 25(OH)D(3): 16 +/- 5 microg/day], the

serum 25(OH)D level increased (30 +/- 19 to 126 +/- 46 nmol/ L, P &lt;

0.001), with 13% of patients in group 1, 57% in group 2 and 30% in

group 3. The serum intact parathyroid hormone (iPTH) level decreased

(235 +/- 186 to 189 +/- 137 pg/mL, P = 0.05), except in group 1. Bone

alkaline phosphatase (BALP) showed a tendency to normalize (23 +/- 16

to 18.3 +/- 11 microg/L, P &lt; 0.05), leading to a decrease in

alfacalcidol administration from 66% to 43% (P &lt; 0.05), except in

group 1. The KDOQI targets achieved increased significantly for serum

calcium (76% to 85%) and phosphate levels (66% to 77%) in all

patients. The serum albumin level increased in all groups (34.6 +/- 4

to 36.8 +/- 4 g/L, P &lt; 0.05), without any significant improvement

in normalized protein catabolic rate (nPCR) or C-reactive proteins

(CRP).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>With a daily dose ranging

from 10 to 30 microg, daily oral 25(OH)D(3) supplementation corrects

most vitamin D deficiencies or insufficiencies in HD patients,

without any evident toxicity. The main effects observed included

correction of excessive bone turnover, despite less alfacalcidol

administration, increase in serum albumin level and increase in the

percentage of patients with serum calcium and phosphorus levels

within the recommendation of the KDOQI guidelines.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/18793245"><FONT SIZE=2>J

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> 2008

Dec;264(6):599-609. Epub 2008 Sep 10.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of vitamin D supplementation on symptoms of depression in overweight

and obese subjects: randomized double blind trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Jorde

R</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Sneve

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Figenschau

Y</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Svartberg

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Waterloo

K</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Institute of Clinical

Medicine, University of Troms&oslash;, Troms&oslash;, Norway.

rolf.jorde@unn.no</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVES:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The objective of the

present study was to examine the cross-sectional relation between

serum 25-hydroxyvitamin D [25-(OH) D] levels and depression in

overweight and obese subjects and to assess the effect of vitamin D

supplementation on depressive symptoms.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Cross-sectional study and

randomized double blind controlled trial of 20,000 or 40,000 IU

vitamin D per week versus placebo for 1 year.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SETTING:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A total of 441 subjects

(body mass index 28-47 kg m(-2), 159 men and 282 women, aged 21-70

years) recruited by advertisements or from the out-patient clinic at

the University Hospital of North Norway.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MAIN

OUTCOME MEASURES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Beck Depression Inventory

(BDI) score with subscales 1-13 and 14-21.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Subjects with serum

25(OH)D levels &lt; 40 nmol L(-1) scored significantly higher (more

depressive traits) than those with serum 25(OH)D levels &gt; or = 40

nmol L(-1) on the BDI total [6.0 (0-23) versus 4.5 (0-28) (median and

range)] and the BDI subscale 1-13 [2.0 (0-15) versus 1.0 (0-29.5)] (P

&lt; 0.05). In the two groups given vitamin D, but not in the placebo

group, there was a significant improvement in BDI scores after 1

year. There was a significant decrease in serum parathyroid hormone

in the two vitamin D groups without a concomitant increase in serum

calcium.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>It appears to be a

relation between serum levels of 25(OH)D and symptoms of depression.

Supplementation with high doses of vitamin D seems to ameliorate

these symptoms indicating a possible causal relationship.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/18795378"><FONT SIZE=2>Obes

Surg.</FONT></A></U></FONT><FONT SIZE=2> 2009 Feb;19(2):173-9. Epub

2008 Sep 16.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Finding

the optimal dose of vitamin D following Roux-en-Y gastric bypass: a

prospective, randomized pilot clinical trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Goldner

WS</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stoner

JA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lyden

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Thompson

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Taylor

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Larson

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Erickson

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McBride

C</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Section of Diabetes,

Endocrinology, and Metabolism, Department of Internal Medicine,

University of Nebraska Medical Center, Omaha, NE 68198-3020, USA.

wgoldner@unmc.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D deficiency is

common following bariatric surgery and is due to a combination of

baseline deficiency and postoperative malabsorption. There are few

prospective studies evaluating the appropriate dose of vitamin D to

prevent and treat vitamin D deficiency following bariatric surgery.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We evaluated three doses

of vitamin D3 (800, 2,000, and 5,000 IU/day) in a prospective,

randomized pilot trial of 45 patients undergoing Roux-en-Y gastric

bypass. Serum 25 hydroxy Vitamin D (25OHD), intact PTH (iPTH),

calcium, and urine calcium/creatinine ratios were measured at 6, 12,

and 24 months postoperatively. Due to a high dropout rate at 24

months, we focus on the 12-month data.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>At 12 months, the 800-,

2,000-, and 5,000-IU groups had a mean +/- SD increase in 25OHD of

27.5 +/- 40.0, 60.2 +/- 37.4, and 66.1 +/- 42.2 nmol/L, respectively

(p = 0.09) with a maximum increase in each group of 87.4, 114.8, and

129.8 nmol/L. Forty-four percent, 78%, and 70% achieved 25OHD levels

&gt;or=75 nmol/L (p = 0.38). Results for the 6- and 24-month time

points were similar to the 12-month results. Mean weight loss at 24

months of the study was not different among groups (p = 0.52). Serum

calcium did not change significantly, and there were no cases of

hypercalcemia or sustained hypercalciuria.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Higher doses of vitamin D

supplementation trend towards higher levels of 25OHD. Vitamin D

replacement as high as 5,000 IU /day is safe and necessary in many

patients to treat vitamin D deficiency following Roux-en-Y gastric

bypass yet is still suboptimal in others.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/18629569"><FONT SIZE=2>Osteoporos

Int.</FONT></A></U></FONT><FONT SIZE=2> 2009 Feb;20(2):315-22. Epub

2008 Jul 16.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of a long-term vitamin D and calcium supplementation on falls and

parameters of muscle function in community-dwelling older

individuals.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pfeifer

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Begerow

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Minne

HW</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Suppan

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Fahrleitner-Pammer

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dobnig

H</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Institute of Clinical

Osteology Gustav Pommer and Clinic Der F&uuml;rstenhof, Bad Pyrmont,

Germany. iko_pyrmont@t-online.de</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In 242 community-dwelling

seniors, supplementation with either 1000 mg of calcium or 1000 mg of

calcium plus vitamin D resulted in a decrease in the number of

subjects with first falls of 27% at month 12 and 39% at month 20.

Additionally, parameters of muscle function improved significantly.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTRODUCTION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The efficacy of vitamin D

and calcium supplementation on risk of falling in the elderly is

discussed controversially. Randomized controlled trials using falls

as primary outcome are needed. We investigated long-term effects of

calcium and vitamin D on falls and parameters of muscle function in

community-dwelling elderly women and men.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Our study population

consisted of 242 individuals recruited by advertisements and mailing

lists (mean [ +/- SD] age, 77 +/- 4 years). All serum

25-hydroxyvitamin D (25[OH]D) levels were below 78 nmol/l.

Individuals received in a double blinded fashion either 1000 mg of

calcium or 1000 mg of calcium plus 800 IU of vitamin D per day over a

treatment period of 12 months, which was followed by a treatment-free

but still blinded observation period of 8 months. Falls were

documented using diaries. The study took place in Bad Pyrmont,

Germany (latitude 52 degrees ) and Graz, Austria (latitude 46 degrees

).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Compared to calcium mono,

supplementation with calcium plus vitamin D resulted in a significant

decrease in the number of subjects with first falls of 27% at month

12 (RR = 0.73; CI = 0.54-0.96) and 39% at month 20 (RR = 0.61; CI =

0.34-0.76). Concerning secondary endpoints, we observed significant

improvements in quadriceps strength of 8%, a decrease in body sway of

28%, and a decrease in time needed to perform the TUG test of 11%.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DISCUSSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Combined calcium and

vitamin D supplementation proved superior to calcium alone in

reducing the number of falls and improving muscle function in

community-dwelling older individuals.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/17656420"><FONT SIZE=2>Age

Ageing.</FONT></A></U></FONT><FONT SIZE=2> 2007 Sep;36(5):507-13.

Epub 2007 Jul 26.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Does

vitamin D stop inpatients falling? A randomised controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Burleigh

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McColl

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Potter

J</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Medicine for

the Elderly, Mansionhouse Unit, Victoria Infirmary, 21 Mansionhouse

Road, Glasgow, G41 3DX, UK. Liz.Burleigh@sgh.scot.nhs.uk</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D deficiency is

common in older people and may increase risk of falls and fracture.

Hospital inpatients are at particular risk of falling. Previous

studies suggest that vitamin D improves neuromuscular function and

reduces falls.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To determine whether

routine supplementation with vitamin D plus calcium reduces numbers

of fallers and falls in a cohort of hospital admissions while they

are inpatients.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomised, double-blind,

controlled study. Participants: two hundred and five acute admissions

&gt;65 years to a geriatric medical unit.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients were randomised

to intervention of daily vitamin D 800 iu plus calcium 1,200 mg or

control group of daily calcium 1,200 mg, until discharge or death.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Baseline characteristics

were similar in both groups with a median age 84 years and a median

length of stay = 30 days (IQR 14.75-71.00). In a pre-selected

sub-group (54/205 participants), median admission vitamin D level =

22.00 nmol/l (IQR 15.00-30.50). This did not significantly increase

in the treatment versus control group. Median study drug adherence =

88%, with no significant difference between study groups

(Mann-Whitney: P = 0.711). Although there were fewer fallers in the

vitamin D cohort, this did not reach statistical significance

(vitamin D: calcium = 36:45 fallers; RR 0.82 (CI 0.59-1.16). Neither

the mean number of falls (vitamin D: calcium = 1.040:1.155;

Mann-Whitney P = 0.435) or time to first fall (Log-rank test P =

0.377) differed between groups.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In a population of

geriatric hospital inpatients, vitamin D did not reduce the number of

fallers. Routine supplementation cannot be recommended to reduce

falls in this</FONT> group.</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/15501836"><FONT SIZE=2>Age

Ageing.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2004</FONT><FONT SIZE=2>

Nov;33(6):589-95.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation improves neuromuscular function

in older people who fall.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Dhesi</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

JK</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Jackson

SH</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bearne

LM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Moniz

C</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hurley

MV</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Swift

CG</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Allain

TJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Elderly Day Hospital,

Thomas Guy House, Guys Hospital, St Thomas Street, London, UK.

jugdeep.</FONT><FONT SIZE=2>dhesi</FONT><FONT SIZE=2>@gsst.nhs.uk</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation reduces the incidence of fractures in older adults.

This may be partly mediated by effects of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> on neuromuscular function.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>to determine the effects

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

on aspects of neuromuscular function known to be risk factors for

falls and fractures.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>randomised, double-blind,

placebo-controlled study.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SETTING:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>falls clinic taking

referrals from general practitioners and accident and emergency

department.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SUBJECTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>139 ambulatory subjects

(&gt;/=65 years) with a history of falls and 25-hydroxyvitamin D

(25OHD) &lt;/=12 microg/l. Intervention: patients were randomised to

receive a single intramuscular injection of 600,000 i.u.

ergocalciferol or placebo.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OUTCOME

MEASURES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>assessments including

biochemistry, postural sway, choice reaction time (CRT), aggregate

functional performance time (AFPT), and quadriceps strength were

carried out at baseline and 6 months post-intervention.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>baseline characteristics

were comparable between both groups. 25OHD in the treatment group

increased significantly at 6 months. AFPT deteriorated in the control

group and improved in the intervention group, representing a

significant difference between groups (+6.6 s versus -2.0 s, t =

2.80, P &lt; 0.05). Similar changes were observed for CRT (-0.06 s

versus +0.41 s, t = -2.52, P &lt; 0.01) and postural sway (+0.0025

versus -0.0138, t = 2.35, P &lt; 0.02). There was no significant

difference in muscle strength change between groups (-10 N versus -2

N, t = -1.26, ns). A significant correlation between change in AFPT

and change in 25OHD levels was observed (r = 0.19, P = 0.03). There

was no significant difference in the number of falls (0.39 versus

0.24, t = 1.08, P = 0.28) or fallers (14 versus 11, P = 0.52) between

two groups.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation, in fallers with </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

insufficiency, has a significant beneficial effect on functional

performance, reaction time and balance, but not muscle strength. This

suggests that </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation improves neuromuscular or neuroprotective function,

which may in part explain the mechanism whereby </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> reduces falls and fractures.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19179490"><FONT SIZE=2>Am

J Respir Crit Care Med.</FONT></A></U></FONT><FONT SIZE=2> 2009 May

1;179(9):843-50. Epub 2009 Jan 29.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> as supplementary treatment for tuberculosis: a

double-blind, randomized, placebo-controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Wejse</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

C</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gomes

VF</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Rabna

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gustafson

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Aaby

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lisse

IM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Andersen

PL</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Glerup

H</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Sodemann

M</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Infectious Disease

Research Unit, Aarhus University Hospital, Skejby,

Brendstrupgaardsvej, 8200 Aarhus N, Denmark. </FONT><FONT SIZE=2>wejse</FONT><FONT SIZE=2>@dadlnet.dk</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RATIONALE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

has been shown to be involved in the host immune response toward

Mycobacterium tuberculosis.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVES:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To test whether </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplementation of patients with tuberculosis

(TB) improved clinical outcome and reduced mortality.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We conducted a randomized,

double-blind, placebo-controlled trial in TB clinics at a demographic

surveillance site in Guinea-Bissau. We included 365 adult patients

with TB starting antituberculosis treatment; 281 completed the

12-month follow-up. The intervention was 100,000 IU of

cholecalciferol or placebo at inclusion and again 5 and 8 months

after the start of treatment.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MEASUREMENTS

AND MAIN RESULTS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The primary outcome was

reduction in a clinical severity score (TBscore) for all patients

with pulmonary TB. The secondary outcome was 12-month mortality. No

serious adverse effects were reported; mild hypercalcemia was rare

and present in both arms. Reduction in TBscore and sputum smear

conversion rates did not differ among patients treated with </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> or placebo. Overall mortality was 15% (54 of

365) at 1 year of follow-up and similar in both arms (30 of 187 for

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> treated and 24 of

178 for placebo; relative risk, 1.19 [0.58-1.95]). HIV infection was

seen in 36% (131 of 359): 21% (76 of 359) HIV-1, 10% (36 of 359)

HIV-2, and 5% (19 of 357) HIV-1+2.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

does not improve clinical outcome among patients with TB and the

trial showed no overall effect on mortality in patients with TB; it

is possible that the dose used was insufficient. Clinical trial

registered with www.controlled-trials.com/isrctn (ISRCTN35212132).</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/17277040"><FONT SIZE=2>Diabetes

Care.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2007</FONT><FONT SIZE=2>

Apr;30(4):980-6. Epub </FONT><FONT SIZE=2>2007</FONT><FONT SIZE=2>

Feb 2.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>The

effects of calcium and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation on blood glucose and markers of inflammation in

nondiabetic adults.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Pittas</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

AG</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Harris

SS</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stark

PC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dawson-Hughes

B</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Endocrinology, Diabetes, and Metabolism, Tufts-New England Medical

Center, Boston, MA 02111, USA. apittas@tufts-nemc.org</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We sought to compare the

effects of combined calcium and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation versus placebo on blood glucose and markers of

inflammation in nondiabetic adults aged &gt; or =65 years.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESEARCH

DESIGN AND METHODS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A total of 314 Caucasian

adults without diabetes received either 500 mg calcium citrate and

700 IU </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) or

placebos daily for 3 years in a double-blind, randomized, controlled

trial designed for bone-related outcomes. In a post hoc analysis,

fasting plasma glucose (FPG), insulin sensitivity (estimated by

homeostasis model assessment of insulin resistance [HOMA-IR]), plasma

C-reactive protein, and interleukin-6, were measured at baseline and

3 years.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The effects of combined

calcium-</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation on 3-year change in FPG depended on baseline FPG (P =

0.02 for interaction). Therefore, we conducted analyses separately in

participants with normal fasting glucose (NFG) (FPG &lt;5.6 mmol/l, n

= 222) and impaired fasting glucose (IFG) (FPG 5.6-6.9 mmol/l, n =

92) at baseline. Among participants with IFG at baseline, those who

took combined calcium-</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements had a lower rise in FPG at 3 years compared with those on

placebo (0.02 mmol/l [0.4 mg/dl] vs. 0.34 mmol/l [6.1 mg/dl],

respectively, P = 0.042) and a lower increase in HOMA-IR (0.05 vs.

0.91, P = 0.031). In the NFG subgroup, there was no difference in the

change in FPG or HOMA-IR between the two treatment arms. There were

no differences in C-reactive protein or interleukin-6 between the two

treatment arms in either subgroup.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In healthy, older adults

with IFG, supplementation with calcium and </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> may attenuate increases in glycemia and insulin

resistance that occur over time. However, our findings should be

considered hypothesis generating and need to be confirmed in

randomized trials specifically designed for the outcomes of interest.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20194238"><FONT SIZE=2>Ann

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> </FONT><FONT SIZE=2>2010</FONT><FONT SIZE=2>

Mar 2;152(5):315-23.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Systematic

review: </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> and calcium

supplementation in prevention of cardiovascular events.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2><SPAN LANG="de-DE">Wang</SPAN></FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2><SPAN LANG="de-DE">

L</SPAN></FONT></U></FONT></A><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Manson

JE</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Song

Y</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Sesso

HD</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Brigham and Women's

Hospital and Harvard School of Public Health, Boston, Massachusetts

02215, USA. luwang@rics.bwh.harvard.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

and calcium may affect the cardiovascular system independently and

interactively.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PURPOSE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To assess whether </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> and calcium supplements reduce the risk for

cardiovascular events in adults.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SOURCES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Studies published in

English from 1966 to July 2009 in MEDLINE, EMBASE, and the Cochrane

Central Register of Controlled Trials.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>STUDY

SELECTION: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Two investigators

independently selected 17 prospective studies and randomized trials

that examined </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation, calcium supplementation, or both and subsequent

cardiovascular events.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

EXTRACTION: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Three investigators

extracted and checked data about study designs, participants,

exposures or interventions, outcomes, and data quality.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SYNTHESIS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Five prospective studies

of patients receiving dialysis and 1 study involving a general

population showed consistent reductions in cardiovascular disease

(CVD) mortality among adults who received </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements. Four prospective studies of

initially healthy persons found no differences in incidence of CVD

between calcium supplement recipients and nonrecipients. Results of

secondary analyses in 8 randomized trials showed a slight but

statistically nonsignificant reduction in CVD risk (pooled relative

risk, 0.90 [95% CI, 0.77 to 1.05]) with </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation at moderate to high doses (approximately 1000 IU/d)

but not with calcium supplementation (pooled relative risk, 1.14 [CI,

0.92 to 1.41]), or a combination of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

and calcium supplementation (pooled relative risk, 1.04 [CI, 0.92 to

1.18]) compared with placebo.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>LIMITATIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Only articles published in

English that reported cardiovascular event outcomes were included.

The small number of studies, the lack of trials designed specifically

to assess primary effects on cardiovascular outcomes, and important

between-study heterogeneity preclude definitive conclusions.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Evidence from limited data

suggests that </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements at moderate to high doses may reduce CVD risk, whereas

calcium supplements seem to have minimal cardiovascular effects.

Further research is needed to elucidate the role of these supplements

in CVD prevention.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/16043680"><FONT SIZE=2>Arch

Intern Med.</FONT></A></U></FONT><FONT SIZE=2> 2005 Jul

25;165(14):1618-23.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

randomized controlled trial of vitamin D3 supplementation in African

American women.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Aloia

JF</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Talwar

SA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pollack

S</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Yeh

J</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Medicine,

Bone Mineral Research Center, Winthrop University Hospital, Mineola,

NY 11501, USA. jaloia@winthrop.org</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We conducted a randomized,

placebo-controlled, double-blind trial to test the hypothesis that

vitamin D(3) supplementation would prevent bone loss in

calcium-replete, African American postmenopausal women.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Two hundred eight healthy

black postmenopausal women, 50 to 75 years of age, were assigned to

receive either placebo or 20 microg/d (800 IU) of vitamin D(3).

Calcium supplements were provided to ensure a total calcium intake of

1200 to 1500 mg/d. After 2 years, the vitamin D(3) dose was increased

to 50 microg/d (2000 IU) in the active group, and the study continued

for an additional year. Bone mineral density (BMD) was measured every

6 months. Markers of bone turnover, vitamin D metabolites, and

parathyroid hormone (PTH) levels were measured in serum.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>There were no significant

differences in BMD between the active and control groups throughout

the study. There was also no relationship between serum

25-hydroxyvitamin D levels attained and rates of bone loss. There was

an increase in BMD of the total body, hip, and radius at 1 year in

both groups. Over the 3 years, BMD declined at these sites by 0.26%

to 0.55% per year. The BMD of the lumbar spine increased slightly in

the placebo and active groups. There were no persistent changes in

serum PTH levels or the markers of bone turnover, although there was

a transient decline in PTH in both groups at 3 months. No significant

adverse events were attributed to vitamin D supplementation.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>There was no observed

effect of vitamin D(3) supplementation on bone loss or bone turnover

markers in calcium-replete, postmenopausal African American women.

Further studies are needed to determine if these findings are

applicable to women of other ethnic groups.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/15231008"><FONT SIZE=2>J

Bone Miner Res.</FONT></A></U></FONT><FONT SIZE=2> 2004

Aug;19(8):1221-30. Epub 2004 May 24.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Supplementation

with oral vitamin D3 and calcium during winter prevents seasonal bone

loss: a randomized controlled open-label prospective trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Meier</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

C</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Woitge

HW</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Witte

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lemmer

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Seibel

MJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Bone Research Program,

ANZAC Research Institute, University Sydney, Concord, New South

Wales, Australia.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Bone metabolism follows a

seasonal pattern with high bone turnover and bone loss during the

winter. In a randomized, open-label 2-year sequential follow-up study

of 55 healthy adults, we found that supplementation with oral vitamin

D3 and calcium during winter abolished seasonal changes in

calciotropic hormones and markers of bone turnover and led to an

increase in BMD. Supplementation with oral vitamin D3 and calcium

during the winter months seems to counteract the effects of seasonal

changes in </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> and thus

may be beneficial as a primary prevention strategy for age-related

bone loss.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTRODUCTION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Bone metabolism follows a

seasonal pattern characterized by high bone turnover and bone loss

during winter. We investigated whether wintertime supplementation

with oral vitamin D3 and calcium had beneficial effects on the

circannual changes in bone turnover and bone mass.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MATERIALS

AND METHODS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This prospective study

comprised an initial observation period of 12 months (&quot;year 1&quot;),

followed by an intervention during parts of year 2. Fifty-five

healthy subjects living in southwestern Germany (latitude, 49.5

degrees N) were randomized into two groups: 30 subjects were assigned

to the treatment group and received oral cholecalciferol (500 IU/day)

and calcium (500 mg/day) during the winter months of year 2

(October-April), while 25 subjects assigned to the control group

obtained no supplements. Primary endpoints were changes in

calciotropic hormones [serum 25(OH)D, 1,25(OH)2D, and parathyroid

hormone], markers of bone formation (serum bone-specific alkaline

phosphatase) and of bone resorption (urinary pyridinoline and

deoxypyridinoline), and changes in lumbar spine and femoral neck BMD.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Forty-three subjects

completed the study. During year 1, calciotropic hormones, markers of

bone turnover, and BMD varied by season in both groups. During the

winter months of year 1, bone turnover was significantly accelerated,

and lumbar spine and femoral BMD declined by 0.3-0.9%. In year 2,

seasonal changes in calciotropic hormones and markers of bone

turnover were either reversed or abolished in the intervention group

while unchanged in the control cohort. In the subjects receiving oral

vitamin D3 and calcium, lumbar and femoral BMD increased

significantly (lumbar spine: +0.8%, p = 0.04 versus year 1; femoral

neck: +0.1%, p = 0.05 versus year 1), whereas controls continued to

lose bone (intervention group versus control group: lumbar spine, p =

0.03; femoral neck, p = 0.05).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Supplementation with oral

vitamin D3 and calcium during winter prevents seasonal changes in

bone turnover and bone loss in healthy adults. It seems conceivable

that annually recurring cycles of low </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

and mild secondary hyperparathyroidism during the winter months

contributes, at least in part and over many years, to age-related

bone loss. Supplementation with low-dose oral vitamin D3 and calcium

during winter may be an efficient and inexpensive strategy for the

primary prevention of bone loss in northern latitudes.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/16600924"><FONT SIZE=2><SPAN LANG="de-DE">Am

J Clin Nutr.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

</SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">2006</SPAN></FONT><FONT SIZE=2><SPAN LANG="de-DE">

Apr;83(4):754-9.</SPAN></FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation improves cytokine profiles in

patients with congestive heart failure: a double-blind, randomized,

placebo-controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2><SPAN LANG="de-DE">Schleithoff</SPAN></FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2><SPAN LANG="de-DE">

SS</SPAN></FONT></U></FONT></A><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Zittermann

A</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Tenderich

G</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Berthold

HK</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Stehle

P</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Koerfer

R</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Institute of Nutrition and

Food Science, University of Bonn, Bonn, Germany.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Elevated circulating

concentrations of proinflammatory cytokines may contribute to the

pathogenesis of congestive heart failure (CHF). In vitro studies

suggest that </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

suppresses proinflammatory cytokines and increases antiinflammatory

cytokines.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We evaluated the effect of

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation on

the survival rate and different biochemical variables in patients

with CHF.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>One hundred twenty-three

patients randomly received either 50 mug </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3)/d plus 500 mg Ca/d [D(+) group] or placebo

plus 500 mg Ca/d [D(-) group] for 9 mo. Biochemical variables were

assessed at baseline and after 9 mo. The survival rate was calculated

for a follow-up period of 15 mo.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Ninety-three patients

completed the study. Significant treatment effects were observed on

logarithmic-transformed serum concentrations of 25-hydroxyvitamin D

(P = 0.001), parathyroid hormone (P = 0.007), tumor necrosis factor

alpha (P = 0.006), and interleukin 10 (P = 0.042). 25-Hydroxyvitamin

D increased by 26.8 ng/mL in the D(+) group but increased only by 3.6

ng/mL in the D(-) group. Compared with baseline, parathyroid hormone

was significantly lower and the antiinflammatory cytokine interleukin

10 was significantly higher in the D(+) group after 9 mo. The

proinflammatory cytokine tumor necrosis factor alpha increased in the

D(-) group but remained constant in the D(+) group. The survival rate

did not differ significantly between the study groups during the

follow-up period.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>(3)

reduces the inflammatory milieu in CHF patients and might serve as a

new antiinflammatory agent for the future treatment of the disease.

Our data provide evidence for the involvement of an impaired </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>-parathyroid hormone axis in the progression of

CHF.</FONT></P>

<P STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/16278262"><FONT SIZE=2>J

Clin Endocrinol Metab.</FONT></A></U></FONT><FONT SIZE=2> 2006

Feb;91(2):405-12. Epub 2005 Nov 8.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effect

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> replacement on

musculoskeletal parameters in school children: a randomized

controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>El-Hajj

Fuleihan G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Nabulsi

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Tamim

H</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Maalouf

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Salamoun

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Khalife

H</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Choucair

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Arabi

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Vieth

R</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Calcium Metabolism and

Osteoporosis Program, American University of Beirut-Medical Center,

Bliss Street, 113-6044 Beirut, Lebanon. gf01@aub.edu.lb</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Despite the high

prevalence of hypovitaminosis D in children and adolescents

worldwide, the impact of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

deficiency on skeletal health is unclear.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>One hundred seventy-nine

girls, ages 10-17 yr, were randomly assigned to receive weekly oral

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> doses of 1,400 IU

(equivalent to 200 IU/d) or 14,000 IU (equivalent to 2,000 IU/d) in a

double-blind, placebo-controlled, 1-yr protocol. Areal bone mineral

density (BMD) and bone mineral content (BMC) at the lumbar spine,

hip, forearm, total body, and body composition were measured at

baseline and 1 yr. Serum calcium, phosphorus, alkaline phosphatase,

and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> metabolites

were measured during the study.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In the overall group of

girls, lean mass increased significantly in both treatment groups (P

&lt; or = 0.05); bone area and total hip BMC increased in the

high-dose group (P &lt; 0.02). In premenarcheal girls, lean mass

increased significantly in both treatment groups, and there were

consistent trends for increments in BMD and/or BMC at several

skeletal sites, reaching significance at lumbar spine BMD in the

low-dose group and at the trochanter BMC in both treatment groups.

There was no significant change in lean mass, BMD, or BMC in

postmenarcheal girls.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

replacement had a positive impact on musculoskeletal parameters in

girls, especially during the premenarcheal period.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21628364"><FONT SIZE=2>BMJ.</FONT></A></U></FONT><FONT SIZE=2>

2011 May 31;342:d2975. doi: 10.1136/bmj.d2975.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effect

of weekly </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements on mortality, morbidity, and growth of low birthweight

term infants in India up to age 6 months: </FONT><FONT SIZE=2>randomised

controlled trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Kumar

GT</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Sachdev

HS</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Chellani

H</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Rehman

AM</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Singh

V</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Arora

H</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Filteau

S</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Institute of Home

Economics, Delhi University, F-4 Haus Khas Enclave, New Delhi 110016,

India. geetatrilokkumar@gmail.com</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To investigate whether

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation can

decrease the mortality and morbidity of low birthweight infants in

low income countries.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomised controlled

trial</FONT><FONT SIZE=2>.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SETTING:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Large government hospital

in New Delhi, India.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PARTICIPANTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>2079 low birthweight

infants born at term (&gt;37 weeks' gestation).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MAIN

OUTCOME MEASURES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Primary outcome was

admission to hospital or death during the first six months of life.

Main secondary outcome was growth.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTERVENTIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Weekly </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements for six months at a dose of one

recommended nutrient intake per day (35 &micro;g/week). Infants were

visited weekly at home for observed supplementation and were brought

to the clinic monthly for clinical examination and anthropometric

measurements.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Between group differences

were not significant for death or hospital admissions (92 among 1039

infants in the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

group v 99 among 1040 infants in the placebo group; adjusted rate

ratio 0.93, 95% confidence interval 0.68 to 1.29; P = 0.68), or

referral to the outpatient clinic for moderate morbidity. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation resulted in better </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> status as assessed by plasma calcidiol levels

at six months. In adjusted analyses, </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

treatment significantly increased standard deviation (z) scores at

six months for weight, length, and arm circumference and decreased

the proportion of children with stunted growth (length for age z

score &le; 2) or with arm circumference z scores of 2 or less.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A weekly dose of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> resulted in better </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> status and benefited the classic </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> function of bone growth but did not decrease

the incidence of severe morbidity or death among young low

birthweight infants. Trial registration ClinicalTrials.gov

NCT00415402.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21689448"><FONT SIZE=2>BMC

Musculoskelet Disord.</FONT></A></U></FONT><FONT SIZE=2> 2011 Jun

20;12:135.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>A

</FONT><FONT SIZE=2>randomized controlled trial</FONT><FONT SIZE=2>

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> dosing

strategies after acute hip fracture: no advantage of loading doses

over daily supplementation.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Papaioannou

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kennedy

CC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Giangregorio

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ioannidis

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pritchard

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hanley

DA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Farrauto

L</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>DeBeer

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Adachi

JD</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>McMaster University, HHSC,

St. Peter's Hospital Juravinski Research Centre, 88 Maplewood Avenue

Hamilton, ON L8M 1W9, Canada. papaioannou@hhsc.ca</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>There remains uncertainty

regarding the appropriate therapeutic management of hip fracture

patients. The primary aim of our study was to examine whether large

loading doses in addition to daily </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

offered any advantage over a simple daily low-dose </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> regimen for increasing </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> levels.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In this randomized

controlled study, patients over age 50 with an acute fragility hip

fracture were enrolled from two hospital sites in Ontario, Canada.

Participants were randomized to one of three loading dose groups:

placebo; 50,000 IU vitamin D2; or 100,000 IU D2. Following a

placebo/loading dose, all patients received a daily tablet of 1,000

IU vitamin D3 for 90 days. Serum 25-hydroxy </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> (25-OHD) was measured at baseline, discharge

from acute care (approximately 4-weeks), and 3-months.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Sixty-five patients were

enrolled in the study (44% male). An immediate rise in 25-OHD

occurred in the 100,000 group, however there were no significant

differences in 25-OHD between the placebo, 50,000 and 100,000 loading

dose groups after 4-weeks (69.3, 84.5, 75.6 nmol/L, p = 0.15) and

3-months (86.7, 84.2, 73.3 nmol/L, p = 0.09), respectively. At the

end of the study, approximately 75% of the placebo and 50,000 groups

had reached the target therapeutic range (75 nmol/L), and 44% of the

100,000 group.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In correcting </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> insufficiency/deficiency in elderly patients

with hip fracture, our findings suggest that starting with a lower

daily dose of Vitamin D3 achieved similar results as providing an

additional large loading dose of Vitamin D2. At the end of the study,

all three groups were equally effective in attaining improvement in

25-OHD levels. Given that a daily dose of 1,000 IU vitamin D3 (with

or without a loading dose) resulted in at least 25% of patients

having suboptimal </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

status, patients with acute hip fracture may benefit from a higher

daily dose of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21715514"><FONT SIZE=2><SPAN LANG="de-DE">Am

J Clin Nutr.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

2011 Aug;94(2):486-94. </SPAN></FONT><FONT SIZE=2>Epub 2011 Jun 29.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> and calcium

supplementation on pancreatic &beta; cell function, insulin

sensitivity, and glycemia in adults at high risk of diabetes: the

Calcium and </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> for

Diabetes Mellitus (CaDDM) </FONT><FONT SIZE=2>randomized controlled

trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Mitri

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dawson-Hughes

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hu

FB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pittas

AG</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of Endocrinology,

Diabetes, and Metabolism, Tufts Medical Center, Boston, MA 02111,

USA.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A suboptimal </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> and calcium status has been associated with

higher risk of type 2 diabetes in observational studies, but evidence

from trials is lacking.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We determined whether

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation,

with or without calcium, improved glucose homeostasis in adults at

high risk of diabetes.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Ninety-two adults were

randomly assigned in a 2-by-2 factorial-design, double-masked,

placebo-controlled trial to receive either cholecalciferol (2000 IU

once daily) or calcium carbonate (400 mg twice daily) for 16 wk. The

primary outcome was the change in pancreatic &beta; cell function as

measured by the disposition index after an

intravenous-glucose-tolerance test. Other outcomes were acute insulin

response, insulin sensitivity, and measures of glycemia.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Participants had a mean

age of 57 y, a body mass index (BMI; in kg/m(2)) of 32, and glycated

hemoglobin (Hb A(1c)) of 5.9%. There was no significant </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> &times; calcium interaction on any outcomes.

The disposition index increased in the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

group and decreased in the no-</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

group (adjusted mean change &plusmn; SE: 300 &plusmn; 130 compared

with -126 &plusmn; 127, respectively; P = 0.011), which was explained

by an improvement in insulin secretion (62 &plusmn; 39 compared with

-36 &plusmn; 37 mU &middot; L(-1) &middot; min, respectively; P =

0.046). Hb A(1c) increased less, but nonsignificantly, in the </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> group than in the no-</FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> group (0.06 &plusmn; 0.03% compared with 0.14 &plusmn;

0.03%, respectively; P = 0.081). There was no significant difference

in any outcomes with calcium compared with no calcium.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In adults at risk of type

2 diabetes, short-term supplementation with cholecalciferol improved

&beta; cell function and had a marginal effect on attenuating the

rise in Hb A(1c). This trial was registered at clinicaltrials.gov as

NCT00436475.</FONT></P>

<P STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21709199"><FONT SIZE=2>J

Clin Oncol.</FONT></A></U></FONT><FONT SIZE=2> 2011 Aug

1;29(22):3078-84. Epub 2011 Jun 27.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Calcium

plus </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation and the risk of nonmelanoma and melanoma skin cancer:

post hoc analyses of the women's health initiative </FONT><FONT SIZE=2>randomized

controlled trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Tang

JY</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Fu

T</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Leblanc

E</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Manson

JE</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Feldman

D</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Linos

E</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Vitolins

MZ</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Zeitouni

NC</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Larson

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Stefanick

ML</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Dermatology,

Stanford University School of Medicine, 450 Broadway, Pavilion C, MC

5334, Redwood City, CA, USA. tangy@stanford.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PURPOSE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In light of inverse

relationships reported in observational studies of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> intake and serum 25-hydroxyvitamin D levels

with risk of nonmelanoma skin cancer (NMSC) and melanoma, we

evaluated the effects of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

combined with calcium supplementation on skin cancer in a randomized

placebo-controlled trial.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Postmenopausal women age

50 to 79 years (N = 36,282) enrolled onto the Women's Health

Initiative (WHI) calcium/</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

clinical trial were randomly assigned to receive 1,000 mg of

elemental calcium plus 400 IU of vitamin D3 (CaD) daily or placebo

for a mean follow-up period of 7.0 years. NMSC and melanoma skin

cancers were ascertained by annual self-report; melanoma skin cancers

underwent physician adjudication.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Neither incident NMSC nor

melanoma rates differed between treatment (hazard ratio [HR], 1.02;

95% CI, 0.95 to 1.07) and placebo groups (HR, 0.86; 95% CI, 0.64 to

1.16). In subgroup analyses, women with history of NMSC assigned to

CaD had a reduced risk of melanoma versus those receiving placebo

(HR, 0.43; 95% CI, 0.21 to 0.90; P(interaction) = .038), which was

not observed in women without history of NMSC.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

supplementation at a relatively low dose plus calcium did not reduce

the overall incidence of NMSC or melanoma. However, in women with

history of NMSC, CaD supplementation reduced melanoma risk,

suggesting a potential role for calcium and </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements in this high-risk group. Results

from this post hoc subgroup analysis should be interpreted with

caution but warrant additional investigation.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21735411"><FONT SIZE=2><SPAN LANG="nb-NO">Cochrane

Database Syst Rev.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="nb-NO">

2011 Jul 6;(7):CD007470.</SPAN></FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation for prevention of mortality in

adults.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bjelakovic

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gluud

LL</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Nikolova

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Whitfield

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wetterslev

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Simonetti

RG</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bjelakovic

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gluud

C</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Internal

Medicine - Gastroenterology and Hepatology, Medical Faculty,

University of Nis, Zorana Djindjica 81, Nis, Serbia, 18000.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The available evidence on

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> and mortality is

inconclusive.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVES:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To assess the beneficial

and harmful effects of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

for prevention of mortality in adults.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SEARCH

STRATEGY: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We searched The Cochrane

Library, MEDLINE, EMBASE, LILACS, the Science Citation Index

Expanded, and Conference Proceedings Citation Index-Science (to

January 2011). We scanned bibliographies of relevant publications and

asked experts and pharmaceutical companies for additional trials.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SELECTION

CRITERIA: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We included randomised

trials that compared </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

at any dose, duration, and route of administration versus placebo or

no intervention. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

could have been administered as supplemental </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> (</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

(cholecalciferol) or </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(2)

(ergocalciferol)) or an active form of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

(1&alpha;-hydroxyvitamin D (alfacalcidol) or 1,25-dihydroxyvitamin D

(calcitriol)).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

COLLECTION AND ANALYSIS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Six authors extracted data

independently. Random-effects and fixed-effect model meta-analyses

were conducted. For dichotomous outcomes, we calculated the risk

ratios (RR). To account for trials with zero events, meta-analyses of

dichotomous data were repeated using risk differences (RD) and

empirical continuity corrections. Risk of bias was considered in

order to minimise risk of systematic errors. Trial sequential

analyses were conducted to minimise the risk of random errors.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>MAIN

RESULTS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Fifty randomised trials

with 94,148 participants provided data for the mortality analyses.

Most trials included elderly women (older than 70 years). </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> was administered for a median of two years.

More than one half of the trials had a low risk of bias. Overall,

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> decreased mortality

(RR 0.97, 95% confidence interval (CI) 0.94 to 1.00, I(2) = 0%). When

the different forms of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

were assessed separately, only </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

decreased mortality significantly (RR 0.94, 95% CI 0.91 to 0.98, I(2)

= 0%; 74,789 participants, 32 trials) whereas </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(2), alfacalcidol, or calcitriol did not. Trial

sequential analysis supported our finding regarding </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3), corresponding to 161 individuals treated to

prevent one additional death. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>(3)

combined with calcium increased the risk of nephrolithiasis (RR 1.17,

95% CI 1.02 to 1.34, I(2) = 0%). Alfacalcidol and calcitriol

increased the risk of hypercalcaemia (RR 3.18, 95% CI 1.17 to 8.68,

I(2) = 17%). Data on health-related quality of life and health

economics were inconclusive.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>AUTHORS'

CONCLUSIONS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

in the form of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

seems to decrease mortality in predominantly elderly women who are

mainly in institutions and dependent care. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2>(2), alfacalcidol, and calcitriol had no

statistically significant effect on mortality. </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2>(3) combined with calcium significantly

increased nephrolithiasis. Both alfacalcidol and calcitriol

significantly increased hypercalcaemia.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21911741"><FONT SIZE=2>Diabetes.</FONT></A></U></FONT><FONT SIZE=2>

2011 Nov;60(11):2748-57. Epub 2011 Sep 12.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2>, insulin secretion, sensitivity, and lipids:

results from a case-control study and a </FONT><FONT SIZE=2>randomized

controlled trial</FONT><FONT SIZE=2> using hyperglycemic clamp

technique.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Grimnes

G</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Figenschau

Y</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Alm&aring;s

B</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="da-DK">Jorde

R</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="da-DK">.</SPAN></FONT></P>

<H3 LANG="da-DK" CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in">

<FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Troms&oslash; Endocrine

Research Group, Department of Clinical Medicine, University of

Troms&oslash;, Troms&oslash;, Norway. guri.grimnes@unn.no</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

deficiency is associated with an unfavorable metabolic profile in

observational studies. The intention was to compare insulin

sensitivity (the primary end point) and secretion and lipids in

subjects with low and high serum 25(OH)D (25-hydroxyvitamin D) levels

and to assess the effect of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation on the same outcomes among the participants with low

serum 25(OH)D levels.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESEARCH

DESIGN AND METHODS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Participants were

recruited from a population-based study (the Troms&oslash; Study)

based on their serum 25(OH)D measurements. A 3-h hyperglycemic clamp

was performed, and the participants with low serum 25(OH)D levels

were thereafter randomized to receive capsules of 20,000 IU </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) or identical-looking placebo twice weekly

for 6 months. A final hyperglycemic clamp was then performed.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The 52 participants with

high serum 25(OH)D levels (85.6 &plusmn; 13.5 nmol/L [mean &plusmn;

SD]) had significantly higher insulin sensitivity index (ISI) and

lower HbA(1c) and triglycerides (TGs) than the 108 participants with

low serum 25(OH)D (40.3 &plusmn; 12.8 nmol/L), but the differences in

ISI and TGs were not significant after adjustments. After

supplementation, serum 25(OH)D was 142.7 &plusmn; 25.7 and 42.9 &plusmn;

17.3 nmol/L in 49 of 51 completing participants randomized to </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> and 45 of 53 randomized to placebo,

respectively. At the end of the study, there were no statistically

significant differences in the outcome variables between the two

groups.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

supplementation to apparently healthy subjects with insufficient

serum 25(OH)D levels does not improve insulin sensitivity or

secretion or serum lipid profile.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21956713"><FONT SIZE=2>J

Bone Miner Res.</FONT></A></U></FONT><FONT SIZE=2> 2011 Sep 28. doi:

10.1002/jbmr.524. [Epub ahead of print]</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of three monthly oral 150,000 IU cholecalciferol supplementation on

falls, mobility and muscle strength in older postmenopausal women: a

</FONT><FONT SIZE=2>randomised controlled trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Glendenning

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Zhu

K</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Inderjeeth

C</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Howat

P</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lewis

JR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Prince

RL</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>School of Medicine and

Pharmacology, University of Western Australia, Perth, Australia;

School of Pathology and Laboratory Medicine, University of Western

Australia, Perth, Australia; Department of Core Clinical Pathology

and Biochemistry, Royal Perth Hospital, Perth, Australia.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Daily </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> in addition to calcium supplementation reduces

falls and fractures in older women. However, poor adherence to

therapy is a common clinical problem. To examine the effects of

supervised oral 3 monthly </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

therapy on falls, muscle strength and mobility, we conducted a

nine-month randomised, double-blind, placebo-controlled trial in 686

community-dwelling ambulant women aged over 70 years. Participants

received either oral cholecalciferol 150,000 IU every 3 months

(n</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>353)

or an identical placebo (n</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>333).

All participants were advised to increase dietary calcium intake.

Falls data were collected three monthly. At baseline, 3, 6 and 9

months, muscle strength was measured by a handheld dynamometer and

mobility by the Timed Up and Go (TUG) test. Serum 25 hydroxyvitamin D

(25OHD) was measured in a subgroup of 40 subjects. Mean age at

baseline was 76.7</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&plusmn;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>4.1

years. The average serum 25OHD value at baseline was 65.8</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&plusmn;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>22.7

nmol/L. By three, six and nine months after supplementation, 25OHD

levels of the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> group

were approximately 15 nmol/L higher than the placebo group. Calcium

intake did not change significantly between baseline

(864</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&plusmn;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>412</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>mg/day)

and 9 months (855</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&plusmn;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>357</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>mg/day).

Faller rates in the two groups did not differ: </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> group 102/353(29%); placebo group 89/333(27%).

At 9 months, compared to placebo or baseline, muscle strength and TUG

were not altered by </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>.

In conclusion, oral cholecalciferol 150,000 IU therapy administered

three monthly had neither beneficial nor adverse effects on falls or

physical function. These data together with previous findings confirm

that intermittent large doses of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

are ineffective or have a deleterious effect on falls. Thus despite

adherence issues with daily </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

replacement, an intermittent, high dose </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

regimen cannot be supported as a strategy to reduce falls and

fractures. &copy; 2011 American Society for Bone and Mineral

Research.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/22073146"><FONT SIZE=2>PLoS

One.</FONT></A></U></FONT><FONT SIZE=2> 2011;6(11):e25966. Epub 2011

Nov 4.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of </FONT><FONT SIZE=2>vitamin d</FONT><FONT SIZE=2> supplementation

on cognitive and emotional functioning in young adults - a </FONT><FONT SIZE=2>randomised

controlled trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dean

AJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bellgrove

MA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hall

T</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Phan

WM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Eyles

DW</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Kvaskoff

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McGrath

JJ</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Queensland Brain

Institute, The University of Queensland, St Lucia, Australia.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Epidemiological research

links </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> status to

various brain-related outcomes. However, few trials examine whether

supplementation can improve such outcomes and none have examined

effects on cognition. This study examined whether </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation led to improvements in diverse

measures of cognitive and emotional functioning, and hypothesised

that supplementation would lead to improvements in these outcomes

compared to placebo.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS/PRINCIPAL

FINDINGS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Healthy young adults were

recruited to a parallel-arm, double-blind trial conducted at The

University of Queensland. Participants were randomly allocated to

receive </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2> (one

capsule daily, containing 5000 IU cholecalciferol) or identical

placebo capsule for six weeks. All participants and outcome assessors

were blinded to group assignment. Primary outcome measures assessed

at baseline and 6 weeks were working memory, response inhibition and

cognitive flexibility. Secondary outcomes were:

hallucination-proneness, psychotic-like experiences, and ratings of

depression, anxiety and anger. 128 participants were recruited,

randomised and included in primary analyses (</FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> n</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>63;

placebo n</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>65).

Despite significant increases in </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

status in the active group, no significant changes were observed in

working memory (F</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>1.09;

p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>0.30),

response inhibition (F</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>0.82;

p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>0.37),

cognitive flexibility (F</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>1.37;

p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>

</FONT></FONT><FONT SIZE=2>0.24)

or secondary outcomes. No serious adverse effects were reported.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Our findings indicate that

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

does not influence cognitive or emotional functioning in healthy

young adults. Future controlled trials in targeted populations of

interest are required to determine whether supplementation can

improve functioning in these domains. Australian and New Zealand

Clinical Trials Registry; ACTRN12610000318088.</FONT></P>

<P STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21992858"><FONT SIZE=2>Indian

Pediatr.</FONT></A></U></FONT><FONT SIZE=2> 2011 Aug 15. pii:

S097475591100214-1. [Epub ahead of print]</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> Supplementation for Severe Pneumonia A

</FONT><FONT SIZE=2>Randomized Controlled Trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Choudhary

N</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gupta

P</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Pediatrics,

University College of Medical Sciences and Guru Teg Bahadur Hospital,

Dilshad Garden, Delhi, India. Correspondence to: Dr Nidhi Choudhary,

Block ED, 72A, Pitampura, Delhi 110 034, India,

nidhi_mamc2001@yahoo.co.in.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To determine the role of

oral </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation for resolution of severe pneumonia in under-five

children.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomized double blind

placebo-controlled trial.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>SETTING:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Inpatients from a tertiary

care hospital.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PARTICIPANTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Two hundred children [mean

(SD) age: 13.9 (11.7) months; boys: 120] between 2 months to 5 years

with severe pneumonia. Pneumonia was diagnosed in the presence of

fever, cough, tachypnea (as per WHO cutoffs) and crepitations.

Children with pneumonia and chest indrawing or at least one of the

danger sign (inability to feed, lethargy, cyanosis) were diagnosed as

having severe pneumonia. The two groups were comparable for baseline

characteristics including age, anthropometry, socio-demographic

profile and clinical and laboratory parameters.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTERVENTION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Oral </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> (1000 IU for &lt;1 year and 2000 IU for &gt;1

year) (n=100) or placebo (lactose) (n=100) once a day for 5 days,

from enrolment. Both the groups received antibiotics as per the

Indian Academy of Pediatrics guidelines, and supportive care (oxygen,

intravenous fluids and monitoring).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OUTCOME

VARIABLES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Primary: time to

resolution of severe pneumonia. SECONDARY: duration of

hospitalization and time to resolution of tachypnea, chest

retractions and inability to feed.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Median duration (SE, 95%

CI) of resolution of severe pneumonia was similar in the two groups

[</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>: 72 (3.7,

64.7-79.3) hours; placebo: 64 (4.5, 55.2-72.8)hours]. Duration of

hospitalization and time to resolution of tachypnea, chest

retractions, and inability to feed were also comparable between the

two groups.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Short-term supplementation

with oral </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

(1000-2000 IU per day for 5 days) has no beneficial effect on

resolution of severe pneumonia in under-five children. Further

studies needs to be conducted with higher dose of </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> or longer duration of supplementation to

corroborate these findings.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/22086300"><FONT SIZE=2>Eur

J Nutr.</FONT></A></U></FONT><FONT SIZE=2> 2011 Nov 16. [Epub ahead

of print]</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Is

a daily supplementation with 40 microgram </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) sufficient? A </FONT><FONT SIZE=2>randomised

controlled trial</FONT><FONT SIZE=2>.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Toss

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Magnusson

P</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of

Endocrinology and Gastroenterology, County Council of &Ouml;sterg&ouml;tland,

SE-581 85, Link&ouml;ping, Sweden.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>PURPOSE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The effect of 40&nbsp;&mu;g

(1,600&nbsp;IU) per day of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

on serum 25-hydroxyvitamin D (25(OH)D) and markers of bone and

mineral metabolism was evaluated.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This intervention study

was designed as a double-blind </FONT><FONT SIZE=2>randomised

controlled trial</FONT><FONT SIZE=2>. Forty-five community-dwelling

subjects (32 females), age 55-84&nbsp;years, at 58&deg; North

latitude were supplemented for 1&nbsp;year with 40&nbsp;&mu;g </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) plus 1,000&nbsp;mg calcium per day, or with

1,000&nbsp;mg calcium per day for controls. Safety parameters and

25(OH)D, intact parathyroid hormone (PTH), ionized calcium,

bone-specific alkaline phosphatase (BALP), and tartrate-resistant

acid phosphatase isoform 5b (TRACP5b) were measured over the study

period.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>All subjects supplemented

with </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) reached a

25(OH)D level above 50&nbsp;nmol/L. Mean (SD) serum 25(OH)D increased

from 50.4 (13.5) nmol/L to 84.2 (17.5) nmol/L, range

55.0-125.0&nbsp;nmol/L in the </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

supplemented group and the corresponding levels for the control group

were 47.3 (14.1) nmol/L and 45.7 (13.4) nmol/L, range

26.0-73.0&nbsp;nmol/L. No serious adverse event was recorded and the

highest 25(OH)D level reached, 125.0&nbsp;nmol/L, is well below toxic

levels. BALP and TRACP5b did not change significantly over the study

period.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This trial suggests that a

daily supplementation with 40&nbsp;&mu;g </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) is sufficient to secure a 25(OH)D level of

50&nbsp;nmol/L. No side effects were observed in the study group.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/22112804"><FONT SIZE=2>J

Clin Endocrinol Metab.</FONT></A></U></FONT><FONT SIZE=2> 2011 Nov

23. [Epub ahead of print]</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Long-Term

Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled

Trial of Vitamin D3 and/or Calcium (RECORD Trial).</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Avenell

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Maclennan

GS</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Jenkinson

DJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McPherson

GC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>McDonald

AM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Pant

PR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Grant

AM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Campbell

MK</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Anderson

FH</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Cooper

C</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Francis

RM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gillespie

WJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Robinson

CM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Torgerson

DJ</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wallace

WA</FONT></A></U></FONT><FONT SIZE=2>; </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>the

RECORD Trial Group</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Health Services Research

Unit (A.A., G.S.M., D.J.J., G.C.M., A.M.M., P.R.P., A.M.G., M.K.C.),

University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United

Kingdom; Geriatric Medicine (F.H.A.), Developmental Origins of Health

and Disease, Research Division, and Medical Research Council

Lifecourse Epidemiology Unit (C.C.), University of Southampton,

Southampton SO16 6YD, and Institute of Musculoskeletal Sciences,

University of Oxford, Oxford OX3 7LD, United Kingdom; Institute for

Ageing and Health (R.M.F.), Newcastle University, Newcastle upon Tyne

NE4 5PL, United Kingdom; Hull York Medical School (W.J.G.),

University of Hull, Hull HU6 7RX, United Kingdom; Royal Infirmary of

Edinburgh (C.M.R.), Edinburgh EH3 9HB, United Kingdom; York Trials

Unit (D.J.T.), University of York, York YO10 5DD, United Kingdom; and

Medical and Surgical Sciences (W.A.W.), University of Nottingham,

Nottingham NG7 2UH, United Kingdom.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Context:</FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> or calcium supplementation may have effects on

vascular disease and cancer.Objective:Our objective was to

investigate whether </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

or calcium supplementation affects mortality, vascular disease, and

cancer in older people.Design and Setting:The study included

long-term follow-up of participants in a two by two factorial,

</FONT><FONT SIZE=2>randomized controlled trial</FONT><FONT SIZE=2>

from 21 orthopedic centers in the United

Kingdom.Participants:Participants were 5292 people (85% women) aged

at least 70 yr with previous low-trauma fracture.</FONT></P>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Interventions:Participants

were randomly allocated to daily </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3)

(800 IU), calcium (1000 mg), both, or placebo for 24-62 months, with

a follow-up of 3 yr after intervention.Main Outcome

Measures:All-cause mortality, vascular disease mortality, cancer

mortality, and cancer incidence were evaluated.</FONT></P>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Results:In

intention-to-treat analyses, mortality [hazard ratio (HR) = 0.93; 95%

confidence interval (CI) = 0.85-1.02], vascular disease mortality (HR

= 0.91; 95% CI = 0.79-1.05), cancer mortality (HR = 0.85; 95% CI =

0.68-1.06), and cancer incidence (HR = 1.07; 95% CI = 0.92-1.25) did

not differ significantly between participants allocated </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> and those not. All-cause mortality (HR = 1.03;

95% CI = 0.94-1.13), vascular disease mortality (HR = 1.07; 95% CI =

0.92-1.24), cancer mortality (HR = 1.13; 95% CI = 0.91-1.40), and

cancer incidence (HR = 1.06; 95% CI = 0.91-1.23) also did not differ

significantly between participants allocated calcium and those not.

In a post hoc statistical analysis adjusting for compliance, thus

with fewer participants, trends for reduced mortality with </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> and increased mortality with calcium were

accentuated, although all results remain nonsignificant.</FONT></P>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Conclusions:Daily </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> or calcium supplementation did not affect

mortality, vascular disease, cancer mortality, or cancer incidence.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/22071212"><FONT SIZE=2>Am

J Cardiol.</FONT></A></U></FONT><FONT SIZE=2> 2011 Nov 7. [Epub ahead

of print]</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> Deficiency and </FONT><FONT SIZE=2>Supplementation</FONT><FONT SIZE=2>

and Relation to </FONT><FONT SIZE=2>Cardiovascular</FONT><FONT SIZE=2>

Health.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Vacek

JL</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Vanga

SR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Good

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lai

SM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Lakkireddy

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Howard

PA</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Mid America Cardiology,

Division of </FONT><FONT SIZE=2>Cardiovascular</FONT><FONT SIZE=2>

Medicine, University of Kansas Medical Center and Hospital, Kansas

City, Kansas.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Recent evidence supports

an association between </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

deficiency and hypertension, peripheral vascular disease, diabetes

mellitus, metabolic syndrome, coronary artery disease, and heart

failure. The effect of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2>, however, has

not been well studied. We examined the associations between </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> deficiency, </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2>, and patient

outcomes in a large cohort. Serum </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

measurements for 5 years and 8 months from a large academic

institution were matched to patient demographic, physiologic, and

disease variables. The </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

levels were analyzed as a continuous variable and as normal (&ge;30

ng/ml) or deficient (&lt;30 ng/ml). Descriptive statistics,

univariate analysis, multivariate analysis, survival analysis, and

Cox proportional hazard modeling were performed. Of 10,899 patients,

the mean age was 58 &plusmn; 15 years, 71% were women (n = 7,758),

and the average body mass index was 30 &plusmn; 8 kg/m(2). The mean

serum </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> level was

24.1 &plusmn; 13.6 ng/ml. Of the 10,899 patients, 3,294 (29.7%) were

in the normal </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> range

and 7,665 (70.3%) were deficient. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

deficiency was associated with several </FONT><FONT SIZE=2>cardiovascular</FONT><FONT SIZE=2>-related

diseases, including hypertension, coronary artery disease,

cardiomyopathy, and diabetes (all p &lt;0.05). </FONT><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> deficiency was a strong independent predictor

of all-cause death (odds ratios 2.64, 95% confidence interval 1.901

to 3.662, p &lt;0.0001) after adjusting for multiple clinical

variables. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2> conferred

substantial survival benefit (odds ratio for death 0.39, 95%

confidence interval 0.277 to 0.534, p &lt;0.0001). In conclusion,

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> deficiency was

associated with a significant risk of </FONT><FONT SIZE=2>cardiovascular</FONT><FONT SIZE=2>

disease and reduced survival. </FONT><FONT SIZE=2>Vitamin D</FONT><FONT SIZE=2>

</FONT><FONT SIZE=2>supplementation</FONT><FONT SIZE=2> was

significantly associated with better survival, specifically in

patients with documented deficiency.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21880848"><FONT SIZE=2>Am

J Clin Nutr.</FONT></A></U></FONT><FONT SIZE=2> 2011

Oct;94(4):1144-9. Epub 2011 Aug 31.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Calcium

and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplements and

health outcomes: a reanalysis of the Women's Health Initiative (WHI)

limited-access data set.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Bolland</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

MJ</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Grey

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Gamble

GD</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Reid

IR</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Medicine,

University of Auckland, New Zealand. m.</FONT><FONT SIZE=2>bolland</FONT><FONT SIZE=2>@auckland.ac.nz</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Frequent use of personal,

nonprotocol calcium supplements obscured an adverse effect of

coadministered calcium and </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

(CaD) on cardiovascular risk in the Women's Health Initiative (WHI).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>We investigated the

effects of the use of personal calcium or </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements on other outcomes in the WHI CaD

Study (WHI CaD) by using the WHI limited-access clinical trials data

set.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The WHI CaD was a 7-y,

randomized, placebo-controlled trial of CaD (1 g Ca/400 IU </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> daily) in 36,282 community-dwelling,

postmenopausal women. The incidence of total cancer (excluding

nonmelanoma skin cancers), breast and colorectal cancers, hip and

total fracture, and mortality was assessed by using Cox proportional

hazards models.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In the WHI CaD,

interactions between the use of either personal calcium or </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements and CaD were found for total,

breast, and colorectal cancers but not for fracture or mortality. In

15,646 women (43%) who were not taking personal calcium or </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements at randomization, CaD significantly

decreased the risk of total, breast, and invasive breast cancers by

14-20% and nonsignificantly reduced the risk of colorectal cancer by

17%. In women taking personal calcium or </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplements, CaD did not alter cancer risk (HR:

1.06-1.26).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>For women in the WHI CaD

who were not taking personal calcium or </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplements at randomization, CaD decreased the risk of total,

breast, and colorectal cancers and did not change the risk of

fractures or total mortality. The nonskeletal effects of CaD may be

more important than the skeletal effects and should be considered

when evaluating these supplements. The WHI CaD trial is registered at

clinicaltrials.gov as NCT00000611.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/17556697"><FONT SIZE=2><SPAN LANG="de-DE">Am

J Clin Nutr.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

2007 Jun;85(6):1586-91.</SPAN></FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> and calcium supplementation reduces cancer

risk: results of a randomized trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Lappe</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

JM</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Travers-Gustafson

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Davies

KM</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Recker

RR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Heaney

RP</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Osteoporosis Research

Center, Creighton University, Omaha, NE 68131, USA.

jmlappe@creighton.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Erratum

in</FONT></H3>

<UL>

<LI><P LANG="de-DE" CLASS="western" STYLE="margin-bottom: 0in"><FONT SIZE=2>Am

J Clin Nutr. 2008 Mar;87(3):794. </FONT>

</P>

</UL>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>BACKGROUND:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Numerous observational

studies have found supplemental calcium and </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> to be associated with reduced risk of common

cancers. However, interventional studies to test this effect are

lacking.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The purpose of this

analysis was to determine the efficacy of calcium alone and calcium

plus </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> in reducing

incident cancer risk of all types.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DESIGN:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This was a 4-y,

population-based, double-blind, randomized placebo-controlled trial.

The primary outcome was fracture incidence, and the principal

secondary outcome was cancer incidence. The subjects were 1179

community-dwelling women randomly selected from the population of

healthy postmenopausal women aged &gt;55 y in a 9-county rural area

of Nebraska centered at latitude 41.4 degrees N. Subjects were

randomly assigned to receive 1400-1500 mg supplemental calcium/d

alone (Ca-only), supplemental calcium plus 1100 IU vitamin D3/d (Ca +

D), or placebo.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>When analyzed by intention

to treat, cancer incidence was lower in the Ca + D women than in the

placebo control subjects (P &lt; 0.03). With the use of logistic

regression, the unadjusted relative risks (RR) of incident cancer in

the Ca + D and Ca-only groups were 0.402 (P = 0.01) and 0.532 (P =

0.06), respectively. When analysis was confined to cancers diagnosed

after the first 12 mo, RR for the Ca + D group fell to 0.232 (CI:

0.09, 0.60; P &lt; 0.005) but did not change significantly for the

Ca-only group. In multiple logistic regression models, both treatment

and serum 25-hydroxyvitamin D concentrations were significant,

independent predictors of cancer risk.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Improving calcium and

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> nutritional status

substantially reduces all-cancer risk in postmenopausal women. This

trial was registered at clinicaltrials.gov as NCT00352170.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20723187"><FONT SIZE=2>Trop

Med Int Health.</FONT></A></U></FONT><FONT SIZE=2> 2010

Oct;15(10):1148-55. doi: 10.1111/j.1365-3156.2010.02578.x. Epub 2010

Aug 17.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effects

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2> supplementation

to children diagnosed with pneumonia in </FONT><FONT SIZE=2>Kabul</FONT><FONT SIZE=2>:

a randomised controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Manaseki-Holland

S</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Qader

G</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Isaq

Masher M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bruce

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Zulf

Mughal M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Chandramohan

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Walraven

G</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Aga Khan Health Services,

</FONT><FONT SIZE=2>Kabul</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&ensp;</FONT></FONT><FONT SIZE=2>,

Afghanistan </FONT><FONT SIZE=2>Kabul</FONT><FONT SIZE=2> Medical

University, </FONT><FONT SIZE=2>Kabul</FONT><FONT SIZE=2>,

Afghanistan.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVES:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To determine whether (i)

supplementation of oral 100,000 iu of </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) (cholecalciferol) along with antibiotics

will reduce the duration of illness in children with pneumonia; (ii)

supplementation will reduce the risk of repeat episodes.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Double-blind individually

randomised placebo-controlled trial in an inner-city hospital in

</FONT><FONT SIZE=2>Kabul</FONT><FONT SIZE=2>, of 453 children aged

1-36 months, diagnosed with non-severe or severe pneumonia at the

outpatient clinic. Children with rickets, other concurrent severe

diseases, very severe pneumonia or wheeze, were excluded. Children

were given </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) or

placebo drops additional to routine pneumonia treatment.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>RESULTS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Two hundred and

twenty-four children received </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3;)

and 229 received placebo. There was no significant difference in the

mean number of days to recovery between the </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) (4.74 days; SD 2.22) and placebo arms (4.98

days; SD 2.89; P = 0.17). The risk of a repeat episode of pneumonia

within 90 days of supplementation was lower in the intervention

(92/204; 45%) than the placebo group [122/211; (58%; relative risk

0.78; 95% CI 0.64, 0.94; P = 0.01]. Children in the </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2>(3) group survived longer without experiencing a

repeat episode (72 days vs. 59 days; HR 0.71; 95% CI 0.53-0.95; P =

0.02).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A single high-dose oral

</FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) supplementation

to young children along with antibiotic treatment for pneumonia could

reduce the occurrence of repeat episodes of pneumonia.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/15886381"><FONT SIZE=2>JAMA.</FONT></A></U></FONT><FONT SIZE=2>

2005 May 11;293(18):2257-64.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Fracture

prevention with vitamin D supplementation: a meta-analysis of

randomized controlled trials.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bischoff-Ferrari

HA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Willett

WC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wong

JB</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Giovannucci

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dietrich

T</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dawson-Hughes

B</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Nutrition,

Harvard School of Public Health, Boston, Mass 02115, USA.

hbischof@hsph.harvard.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONTEXT:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The role and dose of oral

vitamin D supplementation in nonvertebral fracture prevention have

not been well established.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>OBJECTIVE:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>To estimate the

effectiveness of vitamin D supplementation in preventing hip and

nonvertebral fractures in older persons.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SOURCES: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>A systematic review of

English and non-English articles using MEDLINE and the Cochrane

Controlled Trials Register (1960-2005), and EMBASE (1991-2005).

Additional studies were identified by contacting clinical experts and

searching bibliographies and abstracts presented at the American

Society for Bone and Mineral Research (1995-2004). Search terms

included randomized controlled trial (RCT), controlled clinical

trial, random allocation, double-blind method, cholecalciferol,

ergocalciferol, 25-hydroxyvitamin D, fractures, humans, elderly,

falls, and bone density.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>STUDY

SELECTION: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Only double-blind RCTs of

oral vitamin D supplementation (cholecalciferol, ergocalciferol) with

or without calcium supplementation vs calcium supplementation or

placebo in older persons (&gt; or =60 years) that examined hip or

nonvertebral fractures were included.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

EXTRACTION: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Independent extraction of

articles by 2 authors using predefined data fields, including study

quality indicators.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>DATA

SYNTHESIS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>All pooled analyses were

based on random-effects models. Five RCTs for hip fracture (n = 9294)

and 7 RCTs for nonvertebral fracture risk (n = 9820) met our

inclusion criteria. All trials used cholecalciferol. Heterogeneity

among studies for both hip and nonvertebral fracture prevention was

observed, which disappeared after pooling RCTs with low-dose (400

IU/d) and higher-dose vitamin D (700-800 IU/d), separately. A vitamin

D dose of 700 to 800 IU/d reduced the relative risk (RR) of hip

fracture by 26% (3 RCTs with 5572 persons; pooled RR, 0.74; 95%

confidence interval [CI], 0.61-0.88) and any nonvertebral fracture by

23% (5 RCTs with 6098 persons; pooled RR, 0.77; 95% CI, 0.68-0.87) vs

calcium or placebo. No significant benefit was observed for RCTs with

400 IU/d vitamin D (2 RCTs with 3722 persons; pooled RR for hip

fracture, 1.15; 95% CI, 0.88-1.50; and pooled RR for any nonvertebral

fracture, 1.03; 95% CI, 0.86-1.24).</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSIONS:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Oral vitamin D

supplementation between 700 to 800 IU/d appears to reduce the risk of

hip and any nonvertebral fractures in ambulatory or institutionalized

elderly persons. An oral vitamin D dose of 400 IU/d is not sufficient

for fracture prevention.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21154195"><FONT SIZE=2>Horm

Metab Res.</FONT></A></U></FONT><FONT SIZE=2> 2011 Mar;43(3):223-5.

Epub 2010 Dec 10.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Effect

of vitamin D supplementation on testosterone levels in men.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Pilz

S</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Frisch

S</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Koertke

H</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Kuhn

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Dreier

J</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Obermayer-Pietsch

B</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">, </SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Wehr

E</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">,

</SPAN></FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2><SPAN LANG="de-DE">Zittermann

A</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">.</SPAN></FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Department of Internal

Medicine, Division of Endocrinology and Metabolism, Medical

University of Graz, Austria.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The male reproductive

tract has been identified as a target tissue for vitamin D, and

previous data suggest an association of 25-hydroxyvitamin D [25(OH)D]

with testosterone levels in men. We therefore aimed to evaluate

whether vitamin D supplementation influences testosterone levels in

men. Healthy overweight men undergoing a weight reduction program who

participated in a randomized controlled trial were analyzed for

testosterone levels. The entire study included 200 nondiabetic

subjects, of whom 165 participants (54 men) completed the trial.

Participants received either 83 &mu;g (3,332 IU) vitamin D daily for

1 year (n = 31) or placebo (n =2 3). Initial 25(OH)D concentrations

were in the deficiency range (&lt; 50 nmol/l) and testosterone values

were at the lower end of the reference range (9.09-55.28 nmol/l for

males aged 20-49 years) in both groups. Mean circulating 25(OH)D

concentrations increased significantly by 53.5 nmol/l in the vitamin

D group, but remained almost constant in the placebo group. Compared

to baseline values, a significant increase in total testosterone

levels (from 10.7 &plusmn; 3.9 nmol/l to 13.4 &plusmn; 4.7 nmol/l; p

&lt; 0.001), bioactive testosterone (from 5.21 &plusmn; 1.87 nmol/l

to 6.25 &plusmn; 2.01 nmol/l; p = 0.001), and free testosterone

levels (from 0.222 &plusmn; 0.080 nmol/l to 0.267 &plusmn; 0.087

nmol/l; p = 0.001) were observed in the vitamin D supplemented group.

By contrast, there was no significant change in any testosterone

measure in the placebo group. Our results suggest that vitamin D

supplementation might increase testosterone levels. Further

randomized controlled trials are warranted to confirm this

hypothesis.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19781131"><FONT SIZE=2><SPAN LANG="de-DE">Br

J Nutr.</SPAN></FONT></A></U></FONT><FONT SIZE=2><SPAN LANG="de-DE">

2010 Feb;103(4):549-55. Epub 2009 Sep 28.</SPAN></FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D supplementation reduces insulin resistance in South Asian women

living in New Zealand who are insulin resistant and vitamin D

deficient - a randomised, placebo-controlled trial.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>von

Hurst PR</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Stonehouse

W</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Coad

J</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Institute of Food,

Nutrition and Human Health, Massey University, Private Bag 102 904,

North Shore Mail Centre, Auckland, New Zealand.

p.r.vonhurst@massey.ac.nz</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Low serum

25-hydroxyvitamin D (25(OH)D) has been shown to correlate with

increased risk of type 2 diabetes. Small, observational studies

suggest an action for vitamin D in improving insulin sensitivity

and/or insulin secretion. The objective of the present study was to

investigate the effect of improved vitamin D status on insulin

resistance (IR), utilising randomised, controlled, double-blind

intervention administering 100 microg (4000 IU) vitamin D(3) (n 42)

or placebo (n 39) daily for 6 months to South Asian women, aged 23-68

years, living in Auckland, New Zealand. Subjects were insulin

resistant - homeostasis model assessment 1 (HOMA1)&gt;1.93 and had

serum 25(OH)D concentration &lt; 50 nmol/l. Exclusion criteria

included diabetes medication and vitamin D supplementation &gt;25

microg (1000 IU)/d. The HOMA2 computer model was used to calculate

outcomes. Median (25th, 75th percentiles) serum 25(OH)D(3) increased

significantly from 21 (11, 40) to 75 (55, 84) nmol/l with

supplementation. Significant improvements were seen in insulin

sensitivity and IR (P = 0.003 and 0.02, respectively), and fasting

insulin decreased (P = 0.02) with supplementation compared with

placebo. There was no change in C-peptide with supplementation. IR

was most improved when endpoint serum 25(OH)D reached &gt; or = 80

nmol/l. Secondary outcome variables (lipid profile and high

sensitivity C-reactive protein) were not affected by supplementation.

In conclusion, improving vitamin D status in insulin resistant women

resulted in improved IR and sensitivity, but no change in insulin

secretion. Optimal vitamin D concentrations for reducing IR were

shown to be 80-119 nmol/l, providing further evidence for an increase

in the recommended adequate levels. Registered Trial No.

ACTRN12607000642482.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/19957164"><FONT SIZE=2>Osteoporos

Int.</FONT></A></U></FONT><FONT SIZE=2> 2010 Jul;21(7):1121-32. Epub

2009 Dec 3.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Benefit-risk

assessment of vitamin D supplementation.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Bischoff-Ferrari

HA</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Shao

A</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Dawson-Hughes

B</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hathcock

J</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Giovannucci

E</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Willett

WC</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Centre on Aging and

Mobility, Department of Rheumatology and Institute of Physical

Medicine, University Hospital Zurich, Gloriastrasse 25, 8091, Zurich,

Switzerland. Heike.Bischoff@usz.ch</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Current intake

recommendations of 200 to 600 IU vitamin D per day may be

insufficient for important disease outcomes reduced by vitamin D.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>INTRODUCTION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>This study assessed the

benefit of higher-dose and higher achieved 25-hydroxyvitamin D levels

[25(OH)D] versus any associated risk.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>METHODS

AND RESULTS: </FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Based on double-blind

randomized control trials (RCTs), eight for falls (n = 2426) and 12

for non-vertebral fractures (n = 42,279), there was a significant

dose-response relationship between higher-dose and higher achieved

25(OH)D and greater fall and fracture prevention. Optimal benefits

were observed at the highest dose tested to date for 700 to 1000 IU

vitamin D per day or mean 25(OH)D between 75 and 110 nmol/l (30-44

ng/ml). Prospective cohort data on cardiovascular health and

colorectal cancer prevention suggested increased benefits with the

highest categories of 25(OH)D evaluated (median between 75 and 110

nmol/l). In 25 RCTs, mean serum calcium levels were not related to

oral vitamin D up to 100,000 IU per day or achieved 25(OH)D up to 643

nmol/l. Mean levels of 75 to 110 nmol/l were reached in most RCTs

with 1,800 to 4,000 IU vitamin D per day without risk.</FONT></P>

<H4 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>CONCLUSION:

</FONT>

</H4>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Our analysis suggests that

mean serum 25(OH)D levels of about 75 to 110 nmol/l provide optimal

benefits for all investigated endpoints without increasing health

risks. These levels can be best obtained with oral doses in the range

of 1,800 to 4,000 IU vitamin D per day; further work is needed,

including subject and environment factors, to better define the doses

that will achieve optimal blood levels in the large majority of the

population.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

<P CLASS="western" STYLE="margin-bottom: 0in"><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed/21706518"><FONT SIZE=2>J

Bone Miner Res.</FONT></A></U></FONT><FONT SIZE=2> 2011

Oct;26(10):2341-57. doi: 10.1002/jbmr.463.</FONT></P>

<H1 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Vitamin

D</FONT><FONT SIZE=2> supplementation during pregnancy: double-blind,

randomized clinical trial of safety and effectiveness.</FONT></H1>

<P CLASS="western" STYLE="margin-bottom: 0in"><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT COLOR="#0000ff"><U><FONT SIZE=2>Hollis</FONT></U></FONT><FONT COLOR="#0000ff"><U><FONT SIZE=2>

BW</FONT></U></FONT></A><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Johnson

D</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Hulsey

TC</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Ebeling

M</FONT></A></U></FONT><FONT SIZE=2>, </FONT><FONT COLOR="#0000ff"><U><A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term="><FONT SIZE=2>Wagner

CL</FONT></A></U></FONT><FONT SIZE=2>.</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Source</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Division of Neonatology

and Department of Obstetrics and Gynecology, Medical University of

South Carolina, Charleston, SC 29425, USA. hollisb@musc.edu</FONT></P>

<H3 CLASS="western" STYLE="margin-top: 0in; margin-bottom: 0in"><FONT SIZE=2>Abstract</FONT></H3>

<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The need, safety, and

effectiveness of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation during pregnancy remain controversial. In this

randomized, controlled trial, women with a singleton pregnancy at 12

to 16 weeks' gestation received 400, 2000, or 4000</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>IU

of </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>(3) per day until

delivery. The primary outcome was maternal/neonatal circulating

25-hydroxyvitamin D [25(OH)D] concentration at delivery, with

secondary outcomes of a 25(OH)D concentration of 80</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>nmol/L

or greater achieved and the 25(OH)D concentration required to achieve

maximal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] production. Of

the 494 women enrolled, 350 women continued until delivery: Mean

25(OH)D concentrations by group at delivery and 1 month before

delivery were significantly different (p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&lt;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>0.0001),

and the percent who achieved sufficiency was significantly different

by group, greatest in 4000-IU group (p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&lt;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>0.0001).

The relative risk (RR) for achieving a concentration of 80</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>nmol/L

or greater within 1 month of delivery was significantly different

between the 2000- and the 400-IU groups (RR</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>1.52,

95% CI 1.24-1.86), the 4000- and the 400-IU groups (RR</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>1.60,

95% CI 1.32-1.95) but not between the 4000- and. 2000-IU groups

(RR</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>=</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>1.06,

95% CI 0.93-1.19). Circulating 25(OH)D had a direct influence on

circulating 1,25(OH)(2)D(3) concentrations throughout pregnancy

(p</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>&lt;</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>0.0001),

with maximal production of 1,25(OH)(2)D(3) in all strata in the

4000-IU group. There were no differences between groups on any safety

measure. Not a single adverse event was attributed to </FONT><FONT SIZE=2>vitamin

D</FONT><FONT SIZE=2> supplementation or circulating 25(OH)D levels.

It is concluded that </FONT><FONT SIZE=2>vitamin D</FONT><FONT SIZE=2>

supplementation of 4000</FONT><FONT FACE="Arial Unicode MS, sans-serif"><FONT SIZE=2>&thinsp;</FONT></FONT><FONT SIZE=2>IU/d

for pregnant women is safe and most effective in achieving

sufficiency in all women and their neonates regardless of race,

whereas the current estimated average requirement is comparatively

ineffective at achieving adequate circulating 25(OH)D concentrations,

especially in African Americans.</FONT></P>

<P CLASS="western" STYLE="margin-bottom: 0in"><BR>

</P>

</BODY>

</HTML>